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ABSTRACT
Exercise limitation is a hallmark of clironic obstructive pulmonary disease (COPD) and 
coimtering this is a major therapeutic goal. Chapter 1 considers the factors contributing to 
exercise intolerance with particular reference to the respective roles of ventilatory limitation 
and skeletal muscle dysfunction. A review of the strategies studied or currently used to 
counter exercise limitation then follows. Chapter 2 describes the methodology of the 
assessments of exercise limitation used in this thesis, along with an evaluation of other 
currently available techniques.
Chapter 3 describes how different means of body composition evaluation can effect the 
functional conclusions made from the data obtained. Assessment of peak exercise capacity 
related to muscle mass was found to be underestimated by antloi'opometry in comparison to 
air displacement plethysmography or bioelectrical impedance. It is concluded that inter- 
method differences in estimation of fat-free mass are large enough to require that a single 
methodology of assessment is used for comparative evaluations.
Chapter 4 describes a trial of creatine supplementation, both in isolation and in combination 
with exercise training. Muscle mass, strength and endurance, and health status were all 
enhanced by creatine, with or without exercise training. Whole body exercise capacity, when 
examined by field and laboratory tests, was not affected. It is concluded that creatine may be 
a potentially useful ergogenic agent for use in COPD patients.
Chapter 5 describes a crossover study of formoterol, a long acting bronchodilator, in 
advanced COPD patients with poor spirometric response to bronchodilation. Formoterol is 
shown to decrease exercise induced dynamic hyperinflation and breathlessness during 
activities. An equivocal effect on exercise tolerance is demonstrated. This study supports the 
rational for the use of long acting bronchodilators in symptomatically limited COPD patients, 
largely iiTcspective of individuals lung function response to bronchodilator.
Chapter 6 considers the implications of the work performed and suggests lines of 
investigation for future research.
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LIST OF SYMBOLS AND ABBREVIATIONS
The following outline defines the key symbols and abbreviations used tlii'oughout the thesis.
Exercise and Gas exchange
VO2 Oxygen (O2) consumption’, expressed in ml.miif
VO2 peak Oxygen consumption at maximal symptom limiied exercise expressed as
L.min'^ or body weight coiTected as mls.min"^kg'\
VO2 AT Oxygen consumption at the anaerobic threshold’, expressed as %predicted 
maximal oxygen uptake
VCO2 Carbon dioxide (CO2) production', expressed in ml.min"\
Ve Expiratory minute ventilation (L.min'\).
VE/VCO2 Ventilatory equivalent for CO2 - also called the ventilatory response expressed 
as L.L'^ carbon dioxide production
M W Maximum voluntary ventilation; a measure of a patients ventilatory capacity 
which can be measured directly or estimated by multiplying the FEVi by 40; 
expressed in litres
HR/VO2 Heart rate réponse on exertion’, expressed as beats L"^  oxygen uptake
O2 Pulse The amount o f oxygen delivered for each heart beat (surrogate marker of
stroke volume) expressed as mis per beat
A-a02 Alveolar-arterial oxygen gradient (a measure of physiological shunting
i.e.indication of lung units with low ventilation for their perfusion) expressed 
in kPa.
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VdWt Dead space to tidal volume ratio ( also known as the physiological dead space
i.e. indication of lung units with a high ventilation for their perfusion)
Lung Volumes and Forced Expiration
FVC Forced vital capacity: the volume of gas which is exhaled during forced
expiration starting from a position of full inspiration and ending at 
full expiration
FEVi Forced expiratory volume in one second: the volume of gas exhaled in the first
second of the FVC manoeuvre.
FRC Functional residual capacity: the volume of gas present in the lung and
airways at the average end-expiratory level.
RV Residual volume: the volume of gas remaining in the lung at the end of a full
expiration.
TLC Total lung capacity: the volume of gas in the lung at the end of full
inspiration.
Diffusion
T L c o  Pulmonary transfer factor for carbon monoxide (CO) - also called pulmonary
diffusing capacity: the rate of carbon monoxide uptake from alveolar gas to 
pulmonary capillary blood; expressed in mmol.miif \kPa"\
K c o  Transfer coefficient - also referred to as Ti/Va: TLco per unit alveolar
volume (V a); expressed in mmol.min'*.kPa‘'L"*.
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Body Composition
ADP Air displacement plethysmography
BIE Bioelectrical impedance
ANTHRO Anthropometry 
FFM Fat-free mass
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CHAPTER 1 
INTRODUCTION
20
This thesis concerns itself with the assessment and treatment of factors relating to exercise 
limitation in clnonic obstructive airways disease (COPD). In this introduction, an overview of 
the disease COPD will be presented. Current and historical evidence for the features relating 
to exercise intolerance will be addressed. Since pulmonary rehabilitation is the current 
cornerstone of intervention for exercise intolerance its applications and effects will be 
discussed. In addition, a range of other interventions aimed at improving exercise tolerance 
are considered; namely dietary, hormonal and pharmacological means.
1.1 COPD overview
1.1.1 Definition
Chronic respiratory diseases became important to the UK medical fraternity following the 
disastrous smog pollutions affecting London in the 1950’s. These caused increased sulphur 
dioxide levels that, when coupled with cigarette smoking, led to a high prevalence of chest 
problems. Following improved environmental conditions a decline in the prevalence of 
clnonic bronchitis occurred. However it was during this time that there became an increased 
awareness of the significance of clnonic airflow limitation. It was established in 1983 that 
mortality in patients with clnonic respiratory disease was related to the degree of airflow 
obstruction rather than symptoms of mucus production, (Peto et al., 1983).
Diseases that led to clnonic airflow limitation became eollectively referred to as “Chronic 
Obstructive Pulmonary Disease” (Fletcher & Pride, 1984). COPD is a clnonic disease 
characterised by largely irreversible airways obstruction. It is a progressive and debilitating 
condition, with one of its hallmarks being exercise intolerance. Previously, COPD was 
commonly subdivided into emphysema or clnonic bronchitis, whereas more recently efforts 
have been made to standar dise classification of this disease (Hurd, 2000b). Publication of a 
series of international consensus statements makes it likely that a universal approach to the 
stratification and clinical management of COPD will be adopted (BTS COPD Guidelines 
Group, 1997a; Celli & MacNee, 2004; American Thoracic Society Standards, 1987; Pauwels 
et al., 2001).
1.1.2 Epidemiology
COPD is at present the only major cause of mortality in the world to have a rising prevalence 
and by 2020 it is expected to beeome the fourth most eommon cause of death worldwide 
(Lopez & Murray, 1998), The health economic costs of this disease are placing ever-
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increasing burdens upon national health services (Hurd, 2000a). Moreover, exacerbations of 
COPD account for at least 10% of wintertime admissions during periods of already great 
strain upon hospital services (Guest, 1999). COPD is usually secondary to tobacco smoking; 
the direct relationship between number of cigarettes consumed and degree of lung damage 
having been established over 30 years ago (Auerbach et al, 1972). Tobacco clearly 
accelerates the annual decline in lung function associated with ageing in susceptible 
individuals (Fletcher & Peto, 1977). Cigarette use has increased in the western world since 
the Second World War and more recently increasing consumption of tobacco by women, 
particularly in the developing world is predicted to result in further rises in the incidence of 
chronic lung disease (Varkey, 2004). It has been estimated that 20% of those presently living 
in developed countries will be killed by tobacco consumption (Peto et al,  1992). This clearly 
devastating impact upon society and individuals as a consequence of COPD has made 
treatment of the symptoms and attempted alteration of the prognosis an international focus of 
research (Hurd, 2000b).
1.1.3 Clinical oveiwiew
The disease is in part due to a clii'onic inflammatory reaction in response to the environmental 
antigen presented within the lungs. The inflammation is largely neutrophil mediated, with 
elastolytic enzymes such as elastase, contributing to the structural damage occurring 
(Stockley, 1994; Barnes, 2000). More recently lymphocyte driven chemokines have been 
implicated in the causation of airway inflammation (Cosio et al,  2002). The impact of the 
inflammation is differing degrees of mucosal gland hypertrophy (chronic bronchitis) and 
alveolar tissue damage (emphysema). A consequence of these pathological processes is 
airflow limitation, caused by the loss of elastic tissue of the lungs, resulting in increased 
compliance and subsequently increased resistance of the airways (Heard, 1969). Although not 
mirroring factors such as exercise tolerance, declining forced expiratory volume (FEVi) is a 
correlate of mortality (Peto et al,  1983). With the inevitable decline of lung function with 
age, there is often an inexorable march towards disability and associated features of severe 
COPD in those with established disease, irrespective of smoking status.
COPD is a clnonic condition with the cardinal feature of lung impairment. However it also 
displays features of multi-systemic disease in many cases, which contributes to the morbidity 
seen (Wouters et al,  2002). Not uncommon are findings such as sarcopaenia, cardiac 
dysfunction and systemic inflammation. It is these very primary and ancillary features of the
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disease that must be addressed in order to improve an individual’s well-being or prognosis 
through intervention.
The pharmacological interventions utilised in COPD are costly and only partially efficacious, 
particularly in comparison to the impact these drugs have in asthma. Although the use of 
inliaied bronchodilators can alter spirometric measurements of lung function, their overall 
benefit is thought to derive more from the reduction both in dynamic hyperinflation and 
“work of breathing” that results from their administration (O'Donnell et al,  2001a). Both 
long and short acting bronchodilators have proven benefits upon exercise tolerance 
(O'Doimell et al,  1999; Ayers et al,  2001). Long acting beta agonists may exert some benefit 
thi'ough improved ciliary motility (Johnson & Rennard, 2001). Recent large and well- 
performed studies have provided a rationale for the use of inhaled steroids in severe 
symptomatic COPD (Burge et al,  2000; Calverley, 2000a). These have been followed by 
similarly designed multi-centre studies which demonstrate the additive benefit of 
combination treatments of long-acting beta agonist and inlialed steroid (Szafranski et al,  
2003; Calverley et al,  2003a). There is also evidence for the administration of oral 
prednisolone and antibiotics dming exacerbation (Davies et al,  1999; Stockley, 1994). Even 
with acceptance that newer drugs such as long acting anticholinergics will improve on present 
pharmacological interventions, a certain pessimism is widespread (Calverley, 2000b; Barnes, 
2001). All our medical treatments in COPD have failed to demonstrate benefit with regard to 
the cornerstone of intervention; namely alteration of prognosis or rate of decline of lung 
function. The only interventions that have been shown to impact upon mortality are long-term 
oxygen therapy and smoking cessation (Medieal Research Council Working Party, 1981; 
Nocturnal Oxygen Therapy Trial Group, 1980). It is in this context of ineffective treatment 
for the established lung problems in COPD that rehabilitation and exereise strategies have 
become of immense interest to health care professionals and scientists (Laçasse et a l , 1996).
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1.2 Pathophysiology of exercise intolerance
1.2.1 Introduction
The ti aditional view of the exercise limitation seen in COPD has considered ventilatory 
impairments to be the overwhelming and largely irreversible barrier (Leaver & Pride, 1971; 
Macklem, 1973). It is now Imown that through the physiological adaptations that take place 
with exeicise training, beneficial impacts on exercise capacity can be achieved (Belman & 
Kendregan, 1982; Casaburl et al,  1991). This implies that not all the factors leading to 
exercise intolerance are fixed and irreversible. It is evident that flow limitation and dynamic 
hyperinflation impair lung function, increase “work of breathing” and cause a ventilatory 
ceiling to be reached during exercise (O'Donnell, 2001). Although loss of a “breathing 
reserve” is evident in almost all exertions to limitation in COPD, there is now a greater 
understanding of the eontribution of other impairments present in the disease.
The acceptance of a multifactorial cause for exercise limitation has furthered our 
understanding of the benefits that derive from interventions such as exercise training. As an 
example, subjects may have different total ventilatory requirements for a specific work rate 
due to variations in their lactate thi*eshold, whereas their absolute oxygen uptake could be 
very similar. With endurance training, skeletal muscle adaptations ean result in a decreased 
ventilatory requirement at sub-maximal work rates (Casaburi et al,  1991; Puente-Maestu et 
al,  2000) and improve the whole body physiological response to exercise.
1.2.2 Ventilatory system
12.2.1 Lung mechanics
In health, predietable and beneficial alterations to lung mechanics and breathing timing occur 
in response to increased ventilatory requirements. Effective minute ventilation (V e, L/min) is
a product of tidal volume (V?) and breathing frequency (BE, breaths/min). During the
transition of rest to moderate exercise the rise in ventilation is first achieved by an increase in 
tidal volume, to approximately 50% VC (Cotes, 1975). Following that there is a 
commensurate rise in Vy and BF. More latterly only BF is able to increase as higher 
ventilation is required (Spiro et al,  1975). The initial increase in VT seen in health is a result 
of the increasing ratio of end inspiratory lung volume (EILV) to expiratory reserve volume 
(ERV), which has the important ancillary benefit of optimising the ratio of respiratory muscle 
power/length (Henke et al,  1988). Furthermore there are alterations in the proportion of time
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spent in the respiratory cycle on inspiration and expiration as work rates change. Increasing 
work leads to a predictable and progressively declining expiratory time (t^) and increasing 
inspiratory time (ti) as breathing frequencies increase to 50-60 breaths per minute (Neder et 
al., 2003). The final major beneficial change affecting lung mechanics in health is exercise 
induced broncho dilatation, which decreases airway resistance and therefore resistive work of 
the lung is lowered (Warren et al,  1984; Jolinson et al,  1999c; Johnson et al,  1995). Despite 
these changes some increase in the elastic work of breathing is inevitable as the tidal volumes 
rise.
In COPD there are a number of factors present at rest that worsen on exercise and produce 
ventilatory impairment during exertion. Most simply there is flow limitation, such that as the 
ventilatoiy iequii ements rise the flow volume loop encroaches upon its maximum, 
particularly during expiration. This is the basis for the crudest, but most effective, tool for 
screening for ventilatory limits to exercise; calculation of the maximum voluntary ventilation 
(M W ).
M W  is calculated by multiplication of the FEVi by a fixed amount (either 35 or 40) or by 
measurement of the maximum ventilation achieved during a fixed period (15 seconds) 
multiplied by a factor of 4. The resulting difference in the calculated M W  and maximum 
ventilation measured during an exercise test will give a value for the “breathing reserve” 
(BR). This may be minimal in COPD but would be expected to be between 30 to 50% in 
health.
In COPD there is a correspondingly lower VT and higher BF for a given Ve than in health. 
The flow limitation seen in COPD prolongs Te; the direct mechanism for the development of 
dynamic hyperinflation (DH) during exercise (O'Domiell et al,  2001b). This directly places 
the respiratory muscles at a mechanical disadvantage with them being forced to work at a 
high proportion of their maximal capacity; tluough increased loading, physical lengthening 
and reduced strength at the larger lung volumes. A vicious cycle becomes evident as the 
required increased tachypnoea necessary to alter ventilation further worsens DH.
The changes described above clearly increase the elastic work of breathing during exercise in 
COPD patients. Furthermore the increased blood flow demands of the ventilatory muscles 
and the impaired venous return may compromise the oxygen delivery to the exercising 
muscles (Aliverti & Macklem, 2001). In particular, it is known in COPD that individual leg 
VO2 can increase in response to improved oxygen delivery, and therefore that oxygen 
delivery to the lower limb muscles, perhaps altered by “respiratory steal”, does play an 
important limiting role (Simon et al,  2001).
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Illustrated below are the lung volume changes seen in health and COPD during exercise.
Figure 1.1 Changes in operational lung volumes are shown as ventilation increases with 
exercise in patients with COPD and in normal subjects.
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Figure 1.1 Changes in operational lung volumes are shown as ventilation increases with 
exercise in patients with COPD and in normal subjects. "Restrictive" constraints on tidal 
volume (VT, solid area) expansion during exercise are significantly greater in the COPD 
group from both below (reduced IC) and above (minimal IRV, open area). Taken from 
Dynamic Hyperinflation and Exercise Intolerance in Chronic Obstructive Pulmonary Disease 
(O'Donnell et a l ,  2001b).
1.2.2 2. Ventilation-perfusion inequality
The ventilatory requirements for exercise in COPD are increased because o f high 
ventilation/perfusion ratios and low tidal volumes that increase V q/Vj , this promotes 
dyspnoea by compromising ventilatory capacity and preventing adequate alveolar ventilation. 
Moreover in COPD, and emphysema particularly, the pulmonary vascular bed is damaged 
which leads to decreased perfusion in certain areas o f the lung and subsequently causes high 
V[VVt values especially on exertion.
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The ventilation and perfusion (V/Q) inequalities within the lung lead to increasing alveolar- 
arterial pO] difference, assessed by concurrent arterial blood gas measurement with the 
knowledge of the inspired fraction of oxygen. Other measures of VQ mismatch approximate 
the degree of physiological shunting and alveolar dead space. Physiological shunting refers to 
the quantity of capillary blood that passes thi'ough the lungs without taking part in gas 
exchange. In figure 1.2 below (adapted from Rahn) this effect is illustrated by the horizontal 
left arrow (Rahn & Fenn, 1955). In quantifying alveolar dead space, one is considering that 
portion of lung that is ventilated without significant perfusion (vertical downwards arrow). 
This portion of lung is functionally the same as the anatomical dead space, and will 
consequently add to the volume of the physiologic dead space. In health the physiologic dead 
space is 30% (or less on exercise) of the tidal volume, whereas in COPD this volume can rise 
to 50% or more due to VQ mismatch.
Figure 1.2 A graphical representation of physiological shunting.
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Taken from “A graphical analysis of the respiratory gas exchange”. (Rahn & Fenn, 1955)
Related to the concept of VQ mismatch is the consideration of shunting. This represents 
blood in the systemic arterial system that has not passed thi'ough ventilated portions of lung. 
In health this occurs to a small degree because of the blood supply to the coronary and 
bronchial arteries. In COPD this can be seen due to extremes of abnormality in VQ, 
particularly in emphysema phenotypes. A particular feature of shunts is that they induce a 
hypoxia that is refractory to oxygen therapy, allowing their detection when subjects are given 
100% oxygen to breathe.
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1.2.2.3 Arterial hypoxaemia
An additional stimulus to ventilation and dyspnoea is the development of arterial hypoxemia 
during exertion. This results from an increased A-a02 gradient and provides the best 
indication of abnormal pulmonary gas exchange. In normal subjects there is little rise in the 
A-a02 gradient on mild to moderate exercise, indeed it typically falls over the lower work 
rates but has been demonstrated to increase during moderate and maximal exercise (Jones et 
al, 1966; Wasserman et al,  1967); while in health values of around 10 inmHg at rest are 
expected, at maximal exertion this rises to 15 mmHg in healthy young men (Wasserman et 
al, 1999). However the A-a02 gradient is characteristically larger at rest in COPD due to the 
perfusion of the relatively poorly ventilated airspaces, and can be somewhat unpredictable in 
its response to exercise, not infrequently rising to values around 50 mmHg (Wasserman et al,
1999).
1.2.2.4 Dyspnoeagenesis
It is generally accepted that the subjective sensations of dyspnoea largely relate to 
corresponding increases in ventilation (Killian & Jones, 1994; Mahler et al, 2001; Ward,
2000). This has largely been based on quantifying the rate of increase of dyspnoeic sensation 
tluough the use of visual analogue or Borg scales (Aitken, 1969; Borg, 1982). Although it is 
likely that the mechanisms contributing to the sensation of dyspnoea are multifactorial, it 
appeal's that afferent information from the lung and chest wall musculature is central. There is 
evidence that the resistive and elastic loads placed upon the chest wall directly influence 
dyspnoeagenesis through length-tension relationships or thi'ough absolute work loads of the 
respiratory musculature (Killian et al, 1979; Killian & Jones, 1984). The carotid bodies and 
other peripheral chemoreceptors, such as ergoreceptors, are also likely to contribute to the 
sensation of dyspnoea (Ward & Whipp, 1989; Grieve et al, 1999). Thereby, in COPD, the 
combination of increased work of breathing, hyperinflation and possibly skeletal muscle 
dysfunction could be seen to contribute to the uncomfortable, and often limiting, sensations 
of dyspnoea at rest and during exertion.
1.2.3 Skeletal muscle
Although the precise mechanisms contributing to skeletal muscle dysfunction in COPD 
remain elusive, the consensus of opinion is that skeletal muscle plays a pivotal role in the 
aetiology of exercise intolerance in COPD.
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Several lines of investigation have produced evidence to clarify the existence of skeletal 
muscle problems in COPD, elucidating some of the potential causes and illuminating the 
impact of interventions on these changes. Whereas for many years the benefits of pulmonary 
rehabilitation have been recognised, without an explanation of how improvements occur, we 
are now in a position to attempt to isolate the meaningful alterations that take place. This is 
one focus of international research: to increase our understanding of muscle dysfunction in 
chronic disease (ATS/ERS Statement, 1999). The second widespread aim is to translate these 
advances into novel treatments (ATS/ERS Statement, 1999). In the sections below the 
structural and functional alterations seen in COPD muscle are discussed, with relation to the 
interventions utilised and postulated for this patient group.
1.2.3.1 Muscle structure
Muscle fibres tend to be arranged within separately functional units, each one comprising of a 
specific muscle type, imiervated by a single motor neuron. Such fibres within one unit tend to 
be of the same muscle fibre type, either, slow twitch type (I) or fast twitch (type Ila or Ild(x) 
-  often called type Ilb) fibres in humans. Fibre type distribution varies in health and such 
differences have been most closely observed from examinations of the vastus lateralis 
muscle. For, example endurance athletes have a high proportion (>90%) of type I 
(predominantly oxidative enzyme activity) whereas sprint runners may have only 20 to 30% 
type I, thereby having a greater percentage of glycolytic enzyme based fibres (Wasserman et 
al, 1999).
Structural changes in the skeletal muscle of patients with COPD have been established 
tlu’ough case-controlled investigations. A degree of atrophy of individual fibres has been 
noted, with suggestion that the severity of these changes correlates with loss of fat-free mass 
and FEVI (Hughes et al,  1983;Sato et al,  1997). The correlations seen are used as evidence 
to demonstrate that muscle fibre atrophy underlies the loss of bulk and function seen in 
COPD. However, the role of atrophy in determining loss of specific function, for example, 
endurance activity is controversial. This has been shown to more likely relate to proportion of 
specific fibre types (Allaire et al, 2004). Analysis of fibre type proportions has produced 
differing results from separate studies. From the quadriceps femoris, histological examination 
revealed no alteration in muscle fibre proportions, but atrophy of type II fibres (Hughes et a l , 
1983). In contrast studies examining the vastus lateralis muscle have reported conflicting 
results. Initial investigations suggested a decreased proportion of type I fibres and associated 
increases in the proportion of type II fibres were present in COPD (Jakobsson et al, 1990;
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Whittom et al, 1998). In support of this is a finding of increased proportion of myosin heavy 
chain type lib isoform from the vastus lateralis in patients with COPD (Satta et al,  1997). 
These features are in keeping with the notion of such changes representing poor aerobic 
function of the skeletal muscle. It is type I fibres (slow-twitch fatigue resistant) that are 
associated with prolonged aerobic activity and conversely type Ilb fibres (fast twitch 
fatigable) are more suited to short bursts of anaerobic activity (Burke et al, 1973). These 
findings have been more recently refuted in a well conducted investigation that took care to 
use appropriately matched subjects and utilised muscle fibre CSA rather than fibre diameter 
(Gosker et al, 2002). The main finding was that atrophy occurs mainly in type Ila and Ilb 
fibres. As additional evidence of alterations that are reasonably specific to these fibres, a 
selective loss of stainable activity of the oxidative enzymes was demonstrated. In association 
with atrophy there is a decreased capillarity of skeletal muscle; these changes have been 
postulated to represent poor aerobic ability resulting from a hypoxic environment (Jobin et 
al, 1998; ATS/ERS Statement, 1999).
While atrophy is an accepted finding in COPD muscles it appears that the individual muscle 
fibre type proportions seen are variable and more closely relate to endurance activity of the 
muscle groups (Allaire et al, 2004).
1.2.3.2 Muscle metabolism
The terminal phosphate bond of adenosine triphosphate (ATP) is the essential source of 
energy for skeletal muscle contraction. The energy provided by breakage of this bond is 
directly used by the myosin/actin cross bridges to enact the functional changes resulting of 
shortening or increasing tension of muscle. ATP can be regenerated predominantly through 
aerobic (oxidation of carbohydrates and transfer of energy utilising a proton shuffle) and 
anaerobic (breakdown of pyruvate to lactate without use of oxygen) glycolysis. The former is 
much more efficient; however the latter becomes a necessary component as energy demands 
rise. Phosphocreatine (PCr) breakdown within the skeletal muscle allows a ready source of 
ATP as the “oxygen deficit” incurred by the rapid energy demand is met. PCr exists in a state 
of flux with creatine and inorganic phosphate, the Lohmami reaction, catalysed by creatine 
kinase.
Along with the structural changes noted, there are alterations in metabolic profiles within the 
skeletal muscle of patients with COPD. Muscle homogenate from the vastus lateralis, as well 
as the staining methods already mentioned, compared to aged matched normal subjects, 
demonstrated reduction in levels of enzymes associated with aerobic glycolysis. These
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included decreases in citrate synthase (CS), succinate dehydrogenase and 3-hydroxy-CoA 
dehydrogenase (HADH) (Jakobsson et al, 1995; Maltais et al, 1996c). More recently it has 
been demonstrated that CS levels correlate with functional status, including V O i p e a k  and 
peripheral isometric endurance muscle function, in patients with COPD (Allaire et al, 
2004;Maltais et al,  2000). In examination of anaerobic enzyme levels, there has been no 
decrease demonstrated, in comparison to normal subjects, (Maltais et al, 1996c). Lactate 
dehydrogenase and hexokinase amounts were normal, phosphofructokinase levels were 
increased possibly suggesting augmented anaerobic activity (Jakobsson et al,  1995).
As fai' back as 1977 it was determined that patients with COPD had lower resting levels of 
phosphocreatine than normal subjects (Gertz et al, 1977). More recently, tlnough work 
utilising the teclmique of phoshorous-31 magnetic resonance spectroscopy, the characteristics 
of phosphocreatine utilisation in COPD have been clarified. This involves the performance of 
exercise within a magnetic resonance scanner, allowing determination of tissue pH, adenosine 
triphosphate, phosphocreatine and inorganic phosphate. From the values determined it is 
possible to quantify rates of PCr level alteration. Consistently it has been demonstrated that 
patients with COPD more rapidly deplete PCr than age matched normal controls at the onset 
of exercise (Thompson et al,  1993; Payen et al,  1993; Kutsuzawa et al,  1992). These 
investigations and one other study also showed slowing of recovery of PCr levels following 
exercise (Marmix et al,  1995). Latterly there has been evidence produced to suggest that 
phosphocreatine utilisation and resynthesis, as determined by magnetic resonance 
spectroscopy, mirrors oxygen uptake kinetics in normal subjects (Rossiter et al,  1999). This 
finding rests comfortably with concepts such as the “oxygen deficit” which relate to that 
amount of work performed utilising anaerobic energy sources. However in subjects with 
COPD the evidence suggests that there are significant differences in oxygen kinetics as 
compared to normal subjects. Although “on and off symmetry” is maintained during 
moderate exercise the “time constant” (c) is markedly prolonged (Nery et al, 1982a; Puente- 
Maestu et al,  2003; Sala et al, 1999a). These findings may relate to alterations in oxidative 
metabolism within the muscle and there is considerable evidence of this occurring (Maltais et 
al,  2000; Maltais et al,  1996c).
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12.3.3 Muscle mass and function
Weight loss is a lecognised feature of COPD. It is well established that compared to normal 
controls, body weight and body mass index are decreased (Schols et al,  1993a). The 
importance of this manifestation is established tlirough studies that have correlated body 
composition with overall prognosis (Engelen et al,  1994; Wilson et al,  1989a; Marquis et 
al,  2002). There is a large body of evidence concluding that muscle mass in COPD is 
decreased compared to aged matched subjects. Antlrropometrical data suggests a high 
incidence of loss of fat free mass in subjects with COPD (Schols et al,  1991b; Schols et al,  
1993b; Engelen et al,  1994). As part of a study utilising MR spectroscopy, the investigators 
were able to demonstrate significantly smaller calf muscle cross sectional area compared to 
age matched subjects (Wuyam et al,  1992).
In particular*, the relationship between body mass and peak exercise capacity is clear and 
positive (Wilson et al,  1989b; Gray-Donald et al,  1989; Palange et al,  1995). The degree by 
which body composition directly impacts upon exercise capacity has therefore been 
investigated. Fat free mass, a surrogate of muscle mass, can be estimated through techniques 
such as 4 site skin fold thickness, dual-energy X-ray absorptiometry and bioelectrical 
impedance. All these methods have been validated for use in COPD (Engelen et al,  1998). 
Initial investigations demonstrated that FFM coiTelated better with exercise capacity, 
represented by 12 minute walking distance to VOiPEAK on a ramp incremental test, than body 
weight (Schols et al,  1991a; Baarends et al,  1997a). Moreover there is evidence to suggest 
that FFM depletion contributes to reduced aerobic capacity, blunted tidal volume responses to 
exertion and lower peak oxygen pulse (Baarends et al,  1997a). Further evidence that 
sarcopenia is involved in inducing early onset of anaerobic glycolysis is formed from the 
negative correlation between nutritional status and the speed of oxygen uptake kinetics, as 
assessed by mean response times (Palange et al,  1998).
Functional studies have demonstrated impairment of skeletal muscle strength and endurance 
in patients with COPD. There is consistent evidence of lower limb weakness (predominantly 
quadriceps), usually in combination with loss of muscle mass (Gosselink et al,  1996; 
Engelen et al,  2000). After matched exercise protocols involving cycle ergometry or twitch 
stimulus, with healthy controls, subjects with COPD have been demonstrated to have 
increased quadriceps fatigability (Mador et al,  2003b; Mador et al,  2003a). Moreover, 
recently it has been demonstrated that impaired quadriceps endurance was present in a COPD
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cohort and that the degree of impairment was unrelated to disease severity or strength of the 
same muscle group (Coronell et al, 2004).
There is substantial consensus now that skeletal muscle dysfunction is a major contributor to 
exercise intolerance as evident through the residual impairment seen following lung 
transplant and the established improvements in exercise capacity following training 
(Casaburi, 2000; Gosker et al, 2000). There are physiological alterations (raised lactate 
thieshold, increased maximum oxygen uptake, speeded oxygen kinetics) seen following 
exercise training that can predominantly be attributed to changes within the skeletal muscle 
(Puente-Maestu et al, 2000; Casaburi et al, 1997). These markers have implications about 
fibre type changes or metabolism and therefore have direct relationships to skeletal muscle 
function. Otherwise the only means of determining whether changes have taken place at the 
level of the skeletal muscle would be through invasive means such as biopsy. Lactate rises 
indicate a reliance on anaerobic means of energy production and decreases following 
interventions such as exercise training tell us that alterations in the function of the skeletal 
muscle have taken place (Casaburi et al, 1991).
1.3 Interventions in COPD for exercise intolerance
1.3.1 Exercise training- strength and endurance
1.3.1.1 Introduction
The role of rehabilitation in the care of patients is established, and coupled with an ageing 
population, is growing in importance. Exercise based interventions performed in subjects 
with pulmonary, cerebrovascular disease, ischaemic heart disease and cardiac failure have 
proven efficacy and are integral to current standards of care (Knekt et al, 1988; Cuzick et al, 
1988). Rehabilitation involves the restoration of, or towards, “normality”; in this context from 
a diseased state. Pulmonary rehabilitation is an established method of successfully addressing 
some of the debilitating features of COPD. Over 20 yeai's ago the improvements in exercise 
tolerance and associated reduction in perception of dyspnoea were accepted to be benefits of 
pulmonary rehabilitation(MacDonell, Jr., 1981; Fergus & Cordasco, 1977). Tlnough recently 
published consensus guidelines, the importance of rehabilitation in appropriately caring for
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those with chronic lung disease has been firmly established(Celli, 1997; ACCP/AACVPR 
Guidelines, 1997c, Weise, 2000). A standard pulmonary rehabilitation programme would 
now be expected to produce enhancements in endurance ability, perception of breathlessness 
at lest and in response to exercise, and health status. These benefits have also been 
demoiistiated in chionic lung diseases other than COPD such as bronchiectasis and fibrosing 
alveolitis (Fostei & Thomas, III, 1990). Although there has long been acceptance of some 
role for rehabilitation in COPD and other diseases, the scientific basis on which to justify 
providing this service was lacking. However there is now a clear understanding that certain 
components of rehabilitation, particularly exercise training, lead to discernable physiological 
benefit (Casaburi et al,  1997; Maltais et al,  1996b; Sala et al,  1999b). Also rehabilitation 
induces fatigue resistance within the exercised muscles (Mador et al,  2001). This overview 
considers current understanding of the effects, particularly physiological, induced by 
rehabilitation, the most effective means of attaining these changes and the prospects for 
improved rehabilitative strategies.
1.3.1.2 Exercise components
Rehabilitation can take many different forms, with some common features deemed essential 
foi success. At the coie of those beneficial programmes, as determined by randomised 
controlled trials, are structured exercise training components (Laçasse et al, 1996). This 
tiaining is efficacious when provided during inpatient stays, tlnough home based programmes 
or, most commonly, as part of an out patient developed programme (Strijbos et a l,  1996; 
Singh et al, 1998a). There is uncertainty concerning the optimal duration of a course of 
rehabilitation. There is evidence to suggest that a successful inpatient programme may last 
just a few weeks, whereas some outpatient courses last 3 months (Casaburi et al, 1997; 
Carnbach et al, 1997). It seems logical that benefits are more likely to be sustained if lifestyle 
adaptations, allowed by the increased exercise capacity, occur.
A core principle of exercise training, in health and disease, is that training effects are task 
specific, and therefore the greatest benefits are usually to be found if one uses the same 
instrument for assessment as used for training (Sale & MacDougall, 1981; Jones & 
Rutherford, 1987). It is essential to direct the training tasks clearly toward the desired goals. 
In the context of chronic disease, the main emphasis of studied interventions has been toward 
improving endurance activities, for example, walking ability. It is thi'ough these simple
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evaluations that overall benefit from rehabilitation programmes have been firmly established 
(Laçasse et al,  1996), This almost universal focus in combination with obvious convenience 
has meant that supervised walking, perhaps using a treadmill, and cycle ergometry are 
invaiiably included in the design of rehabilitation interventions. There is evidence to support 
the training specificity of upper or lower limb endurance activities in COPD, with crossover 
benefit being demonstrated between differing lower limb endurance training modalities 
(Cambach et al,  1997).
1.3.1,3 Endurance training
Intensity of training is a highly contentious issue as it can relate to a number of parameters, 
such as degree of work performed, physiological responses to such loads or perceived 
exertions. The appropriate intensity of exercise training has been examined by assessing 
which levels of work result in physiological adaptations. It may be more beneficial to train 
patients at a level above the lactate thi’eshold (Casaburi et al, 1989; Casaburi et al,  1991). 
Such training enables physiological changes to occur: shortening of oxygen uptake kinetics 
times, increase in the lactate tlireshold (0 l)> and decrease lactate values and ventilation 
demands for a given supra-0L work rate (Casaburi et al, 1991; Maltais et al, 1996a). 
However there is clear evidence that a variety of exercise interventions, at differing training 
intensities also result in physiological benefit (Clark et al, 1996). Even with low intensity 
training exercise benefits are seen, probably relating to tolerance of dyspnoea and factors 
such as improved confidence (Girnenez et al, 2000). Therefore in practice there is support for 
a number of strategies for the setting of work performed; tlnough intensity or duration, 
usually set by work rate, treadmill speed or heart rate. Dyspnoea closely mirrors intensity 
ratings and is a practical alternative (Stulbarg et al,  1999; Horowitz et al, 1996). In one 
randomised study the use of a fixed exercise duration with gradually increasing work rates 
towards a target over the course of training was shown to have benefit (Troosters et al,
2000). Conversely there is proven benefit for setting high work intensities and targeting 
towards increased work duration (Punzal et al, 1991; Strijbos et al, 1996). Although high 
intensity training (80% peak work rate) is regarded as the present gold standard for exercise 
prescription, more severe COPD patients cannot sustain this workload tlnough a 
rehabilitation programme(Maltais et al, 1997; Casaburi et al,  1997). An alternative strategy 
involves short burst high intensity work rates, which have recently been demonstrated to 
provide similar benefit (endurance exercise time, health status) to continuous training at
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identical total work (Vogiatzis et al., 2002). Also the chronic application of functional 
electrical stimulation of the quadriceps muscle has been shown to cause improvements in 
symptom-limited oxygen uptake in a severely debilitated group (Neder et al, 2001a). In 
particular, the active treatment group were then able to enter the standard pulmonary 
rehabilitation programme following the electrical stimulation.
13.1.4 Strength Training
Strength training is feasible and safe in patients with COPD (Kaelin et al,  1999). Isolated 
strength training of quadriceps femoris has been demonstrated to improve endurance exercise 
time, muscle endurance and health status (Clark et al, 2000; Simpson et al,  1992). 
Unforlunately these studies were not able to demonstrate benefit in maximal exercise 
capacity. However the relative importance of lower limb strength intervention, in 
combination with endurance training has not yet been clearly established. Although increased 
muscle bulk and strength are achievable there is no clear additional benefit gained in the 
standard outcome measirres of pulmonary rehabilitation (Bernard et al,  1999a).
1.3.1.5 Respiratory muscle training
Lower limb, skeletal muscle training is an essential component of a successful pulmonary 
rehabilitation programme, however there is no established requirement for respiratory muscle 
training. Consensus statements from the American College of Chest Physicians and the 
Ameiican Tlioiacic Society have concluded that fiirther evidence is required before it is 
appropriate to recommend this approach (1997c; Weise, 2000).
In conjunction with disabling leg effort, dyspnoea is the main limitation to exercise in 
patients with COPD (Llamiiton et al,  1996). In contrast to the skeletal muscles, the 
lespiiatory musculature is continually working, often under stress. Such an enviroinnent has 
been demonstrated to alter the relative fibre type composition in COPD patients: the 
diaphragm has a higher proportion of type I (slow twitch, endurance) fibres (Levine et al,
1997). However the factors that predispose to systemic muscle dysfunction, such as 
malnutrition and hypoxia, remain present. Respiratory muscle function in COPD patients is 
thereby frequently found to be subnormal. This is manifested tlnough decreased maximal 
expiratory and inspiratory pressures and reduced endurance as measured by 2 minute 
tlneshold tests (Morrison et al,  1989; Gosselink et al, 2000; Wijkstra et al,  1995). There is
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also a clear mechanical disadvantage, at rest and exercise, for the respiratory muscles; 
hyperinflation flattens the diaplnagm and impairs peak force generation of the muscles, 
particularly for inspiratory manoeuvres (O'Domiell, 2001). With bronchodilation and 
cumbersome therapies such as heliox inlialation or the use of ventilatory support, the main 
means available to relieve the mechanical impairment, any approach which may be 
favourable to breathing patterns or expiratory flow capability could potentially provide 
benefit. Patients with COPD have established airflow obstruction, resulting in prolongation of 
the total expiratory period ( T e )  in comparison to the inspiratory time (T;) (O'Donnell el al, 
2001b). The increased Te/Ti and rising ventilatory demands during exercise result in dynamic 
hyperinflation and the associated factors that are so detrimental to exercise performance.
It is established in health that directed respiratory muscle training can result in improvements 
in strength or endurance (Leith & Bradley, 1976). Similar benefits, usually targeting strength 
training, have been demonstrated in COPD (Larson et al, 1988; Harver et al, 1989; Lisboa et 
al, 1995; Dekluiijzen et al,  1991). This has largely been through the use of handheld 
resistive devices, whereby repeated manoeuvres are performed against a closed shutter on 
inspiration or tlirough inspiratory flow limitation. The former provides only short bursts of 
training and has been largely replaced by the more efficacious flow-limiting devices. With 
respiratory muscle training as a sole intervention, unfortunately often without controls, there 
have been favourable, but inconsistent beneficial outcomes demonstrated for impact upon 
exercise capacity (Dekhuijzen et al,  1990; Larson et al,  1988; Belman & Mittman, 1980) 
and dyspnoea ratings (Harver et al, 1989; Lisboa et al, 1995) in patients with COPD. The 
impact upon health status has been poorly addressed, however one study of resistive 
inspiratory loading has been able to demonstrate benefits on maximal inspiratory pressures, 
SWT distance at study completion and also dyspnoea and health status at 6 month follow up 
(Sanchez et al., 2001). Unfortunately, any demonstration of improved respiratory muscle 
function has consistently failed to provide additional benefit in conjunction with exercise 
training (1997c). The positive studies that exist represent a small cohort of studied patients 
(Wanke et al, 1994; Weiner et al, 1992), and larger investigations are needed before this 
treatment can be routinely recommended.
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13.1.6 Supplementary oxygen
Exercise induced hypoxemia is a common feature of patients with severe COPD, occurring 
during many activities of day-to-day life (Soguel et ah, 1996). Long-term oxygen therapy in 
hypoxaemic COPD patients has proven physiological benefit; including normalisation of 
polycythaemia, improved exercise performance, and reduced pulmonary hypertension 
(1980;1981; Weitzenblum el al, 1991). There ai'e a number of good reasons why 
supplementary oxygen would have an immediate beneficial effect upon exercise capacity. 
Oxygen alters the sensations of dyspnoea, probably through a combination of central means 
(eg silencing of ongoing drive from carotid body chemoreceptor with increased PaO]) (Ward, 
2000; Whipp & Ward, 1992) and the consequent decreased ventilatory requirement 
(Swinburn et al, 1991). The lowered pulmonary artery and intra thoracic pressures, 
subsequently decreasing both right and left ventricular afterloads, may improve cardiac 
output. In addition myocardial oxygen delivery is enhanced. It directly increases oxygen 
delivery to the stressed muscles tlii'ough raised arterial pOz and indirectly through increased 
cardiac output. However increasing fraction of inspired oxygen (and increased pOz) can cause 
increased vascular resistance in tissues such as skeletal muscle. This may partially offset the 
effect of increased pOz on oxygen delivery. Interestingly an examination of lactate and 
oxygen uptake kinetics during transitions to constant work rate tests of moderate intensity in 
COPD patients failed to demonstrate any alteration of these during supplemental oxygen 
delivery (Somfay et al, 2002). This was despite significant reductions in levels of ventilation. 
However it is established that below the anaerobic threshold VOz kinetics in normal subjects 
are not affected by alterations in levels of ventilation (Diamond et al,  1977). The authors 
concluded that the decreased ventilatory stress was more related to the impact of oxygen 
upon dyspnoea sensation than a later onset of anaerobiosis and lactate formation. Placebo 
controlled studies of oxygen supplementation have demonstrated improved endurance 
exercise capacity irrespective of the presence of exercise induced hypoxaemia (Revill et al, 
2000; Somfay et al, 2002). In particular, a dose-response relationship was evident up to 50% 
FiOz in non hypoxemic patients upon endurance capacity, degree of dynamic hyperinflation 
and associated dyspnoea ratings (Somfay et al,  2002). In attempting to elucidate the primary 
mechanism by which oxygen supplementation aids exercise capacity, it has been 
demonstrated that increased FiOz leads to an associated increase in leg blood flow (measured 
a thermodilution catheter) and leg oxygen uptake (by arterial and venous blood gases coupled 
with leg blood flow), thereby facilitating the improved exercise capacity(Maltais et al,  2001).
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This signifies that the lower limb musculature is operating in COPD patients with a 
performance reserve in situations without oxygen supplementation. It also may be postulated 
that the decreased ventilatory requirements for a given exercise, in the presence of oxygen, 
allows blood flow redistribution to the oxygen requiring skeletal muscles (Simon et al, 
2001).
Although the benefit in the short term is established for improved exercise capacity with 
oxygen supplementation, there is no consensus as to whether it is appropriate in an exercise- 
training situation. A controlled trial of oxygen vs. air supplementation in severe COPD 
subjects, with exercise hypoxemia, undergoing pulmonary rehabilitation demonstrated benefit 
solely in dyspnoea ratings (Garrod et al,  2000). There was no improved outcome in the 
oxygen supplementation group with regard to health status or exercise capacity. This may 
relate to the reduction of muscle hypoxia, thereby possibly alleviating an important training 
stimulus (Sundberg et al,  1993). However one may have expected the higher training 
intensities achievable to be beneficial to the rehabilitation outcomes (Casaburi et al,  1991). 
This has been tested more latterly in a double blind placebo controlled trial of oxygen therapy 
in non hypoxemic patients undergoing exercise training (Emtner et al,  2003). Significant 
increases in the training intensities achieved were demonstrable in the oxygen administered 
group. Subsequent improvements in exercise capacity and breathing rate were evident.
1.3.1.7 Comprehensive rehabilitation
It is usual for additional components to be incorporated into the rehabilitation programme 
structure for COPD. These often include disease education, psychological counselling, 
dietary advice and social support. Although these aspects of rehabilitation are standard, the 
accepted benefits in dyspnoea and quality of life have not been shown to occur with 
programmes lacking in exercise training (Benzo et al, 2000; Devine & Pearcy, 1996; 
Ketelaars et al, 1996; Sassi-Dambron et al, 1995). This leaves an uncertain role for these 
ancillaiy aspects of rehabilitation programmes.
1.3.1.8 Conclusion
Standard pulmonary rehabilitation programmes aimed at patients limited symptomatically by 
their COPD have been shown to have benefits that will last at least one year following 
rehabilitation (Troosters et al, 2000; Guell et al, 2000; Griffiths et al,  2000). These long­
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term benefits include significantly increased walking endurance, sustained improvements in 
health status and decreased total hospital inpatient days. Whether there may be a 
demonstrable survival benefit has yet to be established.
The evidence base for this approach to chronic lung disease has demonstrated pulmonary 
rehabilitation to be most effective when compared to programmes of exercise training 
employed in other clironic diseases. The type of patients enrolled in pulmonary rehabilitation 
are typically debilitated and more severely affected by their illness than patients in 
comparative cardiac schemes (Reardon et al, 1995). And while there is evidence that 
pulmonary rehabilitation programmes are cost effective, pulmonary rehabilitation is 
unfortunately significantly less well resourced than equivalent schemes in other disease states 
(Scherer & Schmieder, 1998; Reina-Rosenbaimi et al, 1997; Parish et al, 1995).
1.3.2 Dietary
It is an appealing proposition to combine rehabilitation with other strategies to improve well­
being in COPD. The structured nature of the standard pulmonary rehabilitation enables the 
compliance and efficacy of any additional intervention to be assessed more easily. A number 
of investigators have utilised such approaches when trying to optimise rehabilitation 
outcomes.
As previously described, anorexia, cachexia, sarcopaenia and skeletal muscle dysfunction are 
crucial problems associated with severe COPD. A number of studies have attempted to 
counter these problems with nutritional supplementation. A recent meta-analysis of these 
approaches concluded that it was not easy to demonstrate success in gaining weight or muscle 
mass in these patients (Ferreira et al, 2000a). Attempts to increase body weight through 
outpatient nutritional intervention proved difficult to demonstrate increases in FFM and did 
not impact upon exercise tolerance (Efthimiou et al, 1988; Sridhar et a l,  1994). Although 
dietary changes may be able to alter morbidity in COPD patients, it is generally thought that 
the difficulty in achieving such positive outcomes will preclude recommendation of such 
approaches (Braun et a l,  1984). Nevertheless, there are data suggesting some benefit in these 
approaches. Nutritional supplementation is proven in aiding weaning of patients with 
respiratory failure from mechanical ventilation (Bassili & Deitel, 1981). An inpatient 
programme has proven to be more successful; leading to increased muscle mass, strength and 
exercise tolerance, albeit requiring a three month intervention period (Rogers et a l , 1992).
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1.3.2 Hormonal
There is demonstrated deficiency of certain hormones in patients with COPD (Casaburi,
1998). Some of these, such as insulin like growth factor-1 (IGF-1) and testosterone, have 
established anabolic influences in healthy subjects. These hormones, when administered to 
healthy people, lead to skeletal muscle changes; randomised controlled trials of testosterone 
injections have demonstrated increased lean body mass and improved muscle strength (Giorgi 
et al, 1999; Bhasin et al, 1996). In COPD, the effects of rehabilitation on skeletal muscle are 
wide ranging, but without strength training appreciable muscle fibre hypertrophy does not 
occur. There is therefore a rationale for using anabolic steroids in chronic lung disease 
(Creutzberg & Schols, 1999). In placebo controlled, randomised trials, nandrolone and 
stanozolol, have been demonstrated to increase fat free mass (Schols et a l,  1995a; Creutzberg 
et al, 2003; Ferreira et al, 1998a). Nandrolone led to a comparatively higher fat free mass 
compared to the control group, with both groups being administered dietary intervention. 
Respiratory muscle strength was significantly improved in the group receiving the anabolic 
steroids. Unfortunately there is no clear benefit with respect to endurance capacity or health 
status. As with anabolic steroid administration in athletes, there is concern as to the safety of 
such interventions (Bagatell & Bremner, 1996).
Growth hormone administration is a strategy that has been tried in health, cachexial diseases 
such as AIDS and in COPD patients. In the only placebo controlled study and in combination 
with exercise training, growth hormone has been shown to lead to comparatively higher 
increases in fat free mass and resting energy expenditure, with no demonstrable translation 
into improved muscle strength or exercise capacity (Burdet et al, 1997).
1.3.4 Pharmacological
Several authors have shown that increased exercise capacity after bronchodilator correlates 
closely with less dynamic hyperinflation (DH) and breathlessness, especially during 
endurance exercise: these studies used salbutamol (Belman et al, 1996), salmeterol 
(O'Donnell et al., 2004b) and anticholinergics (O'Donnell et al,  1999; O'Doimell et al, 
2004a). However the more fundamental question of whether these inhaled medications are 
able to alter exercise capacity remains largely unanswered. A meta-analysis of bronchodilator 
therapies in relation to exercise capacity concluded that there was insufficient evidence to 
show benefit from these strategies (Liesker et al, 2002b). However they did specifically
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indicate that theie is a lack of published data utilising more sensitive indices of exercise 
tolerance, such as constant load cycle ergometry. Despite this, there is evidence through 
landomised controlled trial that in comparison to placebo, agents such as ipratropium can 
impact upon exercise capacity (Liesker et al., 2002a).
1.4 Summary
COPD is a common condition with a major global impact upon health. Exercise intolerance is 
one of the most important manifestations of this disease. The aetiology of this is 
multifactorial and relates to lung function abnormalities, which can be static and dynamic in 
nature. The systemic effects of COPD also play an important role in the causation of exercise 
impairment. Strategies to improve exercise tolerance have targeted either the skeletal muscle 
through hormonal, dietary and physical means or by altering lung function through the use of 
pharmacological agents.
The first study in this thesis addresses evaluation of fat free mass estimation and its 
subsequent clinical relevance. The second study investigates the utility of creatine 
supplementation in COPD. The third study examines the effects seen of a long acting 
bronchodilator upon dynamic hyperinflation and exercise capacity.
This work represents investigations of novel assessments and interventions in COPD patients 
in relation to the diminished exercise capacity that they present.
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CHAPTER 2 
GENERAL METHODS
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2.1 Subjects
All patients taking pai't in the investigations detailed in this thesis had an established clinical 
and functional diagnosis of moderate-to-severe COPD (FEVi < 60% predicted and 
FEVi/FVC ratio < 70%) (1995). Patients were recruited from the Pulmonary Rehabilitation 
Assessment Clinic at the Department of Respiratory Medicine, Glasgow Royal Infirmary. 
Inclusion ciiteiia were absence of locomotor or neurological diseases, and no change in 
medication dosage or exacerbation of symptoms requiring oral prednisolone or antibiotics in 
the preceding 4 weeks. All patients were optimised in terms of standard medical therapy: 
maintenance medication included pz-agonists, anticholinergics, theophylline or inhaled 
steroids.
Fully informed wiitten consent was obtained in all patients for each study. The Research 
Ethics committee of the Glasgow Royal Infirmary approved all the studies.
The following details the standard protocols of the procedures performed during the 
investigations described in chapters 3 to 5.
2.2 Procedures
2.2.1 Pulmonary function
2.2.1.1 Spirometry
Spirometry usually involves the performance of maximal inspiratoiy, then exhalatory 
manoeuvres tlnough a pneumotach. The vohune exhaled in the first second is known as the 
forced expiratory volume (FEY]), with the total volume of air exhaled known as the forced 
vital capacity (FVC). The FEVi and ratio of FEVi/FVC are reduced in COPD. These 
procedures are essential for the diagnosis of COPD, and FEVi remains a strong independent 
predictor of mortality, but they have less clear longitudinal value due to their weak 
relationship to most disease outcome measures (Fletcher & Peto, 1977; Hodgkin, 1990; 
Anthonisen et al., 1986; Corris, 1995). Flow volume curves have a characteristic shape in 
COPD, representing the reduced maximal flow rates in comparison to lung volume and a 
“scooped-out” appearance due to airways collapse following the peak flow rates.
Standard spirometry was measured in our studies using the flow-volume module of a constant 
volume body plethysmograph (V6200 Autobox, SensorMedics Corporation, California 
USA). Flow measurements were carried out using a calibrated pneumotach. Patients
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completed at least tliree acceptable maximal forced and “slow” expiratory manoeuvres. The 
following spirometric variables were recorded and expressed as BTPS values: Forced Vital 
Capacity (FVC), Forced Expiratory Volume in the second (FEVi) (/), Inspiratory Capacity 
(IC). Spirometric tests were performed before and 20 min after 400 pg of inhaled salbutamol: 
an FEVi increase equal to or higher than 12% or 200 ml of control considered a positive 
response to the bronchodilator.
2.2.1.2 Plethysmography
Body plethysmography enables total gas volume within the lung (including gas trapped 
behind closed airways) to be quantified. It utilises Boyle’s law which states that 
volume*pressure is constant for a gas at constant temperature. Subjects performing 
respiratory efforts against closed shutters, in a sealed container, enable total lung volume 
inferences to be made from small lung volume and pressure changes.
2.2.1.3 Lung Diffusion Capacity for Carbon Monoxide (D L c o )
Lung diffusing capacity (DLCO) represents a measine of the combined properties of area, 
thickness and diffusion of the lung and relevant gas (Ki'ogh, 1914; Wagner, 1977). Carbon 
monoxide is used most commonly as its transfer across the alveolar membrane is limited 
solely by diffusion, with blood flow having no influence. As there is a negligible amount of 
carbon monoxide in capillary blood, the DLCO can be derived solely from the volume of 
carbon monoxide transferred.
DLco was measured by the modified Krogh technique (single-breath, SB) using a computer- 
based automated system (Vmax29 System™ , SensorMedics Corp.) (Gardner el al, 1988). 
The procedure was explained to the patients and demonstrated by a designated technician 
prior to testing. The patients did wear noseclips and were in the seated position. After 
exhaling to RV, patients inspired a vital capacity breath of a pre-mixed gas mixture (0.3% 
carbon monoxide, 10% helium, 21% O2 , balance Nz) from the system to TLC, and then held 
their breath for 10 seconds. Patients then exhaled a fixed washout volume (750 ml), and a 
sample of alveolar gas (500 ml) was taken for analysis using a inultiple-gas cinematographic 
analyzer. DLco was then calculated as:
DLco (ml CO/min/mmHg STPD) = VCO/PACO-FcCO
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where VCO is the pulmonary uptake of carbon monoxide (CO) {ml STPD), PACO is the 
mean alveolar CO partial pressure (mmHg), and PcCO is the mean pulmonary capillary CO 
partial pressure {mmHg) - assumed to be negligible (i.e. the affinity of Hb for CO is high, and 
carboxyhaemoglobin levels are very low). Computation of VCO and PACO were obtained 
from measurements taken across the breath-hold and an independent measurement of alveolar 
volume (VA) by the single-breath He dilution teclmique (Gardner et al, 1988; Cotes et al, 
1993).
The following additional teclmical aspects were standardised (Gardner et al,  1988; Cotes et 
al, 1993); inspired volume higher than 90% of VC and attained in less than 2.5 seconds; 
timing from the beginning of inspiration to the begiiming of alveolar sample, and both 
Mueller and Valsalva manoeuvres were avoided by instructing the patients to perform a 
relaxed breath-holding manoeuvre. At least two tests were performed, with the results being 
within 10% or 3 ml CO/min/mmHg STPD, whichever is greater.
2.2.1.4 Maximal Respiratory Pressures
Maximal inspiratory pressure (MIP) followed by maximal expiratory pressure (MEP) were 
obtained from RV and TLC, with the patients seated with a nose clip and a rigid, plastic 
flanged mouthpiece in place. The patients were coimected to an electronic shutter apparatus 
(Sensor Medics Corp.; measurement range: ± 300 cm HzO). A small leak was introduced 
between the occlusion and the mouth in order to prevent glottic closure; in addition, the 
patients supported their cheeks with one hand during the manoeuvre. Inspiratory or expiratory 
effort was sustained for at least one second. The measurements were undertaken by two 
designated teclmicians who explained and demonstrated the correct manoeuvre. The patients 
performed three to five acceptable and reproducible maximal manoeuvres (i.e. differences 
between values within 10%): the recorded value being the highest unless this is obtained from 
the last effort (Celli, 1989). An interval of about one minute will be interposed between 
efforts.
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2.2.2 Body composition
Background
Weight loss and particularly sarcopenia are independent predictors of mortality in COPD 
patients (Schols et a l,  1998a; Marquis et al, 2002). A most simple and essential longitudinal 
measurement in COPD is that of body mass. BMI represents a useful indicator of 
performance status. However measurements that quantify muscle bulk are more accurate 
predictors and when quantifying nutritional status it is essential to take into account loss of 
body tissue other than body fat (Baarends et al,  1997b). This is because subjects may be 
overweight yet have skeletal muscle loss in association with preserved body fat (Schols et al, 
1993a). Also FFM has been demonstrated to be a better predictor of exercise capacity than 
body mass (Schols et al,  1991a). The relationship between tissue fat and fat free mass loss is 
weak enough to mean that a measure that solely examines fat loss will miss some patients 
with fat free mass decline (Schols et al,  1993a). Such loss is poorly represented by measures, 
which normally are utilised in the representation of obesity, such as waist/hip ratio or body 
mass index (Laaban et a l,  1993). Therefore one should incorporate assessments that quantify 
percentage body fat-ffee mass, allowing a relationship to body weight to be determined. One 
such measure is the fat free mass index; a directly relevant measure of body composition in 
those with cachexia.
Underwater weighing
The gold standard method of body composition evaluation is by underwater weighing, where 
the difference between weights in and out of water is used to estimate the proportions of lean 
and fat mass. The method uses the Archimedes principle and is reliant upon accurate 
estimation, or preferably measurement of the residual volume of the lungs.
DEXA scanning
DEXA scamiing utilises the principle of alteration of an X-ray beam by the tissue as it passes 
tlirough, more specifically, the mass attenuation coefficient of the absorber. Homogenous 
absorbers such as water or bone have specific mass attenuation coefficient which in 
conjunction with Icnown X-ray emissions, allow mass of substance per unit area to be 
calculated. DEXA scanning is designed to evaluate body composition using tliree 
components: fat mass, lean body tissue and bone mineral mass. Its dual emission method at 
any one time can differentiate proportions of lean and fat mass in soft tissue, and proportions
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of soft tissue and bone in areas where both are present. This is calculated from the Icnown R- 
values for the differing tissues and allows estimation of whole body proportion by 
extrapolating one region’s behaviour to another’s.
Bio Electrical Impedance
Bio Electrical Impedance (BIE) is based on the use of the differing resistances of body tissue 
to electrical current. In particular, tissue such as fat is Icnown to have high resistance (or low 
impedance) due to its low water content, and vice versa for muscle. Factors which can alter 
the body’s impedance include hydration status, tissue orientation and water distribution. It 
has been demonstrated that patients with COPD can have a selective loss of intracellular 
water compartments(Telfer et al, 1968; Baarends et al, 1997c). Despite this there are 
validated prediction equations for the use of BIE in COPD (Schols et al, 1991b). Therefore 
this technique requires standardisation of hydration status and positioning within and between 
subjects. It allows derivation of level of total body water using prediction equations and 
resistance values, from which fat free mass may be estimated.
It has recently been demonstrated that thigh muscle cross sectional area is a stronger 
independent predictor of mortality than BMI or even FEVi (Marquis et al,  2002). This 
highlights the appropriateness of evaluating body composition over and above weight, the 
exact method which is most appropriate being of considerable controversy (Schols et al, 
1991b; Steiner et al, 2002; Kilduff et al, 2002a).
Procedures
All body composition measurements (ANTHRO, BIE, ADP) were performed on a single day 
by the same investigator. Height was measured (to the nearest 1 cm) using a stadiometer, with 
subjects standing barefoot. Body mass was assessed (to the nearest 0.1 kg) with subjects 
wearing only a swimsuit. Skinfold thickness was measured on the right side at appropriately 
marked sites (to the nearest 0.1 mm) using a Harpenden calliper (British Indicators Ltd, St 
Albans, UK).
2.2.2.1 Anthropometry
Skinfold thickness was assessed at the triceps, biceps, iliac crest and subscapular sites, 
according to the standardised anatomic locations and methods reported by Durnin and
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Wormersley (Dumin & Womersley, 1969). A minimum of three skinfold measurements were 
performed at each location, with a difference o f no greater than 2 mm allowed between 
acceptable measures; the recorded values were the average o f these measurements. The 
appropriate anthropometric and demographic data (sum o f four skinfolds, age, sex) were 
entered into Durnin and Womersley’s regression equation to determine body density (Db) 
(Dumin & Womersley, 1969). Total body fat and FFMANTHRO were calculated from Db, 
using Siri’s equation (Siri, 1961).
2.2.2.2 Bioelectrical Impedance
Bioelectrical Impedance (BIE). Measurement o f FFM by bioelectrical impedance (FFMBIE) 
(Bodystat-5000, Bodystat Ltd, Douglas, UK) was performed on the right side, with subject’s 
supine, and with their limbs slightly apart from the trunk (Figure 2.1).
Figure 2.1 Positioning o f patient for measurement o f BIA.
After the skin had been cleaned with 70% alcohol, two injector electrodes were placed on the 
dorsal surface o f the right hand and foot, and two detector electrodes were placed between the 
radius and ulna and on the ankle between the medial and lateral malleoli. The impedance to 
current flow (50 kHz) between the injector and detector electrodes was determined. Two 
methods for estimating FFM were initially used (see Results):
(i) a patient-specific prediction equation based on resistance (R), body mass (BM), height (H) 
and sex (S, males=l and females= 0) (Kyle et a l ,  1998):
FFM (kg)= -6.06 + (H X 0.283) + (BM x 0.207) -  (R x 0.024) + (S x 4.036) (eq. 1) and
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(ii) a general population prediction equation based on the same covariates and age (A) 
(Deurenberg e ta l ,  1991):
FFM (kg)- -12.44 + (H2/Rx 0.34) + (H x 0.1534 + (BM x 0.186) - ( A x  0.127) + (S x 4.56)
(eq. 2)
This patient specific formulation has been shown to provide the best estimate of FFM in 
COPD subjects amongst the general prediction equations available for FFM estimation 
(Pichard et al,  1997). The patient specific equation examined 75 adult patients with stable 
COPD and was developed to match DEXA body composition evaluations.
2.2.2.3 Air displacement plethysmography
The principles of measurement of FFM by air displacement plethysmography (ADP) have 
been explained in detail elsewhere (Dempster & Aitkens, 1995). Briefly, when a subject sits 
inside an enclosed chamber of fixed volume, a volume of air equal to his or her body volume 
is displaced. Since, under adiabatic conditions, changes in gas volume are inversely related to 
pressure raised to the power 1.4 (Poisson’s law) (Daniels & Alberty, 1967), the magnitude of 
pressure variations relative to those for a reference chamber provide the actual air volume 
displaced by the body.
Initially, a standard two-point volume calibration (0 L, 50 L) of the air-displacement 
plethysmograph (BOD POD®, Life Measurement, Inc, Concord, CA, USA) was performed, 
according to the manufacturer’s instructions. The patients (wearing minimal clothing and a 
swim cap) then entered the chamber (volume -  450 1) and sat quietly with an erect posture, 
breathing normally with hands folded in their laps and feet placed on the floor (illustrated in 
Figure 2.2).
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Figure 2.2 Subject sitting prior to ADP measurement.
Their uncorrected body volume (Vbuncorr) was then measured, over a 50-second period. A 
minimum of two tests were conducted: when two consecutive measurements o f Vbuncorr 
were within 0.2% or 150 ml (whichever was the larger), the results were averaged. The 
corrected Vb (Vbcorr) was then calculated, taking into account the confounding effect of 
isothermal air near the skin surface (surface area artefact, SAA) and the intrathoracic gas 
volume (VTG) (Dempster & Aitkens, 1995):
Vbcorr (1) = Vbuncorr (1) - SAA (1) + 40% VTG (1)
Two methods for estimating VTG were used: (i) employing the standard values provided in 
the system software, and (ii) employing the individual subject values measured by body 
plethysmography (see Results). Db was then calculated as body mass/Vb, and % FFM was 
estimated from Siri’s equation (Siri, 1961).
2.2.3 Skeletal muscle function
All tests o f maximal exercise capacity were carried out on separate testing days, with at least 
48 hours rest in-between.
Background
Measures o f skeletal muscle function are usually performed as part o f research programmes. 
These could include examination o f the histological, biochemical and metabolic features o f  
the COPD skeletal muscle by muscle biopsies or magnetic resonance spectroscopy scanning. 
These techniques are cumbersome, expensive and require considerable expertise. 
Examination o f form or function o f skeletal muscle has been generally thought to be non
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essential in clinical practice. However the GOLD guidelines do suggest that a measure of 
peripheral musele function is incorporated into the assessment of patients with COPD who 
imdergo rehabilitation (Pauwels et al,  2001). This is due to the realisation that rehabilitation 
impacts significantly upon peripheral muscle strength, and particularly can do so even in 
severely affected patients through innovative strategies (Bernard et al,  1999a; Neder et al, 
2001a). This is usually through examination of the lower limb, paiticulaiiy the quadriceps 
muscle. A measure of isometric force is the easiest to obtain, either electronically or 
mechanically, through dynamometry. In the mechanical forms of testing there is usually a 
steel spring that is compressed, thereby moving a pointer. These mechanical rrreans of 
measurement are reliable and can be related to reference values (Mathiowetz et al, 1985; 
Aniansson et al,  1980). Although there is an established relationship between lower and 
upper skeletal muscle strength there is known to be a relative preservation of upper body limb 
musculature (Ringbaek, 2001). Therefore it is not generally accepted that singular' upper limb 
evaluation is appropriate, despite it being a much more easily evaluated entity.
Peripheral muscle performance is reproducible and may be compared to reference values; 
however it is reliant on adequate effort from the subject. Testing through the use of magnetic 
or electrically superimposed twitch contractions removes this variable, but is less practical in 
a routine setting (Allen et al, 1995).
Procedures
2.2.3.1 Lower limb
Peripheral muscle testing occurred on the same day and followed body composition 
measurement. Lower-limb muscle performance was measured using a Kin-Com II isokinetic 
dynamometer (Chattecx Corporation, Chattanooga, USA). Each patient’s position on the 
dynamometer was standardised by having (a) the anatomical axis of the knee joint aligned 
with the rotational axis of the dynamometer (by adjusting the seat position and the lever head 
of the dynamometer) and (b) seat length and height individualised for each patient; these 
settings were retained for all subsequent tests. Patients were maintained in the seated position 
by Velcro belts around the waist, thigh and lower leg proximal to the anlde; this also allowed 
for complete isolation of the leg being tested (i.e. the dominant leg). During the 
measurements, patients kept their arms crossed over the chest, with the non-involved leg and 
upper body being kept stationary. The same investigator conducted all tests.
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Following a standardised warm-up on the dynamometer, quadriceps muscle strength was 
measured as the isokinetic peak torque. Patients were instructed to exert maximal effort 
tlu'oughout the full range of motion during each repetition. Verbal encouragement was given 
to maximise performance. Five consecutive maximal isokinetic concentric contractions were
performed at a speed of 70 °'sec'\ with a 30-second rest period between repetition. After a 5- 
minute recovery period, quadriceps muscle endurance was measured as the cumulative work 
over five sets of 15 repetitions at a speed of 150 °-sec'\ Patients were given a two-minute rest 
period between sets (Greenliaff et al., 1994a).
2.2.3.% Upper limb
Following a further 10-minute rest, upper-limb strength and endurance were measured on the 
dominant and non-dominant hands (the dominant hand was always tested first), using a 
handgrip dynamometer (Grip-A, Takei Scientific Instruments Co., Niigta, Japan). The same 
investigator conducted all tests. Following a handgrip-specific warm-up, handgrip strength 
was measured from five consecutive maximal voluntary isometric contractions, with a 30- 
second rest between each contraction. Handgrip endurance was then measured as the number 
of contractions that a patient could complete to the point of fatigue in each of three 
consecutive sets, with two-minutes rest between each set; intensity was set at 70% of the 
individual pre-determined one-repetition maximum. Fatigue was defined as the failure to 
exert the required intensity for three consecutive eontractions. Verbal encouragement was 
given throughout to maximise performance and to counteract potential boredom.
2.2.4 Exercise capacity
2.2.4.1 Field tests
Background
Evaluation of exercise capabilities most commonly involves lower limb exercise. This is seen 
to be the most appropriate form due to its direct relevance to day-to-day activities such as 
walking. Also use of the lower limb musculature usually sufficiently stresses the 
cardiovascular and respiratory systems for evaluation of their function.
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Walking tests were developed as a means of performing evaluations of exercise capacity in a 
simplified inexpensive setting, while remaining reproducible and meaningful. In 1970 a 
twelve minute test of exercise capacity in healthy young men was described by Cooper. It 
was demonstrated that distance ran correlated to maximum oxygen uptake on a treadmill. 
This was first extrapolated to assessment in COPD in 1976 by McGavin and co-workers 
(McGavin et al, 1976). Subjects (35 for reproducibility testing, 29 in conjunction with 
incremental cyele ergometry) attempted to cover as much ground as possible over 12 minutes 
on a flat corridor. It was established that there was a significant learning effect between 
and 2"  ^ bouts but not subsequently. Weak correlations between peak oxygen uptake and 
walking distance were found. In 1985 Guyatt et al demonstrated the feasibility of a shorter 6- 
minute walking test (Guyatt et al,  1985). However the same limitations of learning effect 
between and 2"  ^bout, and importance of standardising motivational factors was evident. A 
close relationship between the 6 and 12 minute walking tests was later established (Butland et 
al,  1982). Reference values have been published for the six minute walking distance and are 
predicted on the basis of age, weight, sex and height (Enright & Sherrill, 1998; Gibbons et 
al,  2001). In order to address the problem of variability of faetors such as motivation and 
judgement of walking speed, to performance on a walking test, Singh et al. developed the 
incremental shuttle walking test (ISWT) (Singh et al,  1992). Subjects aie asked to walk 
consecutive 10 metre distances, with the pace increasing gradually each minute. Thereby the 
test becomes an evaluation of peak ability rather than that of endurance. As with other 
walking tests there is a published correlation of distance walked to peak oxygen uptake and 
the same awareness of learning effects are necessary. Recently, through direct comparison 
using portable exhaled gas analysis, it has been demonstrated that the ISWT represents a 
more close approximation of maximal oxygen uptake than the 6 minute walking test (Onorati 
et al., 2003). This ISWT has been modified to test endurance capacity (the endurance shuttle 
walk test/ESWT) in order that it may more sensitively detect improvements following 
intervention (Revill et al,  1999). This test requires the subject to perform repeated shuttles 
(in an identical fashion to the ISWT) at a pace set at 85% of the maximal speed achieved on 
the ISWT. This is utilising the likelihood that this value will be close to, but above, the 
critical power for that activity (Neder et al., 2000). Therefore the walking pace will be non 
sustainable at baseline, but may be potentially completed (stopped in the case of the ESWT at 
20 minutes) after an intervention which affects exercise capacity or critical power.
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The walking tests described all share the same disadvantages; a marked learning effect and 
the influence of external factors such as corridor traffic! Also these tests do not include 
detailed physiological measurements.
It is on that basis that laboratory based cardio pulmonary evaluations of exercise capacity 
remain the gold standard.
Procedure
Incremental and endurance shuttle walking tests (ISWT and ESWT respectively) were 
performed according to standardised protocols (Singh et al,  1992; Revill et al,  1999). This 
included the use of practice shuttle walking tests. This was to familiarise the patient with the 
teclinique, and prevent any learning effect by the time it came to performing the second 
incremental walk. All shuttle walking tests were earned out under the supervision of the 
Glasgow Royal Infirmary physiotherapy department. The shuttle walking tests involve the 
patient walking for 10 metres around two markers, 9.5 m apart. Each 10 m walked represents 
one shuttle. In the incremental shuttle walking tests, each patient started off at three shuttles 
per minute. This was increased by a further shuttle every minute, indicated by a bleep on an 
audio cassette, until the exercise became symptom limited. In the endurance shuttle walk test, 
which also takes place over the 10 m course, the speed was determined at 85% of the 
maximum in the incremental test, using figure 2.3 below. This level of work was calculated 
from the predicted maximum oxygen uptake requirement judged by the ISWT. The 
regression equation used to calculate this value, predicted maximum VO2 in ml/kg/min was 
4.19 + (0.025 * distance) (Singh et al, 1994). In this test the patient carried on walking at the 
determined level until they could no longer continue.
/
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Figure 2.3 Oxygen uptake prediction 
/ '  during the ISWT and ESWT walking
speed.
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2.2.4.2 Incremental CPET
Background
Exercise testing in conjunction with breath-by-breath analysis of respired gases has allowed 
non-invasive determination of a number of physiological parameters. Ramp incremental 
exercise evaluation was developed as a rapid means of assessing a number of clinically 
meaningful exercise parameters in a single standardised test (Whipp et al,  1981). In a ramp 
test there is a continuous alteration in the work rate, whereas an incremental test has fixed 
increases at set timepoints. The four aerobic parameters of interest that may be determined 
are: maximum oxygen uptake, lactate thioshold, work efficiency and time constant of oxygen 
uptake. However further interpretation of information obtained during the ramp test can help 
with diagnosis and evaluation of patient groups. For example, there are relationships of 
interest such as those of heart rate or carbon dioxide output with oxygen uptake.
A ramp test involves asking subjects to exercise to the limit of their tolerance. This represents 
a “peak” achieved work rate (or oxygen uptake), but not necessarily the absolute maximum, 
as that is influenced by a number of subject (dyspnoea, leg discomfort) and protocol (ramp 
increment rate, exereise modality) related factors. Investigators commonly use either cycle 
ergometry or treadmill exercise modalities. Although treadmill exercise utilises a higher 
muscle mass, and therefore can produce higher oxygen uptake values, there are a number of 
reasons why cycle ergometry is a more commonly preferred modality (Hansen, 1984). The 
unloaded pedalling work rate relates largely to leg mass, and remains an essentially constant 
factor tlu'oughout a changing test (i.e. leg VO2 = leg mass * rpm). The seated subject is at less 
risk of self-injury. The electromechanically braked versions allow a very accurate 
determination of the actual work rate performed, as the workload is independent of pedalling 
frequency.
A standardised exercise test usually takes the following form: rest, 3 or more minutes of 
unloaded pedalling, incremental exercise and recovery. The incremental exercise portion 
should be gauged to last between 8 and 12 minutes and may take the form of a stepwise work 
rate progression to a linear ramp increase. This length of time gives the most appropriate data 
density for interpretation of the findings (Buchfuhi’er et al,  1983). Appropriate work rate 
increments range from 30 watts per minute in athletes to 5 watts per minute in many patients 
with clu'onic lung disease. Too high slopes of increment can cause the appearance of a 
“pseudo tlireshold” for lactic acid (Ozcelik et al,  1999), too low and subjects may lose 
volition to complete the exercise. A “pseudo tlueshold” can also arise through
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hyperventilation, which prior to a test directly reduces the body’s stored CO2 content, and 
then results in an initially lower slope of theVC02-V02 relationship. The CO2 stores are then 
refilled and when the deficit in stored CO2 is overcome there is subsequently an acceleration 
in VCO2 . This acceleration in VCO2 appears similar to 0 l although at a lower VO2 than 
normally expected.
Appropriate output of the variables allows inferences of the responses of the whole body to 
exercise. Some major parameters have an established role in evaluation and diagnosis. These 
ai'e briefly summarised below and are deseribed in detail in the established texts of exercise 
testing performance, normality and interpretation (Wasserman et al,  1999; Jones, 1975; 
Gallagher, 1990; Roca & Whipp, 1997). More latterly it has been proposed to examine the 
normalcy of relationships over exercise increments, rather than solely examining the peak 
values (Neder et al,  2001c).
VO? -W R relationship
This is largely a consistent value, whether relating to step increments of work rate or 
continuously changing ramp increments and it is normally 9-11 ml/min/Watt in health during 
cycle ergometry (Hansen et al,  1984; Riley et al,  1996). It is generally lower in cardio 
respiratory disease, which may be due to different rates of change of oxygen uptake with 
different work rates or a higher reliance on anaerobic metabolism (Koike et al,  1992). Also 
the slope of oxygen uptake vs. work rate becomes shallower above the lactate tlireshold due 
to the development of the slow phase of oxygen uptake kinetics, but this is not thought to 
have clinical significance due to the small changes seen (Hansen et al,  1988).
Maximum VOi
This is apparent when oxygen uptake plateaus despite increasing work rate. This is rarely 
achieved in clinical setting as subjects tend to stop exercising before this true maximum. 
Therefore a peak” oxygen uptake is only defined as the maximum one if stringent criteria 
are met. However, despite this distinction, the reproducibility of peak oxygen uptake has 
consistently been found to be within 5% (Brown et al,  1985; Cox et al,  1989; Killian et al,  
1992; Marciniuk et al,  1993).
VCO2-VO9 relationship
This slope is influenced at baseline by substrate use and its gradient is altered during exercise 
by the occurrence of the lactate thi'eshold. The lactate tlueshold occurs at the time of lactate 
produetion from the exercising muscles and consequent hydrogen ion release, which causes 
CO2 production due to the bicarbonate buffering of these hydrogen ions. This point has been
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validated as representative of the lactate threshold within COPD patients (Griffiths et al, 
1996;Sue eta l ,  1988).
Vr-VCOo relationship
Tight regulation of acid-base balance is achieved tlirough precise control of ventilation 
(Whipp & Ward, 1998; Ward, 2000; Jones, 1975). Therefore there is close coupling of Ve to 
VCO2 . The expected linear response of VCO2 is modified by the varying influence of lung 
dead space (V d) during differing levels of ventilation. Physiological dead space may be 
increased through altered patterns of breathing (e.g. shallow rapid breaths) as well as lung 
pathology (particularly the dynamic hyperinflation of COPD). The slope of the Ve“V’C02 
ratio is thereby influenced solely by PaC02 and VdWt. Therefore increases in the values of 
Ve/VC02 at a given VCO2 point toward, for example, impaired gas exchange, metabolic 
derangements or increased dead space ventilation. This slope remains linear tluough a ramp 
test until which time a respiratory compensation point is reached, where Ve rises to provide 
buffering of the acidosis occurring. The relationship is linear through the passing of the 
anabolic tlueshold.
Peak exercise variables
In their most simplistic form peak exercise variables can be compared to the expected 
maximal values to allow identification of which major systems are being stressed. Maximal 
predicted HR is crudely calculated by 220 minus age in years, with the actual value being 
rather variable in individuals. Maximum achievable ventilation is commonly measured in one 
of 2 ways -  either forced voluntary maximal respiration over one minute tluough a 
pneumotaehograph, or by multiplying the FEVi by a constant (usually 35 or 40). These 
approaches allow an estimation of whether subjects stop exercise with a reduced “breathing 
reserve” or cardiovascular capacity, thereby indicating potential system disease.
Procedure
Exercise testing was performed using an electomagnetically braked cycle ergometer (Corival) 
with gas exchange variables analysed breath-by-breath using a software based system (MGC- 
CPX System, Medgraphics Copr. (MGC), St Paul, MN, USA) following calibration of flow 
and gas level detection. The equipment used is illustrated below in Figure 2.4.
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Figure 2.4 Cardiopulmonary exercise testing equipment.
Calibration is with a precision three-litre syringe where the flow ranges extend beyond those 
seen during exercise. Patients had a nose clip and customised mouthpiece (MGC) in place. 
Respired flow is measured continuously by a rapid response flow module (MGC) enabling 
ventilation to be measured. A sampling line continuously draws a small amount o f respired 
gases from the mouthpiece to be analysed rapidly for O2 and CO2 concentrations. Cardiac 
monitoring by means o f a 12 lead ECG was also performed.
To begin each test, subjects sat quietly at rest on the ergometer for a period o f ~3 minutes. 
This allowed them to become accustomed to breathing through the mouthpiece as, despite 
thorough familiarisation, there can be a tendency to hyperventilate on insertion o f the 
mouthpiece. This period o f rest was essential to monitor the subject’s breathing to ensure that 
they were not hyperventilating, or had not been in the period immediately prior to 
monitoring. For non-invasive estimation o f the lactate threshold, it is critical that the subject 
does not hyperventilate prior to the test commencing, as this can predispose to a false positive 
or “pseudo” threshold as described previously (Ozcelik et al, 1999; Whipp et al, 1987; Ward 
and Whipp, 1992).
The incremental exercise test consisted of: (i) 3 minutes at rest; (ii) 3 minutes at unloaded 
pedalling (approximately equivalent to 20 W); (iii) the incremental phase; and (iv) a 5 minute 
recovery period. The power (W) was increased each minute o f the incremental phase by 
between 5 and 10 W, dependent on the performance o f the patient during the field tests: the 
aim being to have an incremental phase o f more than 8 and less than 12 minutes.
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The modified Borg category scale was used to rate the perceived intensity of breathlessness 
and leg fatigue during rest, unloaded pedling, at the end of exercise and at 2 and 5 minutes 
recovery (Illustrated in Table 2.1) (Borg, 1982). Simple verbal expressions were linked to 
numbers from 0 to 10, zero being no appreciable breathlessness or leg fatigue and 10 being 
the maximum. Full explanations were given prior to the test and the scale was shown to the 
patient at the end of exercise testing. Care was taken to instruct the patients to rate only the 
breathing effort or leg effort and no other sensation during exercise.
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The scale runs from 0 to 10, 0 being equivalent to "Nothing at all" with 10 being equivalent 
to "Maximal". The word anchors for the scale are reproduced below:
0 Nothing at all
0.5 very, very weak (just noticeable)
1 very weak
2 Weak (light)
3 Moderate
4 Somewhat Strong
5 Strong (heavy)
6
7 Very strong
8
9 Very, very strong (almost max)
10 Maximal
Table 2.1 The modified Borg scale
The modified Borg scale is a ratio scale i.e. a doubling of the numeric value indicates a 
doubling of the perceived breathlessness or leg effort. The scale is designed to be easy to be 
used by a lay population.
The computation of ventilation and pulmonary gas exchange was performed online, breath- 
by-breath, using the algoritluns of Beaver et al (Beaver et al,  1973). These algorithms 
calculate pulmonary gas exchange over the duration of a single breath. The basic concept is 
the same as for gas collection methods (e.g. Douglas bags), whereby the continuously- 
measured expired flow is divided into consecutive temporal samples at the same frequency 
the gas concentrations are being analysed (Wasserman et al,  1999). Therefore, in the limit, 
the volume of gas expired over a given period (T) is given by:
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T
Ve = / Vdotexp(t)dt
t= 0
where Vexp is the expired flow during an infinitesimaiiy short time interval dt, and the 
corresponding increase in expired volume is given by the product Vdotexp(t) x dt. However, 
in practice dt is replaced by a constant At and the mean flow across the time interval (t + At) 
replaces the instantaneous flow at (t):
T
Ve ^ Z Vdotexp(t + At) * At 
t=0
where Vexp is the mean flow rate during the time interval t + At. Minute ventilation (Vdotg) 
is obtained by summing Ve across the duration of an expiration (Te) and that sum divided by 
Te. To calculate V0% and VCO2 the same process is applied to the product of the gas 
concentration and the expired flow for each small sampling period, such that in the limit:
VO2 = J Vexp(t)dt * [(AF02)true]
and, assuming F1CO2 to be quantitatively negligible,
VCO2 = J Vexp(t)dt * FeCO,
However, in practice dt is substituted for the sampling time interval At:
VO2 = E Vexp(t + At) * At [(AF02)ti'ue] 
and:
VCO2 = I  Vexp(t + At) * At FeC02
where the true O2 difference [(AF0 2 )true] -  (FtO? -  pRO? -  F1Q2 FpCQ?)
(I-F1O2)
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Thus VdotOi and VdotCOz are the summed VO2 and VC02’s across the duration of an 
expiration (Te) and subsequently divided by Tg.
Through the principles of these equations and correction to account for the small dead space 
of the turbine assembly, it is possible to measine accurately on-line the pulmonary exchange 
of oxygen and carbon dioxide on a breath-by-breath basis. A note of caution which must be 
remembered when dealing with respiratory variables is the convention to express Ve as body 
temperature, pressure and saturated with water vapour (BTPS), i.e. its natural conditions, but 
to standardise VO2 and VCO2 to standard temperature and pressure dry (STPD). Therefore, 
the computer applied the appropriate correction factors to take account of the atmospheric 
conditions during each experiment.
Therefore using these “expiratory-only” algorithms the following variables were calculated 
breath by breath: oxygen uptake (VO2 , ml/min), carbon dioxide output (VCO2, ml/min), 
respiratory exchange ratio (R), minute ventilation (V e , i/min), breathing frequency (f, /min), 
ventilatory equivalent for O2 and CO2 (Ve/ VO2 and VE/VCO2), end tidal pressures of O2 and 
CO2 (PETO2 and PETCO2 , mmPIg) and oxygen pulse (ml 0 2 /beat). Heart rate was 
determined from the R-R interval of the 12 lead electrocardiogram.
2.2.4.3 Constant Load CPET
Background
Constant work load tests can provide quite distinct information to that gained during 
incremental testing. This is further demonstrated by the differing roles of low and high 
intensity protocols in both the estimation of physiological parameters and the evaluations of 
responses to intervention.
Definition of intensity of work rates performed largely relate to whether the exercise is 
sustainable with attainment of steady state values (low and moderate intensity) or is non 
sustainable with consequent fatigue (severe). The severe intensity work rates will be set 
importantly above the level of the critical power for a particular activity, in order that they are 
fatiguing (Neder et ai,  2000; Wasserman et al,  1999). Heavy work rates are such that they 
are above the lactate thi'eshold (with consequent rise in lactate and hydrogen levels) but at or 
below critical power, allowing a steady state for VO2 .
Constant work rate tests below the level of the critical power (moderate or heavy) allow 
determination of effort independent parameters that may be indicative of performance status
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and response to training. Oxygen uptake kinetics reflect the interplay of gas exchange at the 
level of the muscle mitochondria, muscle capillarity and cardiovascular oxygen transportation 
and are demonstrated to be lengthened in patients with COPD (Nery et al,  1982b). However 
following exercise training in COPD the findings are partially ameliorated (with shortening 
time of the constant) (Casabini et al,  1997; Puente-Maestu et al,  2000). This measure is 
feasibly obtained from one transition and is reproducible in COPD patients with established 
statistically meaningful differences for the time constant established (Puente-Maestu et al,  
2001). Tests which achieve steady state oxygen uptake are able to quantify accurately the 
WR/VO2 relationship.
Severe intensity work rate tests are to the limit of exhaustion. In COPD subjects they provide 
values for V02peak similar to those obtained on ramp testing (Neder et al,  2000). They are 
most widely used as a measure of non sustainable exercise tolerance in relation to an 
intervention. The proximity of the assigned constant load work rate to the critical power 
makes the test more sensitive to intervention than incremental protocols. Whereas one 
commonly expects a rise in the order of 5-10% for V02peak (and thereby absolute WR) after 
exercise training, previously non sustainable constant work rate can become at or below the 
subjects critical power, leading to striking improvements in the time to limitation (Casaburi ei 
al,  1997). Constant load tests have been recently shown to be reproducible at 75% of peak 
work on an incremental and also valid i.e. the work performed related to VO2PEAK and 12 
minute walking distance in a COPD population (Van't et al,  2003).
Procedure
The endurance CPET consisted of: a three minute rest period, three minutes of unloaded 
pedalling and a constant work load test set at 80% of the maximum work rate achieved on the 
incremental test. The time to tolerance (Tlim) is taken as the period, in seconds, between the 
start of the constant high intensity work rate and the point at which the patient can no longer 
sustain a satisfactory pedalling frequency (greater than 40 rev per minute) despite 
encouragement. Following that time the patient continued cycling for 5 minutes, at unloaded 
peddling during the recovery period. Identical variables as to those identified during the 
incremental exercise test are measured breath by breath, along with a 12 lead 
electrocardiogram. Symptom questioning also occurred at rest, during unloaded peddling, at 
maximal exercise and at 2 and 5 minutes recovery time.
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Where appropriate, in order to evaluate the presence and degree of respiratory-mechanical 
limitation during exercise, tidal and maximal inspiratory flow-volume loops will be obtained 
each minute and compared to resting maximal flow-volume curves obtained before and after 
exereise (Martinez et al,  1996; Yan et al,  1997; Johnson et al,  1999a; Johnson et al,  
1999b), This will allow better estimation of the available flow and volume reserves during 
exercise; i.e. by measuring the differences between exercise flow-volume loops and the 
maximal available limits for mechanical generation of both flow and volume (Martinez et a l , 
1996; Yan et al,  1997; Jolmson et al,  1999a; Jolmson et al,  1999b). This will therefore be a 
measure of the degree of exercise related dynamic hyperinflation.
2.2.5 Health status and breathlessness
Background
Health status defines the impact an individuaTs illness has upon his/her well being (Wilson & 
Cleary, 1995). Health related quality of life is becoming to be seen as the most important 
indicator of the benefit of certain treatments, particularly when considering the health
economic value of recommending interventions. The scope of the assessments involved in
these measures tends to cover such areas as physical, emotional, social and cognitive 
functioning: the aim being to gain a broad perspective on an individual’s quality of life. 
These measures have an established role in populations when looking cross-sectionally at 
health status, but the specificity of these tools is less suited to the individual patient, unless 
longitudinal data is being obtained. Once longitudinal evaluations are made then appropriate 
judgments as to whether “minimally clinically significant” changes, i.e. useful ones, have 
been achieved, These tools have allowed us to not only define which interventions improve 
health status, but also establish the natural history of health status decline in COPD patients 
(Spencer et al,  2001).
Health related quality of life can be assessed by generic and disease specific forms. Generic 
measures include the 36-item Short Form (SF-36) and the Nottingham Health Profile 
Questionnaire (Ware, Jr. & Sherbourne, 1992;Hunt et al,  1980). These questionnaires were 
designed for healthier populations, such that the difference in scores between COPD and 
other less ill patient groups can be in the order of 30 points for the SF-36, whereas the 
questionnaire is looking for changes of 5 points to detect minimally clinically significant 
differences in COPD (Spencer et al,  2001).
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Valid, reliable and moreover, disease specific questionnaires have been developed for COPD 
patients. There are 2 in widespread use: The St George’s Respiratory Questionnaire (SGRQ) 
and The Clnonic Disease Respiratory Questionnaire (CRQ) (Jones et al,  1992;Guyatt et al,  
1987). They both assess specific areas of functioning (e.g. for SGRQ symptoms, activity and 
Impacts) and allow a total score to be calculated. The mean SGRQ for a subject with 50% 
FEVi is 50 (out of 100). Worsening health status is signified by increasing scores and a 4 
point difference in the total or impacts score indicates a clinically significant health status 
change, for example, the ability to be free of breathlessness walking with others, bending and 
while washing (Jones, 2002). The CRQ has a minimum clinically significant change of 0.5 
points for all its assessment areas (Jaesclike et al,  1989). Patients with COPD have been 
demonstrated to have a fall in health status equivalent to the clinically meaningful change, 
every 14 months (Spencer et al,  2001). Although health status is lower in COPD patients 
with increased mortality, it has been demonstrated that CRQ is not an independent predictor 
of mortality in COPD, unlike age, FEVi and body composition (Oga et al., 2002).
Procedure
Quality-of-life and symptoms were evaluated using the St George’s Respiratory 
Questiomiaire (Jones et al,  1992). The St George’s Respiratory Questionnaire (SGRQ) 
scores the following parameters: “Symptoms”, “Aetivities” and “Impaets”. A total score, out 
of 100, is also calculated, with a change of 4 points representing the minimum clinically 
significant difference.
The modified Borg scale was used during exercise testing to quantify breathlessness (Borg, 
1982). Mahler’s baseline and transitional dyspnoea measurement questionnaires were 
administered to quantify breathlessness during day to day activities (Mailler et a l , 1984).
2.3 Pulmonary rehabilitation programme
The programme consisted of 2 weekly sessions of 1 hr for a total of 16 sessions. Subject may 
have been permitted to continue the programme if they only missed up to a few sessions. This 
was at the discretion of the physiotherapist, in accordance with standard practice in the 
department. The exercise was conducted by a physiotherapist and took place in the 
physiotherapy gym of Glasgow Royal Infirmary. Prior to the start of each training session, all
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patients underwent a standai'dised warm-up which comprised light intensity exercise for 5 - 
10 min, followed by a series of stretches with an emphasis on stretching the musculature 
associated with the exercises that were to follow. Then dynamic strength training of the upper 
(shoulder abduction and elbow flexion weight lifting, wall presses, bench press) and lower 
extremities (seated leg press, seated leg curl, standing calf raise, sit to stand, step exercises) 
were performed. Each of these components had 3 sets of 10 repetitions completed at 
intensities (where variation possible) set to match perceived exertion scores 2 values less than 
that reached during maximal incremental exercise. Then endurance training on a cycle 
ergometer and repeat stretching were performed. The cycle ergometer work rate was gauged 
as to provide peiwieved breathlessness scores 2 below the maximum reached on the 
incremental exercise protocol. Patients were expected to have increasing training work rates 
during the course of the programme. Patients were also given a copy of alternative exercises, 
so they could train at home.
The training intensity was progressively increased as patients successfully completed the 
required number of sets and repetitions (initially 3 sets of 10 repetitions for each exercise). 
Patients kept training logs throughout the duration of the study detailing rating of dyspnoea 
during exercise sessions and the weight, sets and repetitions lifted during strength training of 
the upper and lower extremities. Training sessions lasted on average 60 min (including the 10 
min warm-up and 10 min cool-down).
2.4 Analysis
2.4.1 Data editing
Recorded breaths in the CPET output have to be edited to ensure that all are appropriate for 
inclusion in analysis. Either the subject voluntarily takes a breath out of synch of the current 
breathing pattern, such as a particularly large or short breath, or the on-line software Tuis- 
triggers’ a breath. This can occur if the subject coughs or swallows during a breath, which the 
computer registers as a change in the direction of the volume signal. A balance between 
choosing higher volumes for accurate breath detection results in less ‘mis-triggering’ of 
breaths, but conversly leads to underestimation of exhaled O2 and CO2 volumes and to more 
breaths with small tidal volumes (e.g. at rest) being ignored.
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To deal with ‘mis-triggered’ breaths, the raw signals of respired 0%, CO2 and volume 
recorded on a chart were analysed in conjunction with numerical print-outs of the constituent 
parts of the breath, i.e. inspired time and expired time, tidal volume and end tidal pC0 2  and 
p02. From this, breaths that were clearly atypical of the surrounding breathing pattern were 
removed from the data set. Breaths where there was any degree of uncertainty over the 
classification of a Tnis-trigger’ were left in the data set.
The Tioise’ typically associated with breath-by-breath gas exchange has been extensively 
classified as an uncorrelated Gaussian distribution (Lamarra et al,  1987; Rossiter et al., 2000; 
Puente-Maestu et al,  2001). Therefore, it is reasonable to conclude that any breaths lying 
outwith prediction bands enveloping 4 standard deviations from the mean are unlikely to be 
part of the underlying physiological response to the imposed work-rate forcing (Lamarra et 
al,  1987; Rossiter et al,  2000; Puente-Maestu et al,  2001). Based on this criterion, breaths 
that were not part of the underlying response, either through ‘mis-triggering’ or the subject 
voluntarily taking an uncharacteristic breath, were removed from the data set.
2 .4 . 2  Calculation of VO2PEAK
VO2PEAK was calculated as the mean VO2 during the final 15s of an incremental test. It is 
often reported in the literature that two of the thi'ee following criteria should be met before 
the test can be classified as having being maximal (e.g. Flale et al, 1998):
1. a plateau in VO2 was achieved.
2. the peak heart-rate was within +/-10 bpm of the age-predicted maximum heart-rate (i.e. 
max. heart-rate = 220 -  age).
3. RER was greater than 1.15 at exhaustion.
However, for a number of reasons, particularly in patient populations, these criteria can not 
be fulfilled. In practice, rapid-incremental tests are unlikely to produce a plateau in VO2 . 
Thus it is conventional to refer to this ‘maximal’ value as the V02peak- In cases where the 
subject provides a full volitional effort and is not limited by symptoms such as dyspnoea, 
angina or leg pain, then VO2PEAK and maximal VO2 are closely related (Cooper et al,  1984). 
Furthermore, the variability in maximum heart rate is too high to reliably exclude subjects on
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the basis of a Tow’ peak heart rate at the end of an incremental test. Additionally, the final 
RER achieved will depend critically on the rate at which stored CO2 is unloaded as a result of 
HCO3’ buffering of metabolic acid and also because of respiratory compensation, both of 
which are highly dependent on the work-rate incrementation rate (Whipp, 1987). Therefore 
all values reported are VO2PEAK rather than V0 2 max-
2.4.3 Lactate threshold estimation
The lactate threshold (0 l) was estimated non-invasively from the pulmonary gas exchange 
and ventilatory consequences of the proton produced in association with the lactate anion. For 
rapid incremental exercise tests, these changes can be detected using a cluster of indices that 
include the V-siope and a series of ventilatory-based variables (Beaver et al., 1986; Reinhard 
et al,  1979; Wasserman et al,  1999; Reinliard et al,  1979; Wasserman et al,  1999). The 
underpinning physiology is the production of extra non-metabolic CO2 during the bicarbonate 
buffering reaction:
La + + HCO3' <---- > H2 CO3 <---- > CO2 + H2O
where La" is the lactate anion and x is Na in the muscle or K in the blood. The result of this is 
an acceleration from 0l onwards of VCO2 relative to VO2 as the work rate continues to 
increase.
The increased rate of CO2 clearance above 0l is associated with a proportional increase in Ve, 
such that V e immediately increases out of proportion to VO2 . This change can be observed as 
the VO2 at which Ve/V0 2  and Pet0 2  begin to increase while there is no concominant rise in 
VeWC02 or PetC02, i.e. hyperventilation relative to O2 but not to CO2 , which has been 
termed isocapnic buffering (Wasserman et al,  1977). The increase in VE/VO2 without change 
in Ve/VC0 2  is important, as it is atypical of hyperventilation caused by non-specific factors 
unassociated with the increasing work-rate (e.g. anxiety or hypoxia). Typically, 2-3 minutes 
after 0 l a further increase in V e , out of proportion to VCO2 , is observed. This is known as the 
‘respiratory compensation point’ (RCP) (Wasserman et al,  1999)and has been argued to 
reflect H’*' stimulation of the carotid bodies although the reason for the delay is as yet not fully 
understood (Rausch et al,  1991; Whipp et al,  1981; Whipp et al,  1981). While the RCP 
does not directly impinge on the determination of 0l, it is used to set the range of data over
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which the determination of 6 l will be made (Beaver et al,  1986). That is, the data from: 
resting, unloaded pedalling, the early kinetic lag phase, and above the RCP is excluded, 
leaving only the two ‘regions of interest’ (Beaver et al,  1986).
The V-slope method estimates the lactate threshold as the intersection of best-fit linear 
regression to the upper and lower regions of interest of the VO2-VCO2 plot. The effects of 0^ 
on ventilatory-based variables can be seen by viewing the changes in Ve/V0 2  and Pet0 2  with 
an absence of change, detailed above, in Vn/VCOa and PetC0 2  from plots of Ve/V0 2  and 
Pet02 vs VO2 with VeA/"C02 and PetC02 vs VO2 . The lactate tlireshold determined is 
therefore expressed as a VO2 value.
2.5 Statistics
All data were sampled and analysed using the Statview statistical package (Statview for 
Windows, Statview corp. USA). Details of the different statistical methods are presented in 
the lespective chapters. The following statistical methods were applied throughout the 
process of analysis as appropriate:
1 Checks for normality: All relevant data were checked for normality of distribution 
before applying any statistical test based on this assumption.
Comparison of means: For normally distributed data, a two independent sample 
Student's t-test was used for comparison between two means for separate groups and a 
paired Student's t-test was used for comparison between two means from the same 
group.
Assessment of the relationship between various factors: The relationship between 
2 or more variables was assessed using the Pearson's correlation coefficient, stepwise 
multiple linear regression analysis and Bland and Altman analysis.
Statistical significance: A level of p<0.05 was considered significant
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CHAPTER 3
CLINICAL RELEVANCE OF INTER-METHOD DIFFERENCES IN 
FAT-FREE MASS ESTIMATION IN CHRONIC OBSTRUCTIVE 
PULMONARY DISEASE
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Abstract
Background: Evaluation of fat-free mass (FFM) is becoming recognised as an important 
component in the assessment of clinical status and prognosis in patients with established 
chi'onic obstructive pulmonary disease (COPD). The aim of this study was to determine 
whether potential differences in FFM estimation performed by differing methods; air- 
displacement plethysmography (ADP), bioelectrical impedance (BIE) and antliropometry 
(ANTHRO), would have clinical significance.
Methods: Twenty-eight patients with moderate-to-severe COPD were submitted to FFM
estimation by ADP, BIE and ANTHRO. FFM was then allometrically related to peak oxygen 
uptake (VO2PEAK) as determined by symptom-limited incremental cycle ergometry.
Results: We found that ANTHRO classified fewer patients as “FFM-depleted” than the
other two teclmiques (P<0.05). Although mean biases of the BIE-ADP differences were close 
to zero, their 95% confidence limits extended as high as 5.9 kg (16 %). The ANTHRO-based 
allometric exponents for VO2PEAK correction of FFM, therefore, were typically higher than 
those obtained by the other two methods in both depleted and non-depleted patients 
(ANTHRO: 1.45-1.41, BIE: 0.97-1.18; ADP: 1.08-1.14, respectively).
Conclusion: We conclude that between-method differences in FFM estimation can be 
sufficiently large to have practical implications in relation to modes of measurement utilised 
and determinants of exercise tolerance in patients with moderate-to-severe COPD. A single 
method of body composition assessment, therefore, should be used for FFM estimation in 
these patients.
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3.1 Introduction
Exercise intolerance is a major feature of clu'onic obstructive pulmonary disease (COPD) 
(Pauwels et al,  2001), which is predominantly due to largely irreversible airflow obstruction 
and particularly dynamic hyperinflation which develops during exertion. Abnormalities of 
skeletal muscle structure and function have more recently become recognised as also playing 
a significant role in such exercise limitation (Wouters et al,  2002). Importantly, for example, 
loss of fat-free mass (FFM), a widely-used surrogate of skeletal muscle mass, has been 
associated with progressive disability, increased utilisation of health-care resources, and 
increased mortality (Mostert et al,  2000; Decramer et al., 1997; Gray-Donald et al,  1996).
Estimation of FFM has traditionally been performed by a wide range of methods, each 
differing with respect to assumptions, level of expertise needed and cost (Ellis, 2000). In 
large part, previous reports of FFM status in patients with COPD have been concerned with 
validation of techniques; comparing relatively inexpensive testing procedures (e.g. 
anthi'opometry (ANTHRO), bioelectrical impedance (BIE)), with more complex “criterion” 
methods (e.g. hydrostatic weighing and deuterium dilution) (Schols et al,  1991b; Pichard et 
al,  1997; Kyle et al,  1998; Engelen et al,  1998).
Whether these differences found between the methodologies used for FFM estimation have a 
clinical significance is a fundamental question. Steiner et al have demonstrated that the body 
composition testing modality used in COPD patients can influence the categorisation of the 
patient as to whether or not they are depleted of fat free mass. Such differences in FFM 
estimation between dual energy X-ray absorption (DEXA) and antlnopometry (ANTHRO) 
have been shown to be of practical importance in normal subjects (Neder et al,  2001b). In 
this particular study, the between-method discrepancies were sufficiently large to 
significantly affect the values of the exercise capacity, corrected for the fat free mass 
component. Since the exponent used to eliminate the functional inequalities (V O ipeak) 
which could be ascribed to differences in ‘size’ (FFM) depended on the method chosen to 
measure FFM, these discrepancies became of clinical importance (Welsman et al,  1996; 
Nevill & Holder, 1995). Whether between-method discrepancies in FFM estimation in 
patients with COPD also yield results that differ to a degree great enough to have clinical 
significance is not known.
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We were therefore interested to determine the clinical implications of between-method 
differences of FFM estimation and how they related to the assessment of exercise limitation 
in patients with COPD. We wished to establish the limits of agreement between three 
methods of body composition assessment, ANTHRO, BIE and the relatively new technique 
of air-displacement plethysmography (ADP). We also wished to evaluate whether any inter­
method differences would be sufficiently large to influence the analysis of maximum aerobic 
capacity (as estimated by V 0 2 peak) when allometrically corrected for FFM.
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3.2 Methods
3.2.1 Subjects
Twenty-eight patients (11 females and 17 males) with established clinical and functional 
diagnosis of moderate-to-severe COPD (FEVl < 60% predicted and FEVl/FVC ratio < 70%) 
comprised the study group (Table 1) (1987). Inclusion criteria were absence of locomotor or 
neurological diseases, and no change in medication dosage or exacerbation of symptoms in 
the preceding 4 weeks. All patients were optimised in terms of standard medical therapy: 
maintenance medication included p2-agonists, theophylline, oral and/or inlialed steroids.
Before the tests, the procedures, including the Imown risks, were described in detail and 
informed consent was obtained from all subjects. The study was approved by the North 
Glasgow University Hospitals NHS Trust Medical Ethics Committee.
3.2.2 Measurements
3.2.2.1 Pulmonary Function Testing
Spirometric tests and static lung volume measurements were performed using methods 
detailed in chapter 2 (Section 2.2.1). Measured variables included forced vital capacity (FVC, 
1), forced expiratory volume in one second (FEVi, 1), FEVi/FVC ratio, and total lung capacity 
(TEC, 1).
3.2.2.2 Body Composition Estimation
All body composition measurements (ANTFIRO, BIE, ADP) were performed on a single day 
by the same investigator. These methodologies are detailed in Chapter 2 (Section 2.2.2).
3.2.2.3 Cardiopulmonary Exercise Testing
Exercise tests were performed on an electromagnetically-braked cycle ergometer with gas 
exchange and cardiovascular variables being analysed breath-by-breath using a calibrated 
computerised exercise system as detailed in Chapter 2 (Section 2.2.4.2).
The exercise test consisted of: (a) 2-3 minutes at rest; (b) 3 minutes of unloaded pedalling, 
and (c) an incremental phase performed to the limit of tolerance, during which the work rate 
was progressively increased at a fixed rate (5-10 W every min) to provide a duration of the 
incremental phase that lay between 8 and 12-minutes (Buchfuhi'er et al,  1983). Peak oxygen
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uptake (VO2 ml.min'^) was calculated as the average of the last 15 seconds of the test. 
Subjects subsequently completed 5 minutes of unloaded pedalling representing a recovery 
period.
3.2,3 Data Analysis
Between-group differences in patients separated by presence or absence of FFM depletion 
(see Results) were analysed by a non-paired Student’s t test. Between-methods concordance 
in classifying the patients as depleted or non-depleted was assessed by McNemar’s test. The 
probability of a Type I error was established at 0.05 for the hypothesis tests.
The limits of agreement between ANTHRO, BIE and ADP were investigated by plotting the 
individual between-method differences against their respective means (Bland-Altman plot) 
(Bland & Altman, 1986). Heterocedasticity was examined by plotting the absolute (positive) 
differences against the individual means and calculating the Spearman’s correlation 
coefficient (Bland & Altman, 1996). If the heterocedasticity correlation was close to zero and 
the differences were normally distributed (Shapiro-Wilk’s test), the mean bias and the 95% 
limits of agreement were calculated as mean ± 1.96 SD of the between-method differences 
(Bland & Altman, 1986). In addition, in order to provide a relative (%) difference between 
any two of the three methods, data were transformed by taking natural logarithms of the 
means for each of the two methods before the calculation of the limits of agreement (Nevill, 
1997). After taking the antilogaritlims of these values, the mean bias and the 95% limits were 
expressed on a ratio scale.
The allometric relationships between V02peak (y) and FFMANTHRO, FFMBIE and 
FFMADP (x) were analysed by applying a linear regression to the logarithmic transformation 
of both X and y:
In y = In a + b In X (eq. 4)
where a is the y-intercept, and the slope b is equal to the exponent of the power function y =
axb.
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3.3 Results
3.3.1 Technical considerations
As discussed in the methods (Section 2.2.2.2), we firstly investigated the effect of using a 
general population equation (Deurenberg et al,  1991) versus a patient-specific equation 
(Kyle et al,  1998) for FFM estimation using BIE. We found substantial differences in these 
estimates, with the Kyle et al. equation providing generally lower values than the Deurenberg 
et al. equation: as illustrated in Figure 3.1 A, these differences increased as a function of FFM 
(P<0.01). The patient-specific equation of Kyle et al. was therefore subsequently used for the 
BIE-based inter-method comparisons.
We also sought to investigate whether the use of measured rather than predicted lung 
volumes would be of practical relevance for FFM estimation by ADP. Systematically higher 
values for FFMADP resulted when the theoretical values were used instead those actually 
measured (Figure 3.IB). This is to be expected, given the increased lung volumes that are 
characteristic of this patient population (e.g., Table 3.1). We therefore chose to use the 
individually-measured VTG values to calculate FFMADP for the ADP-based inter-method 
comparisons.
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Table 3.1 Characteristics of patients separated by presence or absence of fat-free mass 
(FFM) depletion
FFM-Depleted 
Patients 
(n=14, 7 male)
FFM-Non-depleted Patients 
(n=14, 10 male)
Age (yr) 62 ±9 66 ±8
Height (m) 1.6 ± 0.1 1.7±0.1
Body mass (kg) 50.4 ±5.6 76.4 ± 16.5*
BMI (kg.in^) 16± 1 19±3*
VojPEAK (ml.min^) 666 ± 207 974 ± 356*
FVC (1) 2.7 ±0.6 3.0 ±0.8
FEVl (1) 1.0 ±0.2 1.2 ±0.4
FEV1 (% pred) 41.8± 12.9 45.9 ± 15.8
FEVl/FVC (%) 37.4 ±9.6 38.4 ± 10.4
TEC (% pred) 126.3 ± 15.7 125.1 ±21.0
P<0.01. Values are presented as mean ± standard deviation (SD). Definition of 
abbreviations: BMI: body mass index; FVC: forced vital capacity; FEVi: forced expiratory 
volume in one second; TEC: total lung capacity; pred: predicted value.
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Figure 3.1 Limits of agreement of fat free mass estimation.
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A. Mean bias and the upper (UP) and lower (LW) 95% limits of agreement between a patient- 
specific (Kyle et al.) and a general (Deurenberg et al.) equation for fat-free mass (FFM) 
estimation according to bioelectrical impedance (BIE) in FFM-depletcd (open circles) and 
non-depleted (solid circles) patients with COPD. Note that a significant heterocedastic 
correlation was found in non-depleted patients (P<0,01).
B. Mean bias ± 95% limits of agreement between FFM values estimated by air displacement 
plethysmography (ADP) using estimated or measured lung volumes (LV) in the same 
patients.
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3.3.2 FFM Depletion and the Limits of Agreement
Nutritional depletion was established according with the criteria proposed by Vanltallie et al.: 
body mass index (BMI) <21 kg.m'^, or fat-free mass index (FFM.heighf^) <16 and < 15 kg. 
m'^ in males and females, respectively (Vanltallie et al,  1990). If ADP is categorised as a 
criterion method, 14 patients were classified as FFM-depleted and 14 patients as FFM-non- 
depleted (Table 3.1): similai- results were found when the BIE readings were used. In 
contrast, there was a significant association between ANTHRO and FFM-depletion; fewer 
patients were classified as ‘depleted’ by ANTHRO than the other two techniques (21 patients, 
P<0.05).
Consistent with these results, we found that ANTHRO FFM readings were systematically 
higher than those obtained by either BIE or ADP, independent of the degree of FFM 
depletion. The mean bias ± 95% confidence limits of these differences for the FFM-depleted 
and non-depleted groups, respectively, were; ANTHRO-BIE = 3,1 ± 4.3 kg (9 ± 6 %) and 7.1 
± 7.8 kg (16 ± 8 %) and ANTHRO-ADP = 4.8 ± 6.2 kg (15 ± 14 %) and 6.7 ± 8.5 kg (16 + 12 
%) (Figures 3.2A and 3.2B). In contrast, the mean bias of the BIE-ADP differences were 
close to zero, although their 95% limits of agreement were as wide as those found for the 
other comparisons: 1.7 ± 9.6 kg (6 ± 16 %) in the FFM-depleted group and -0.4 + 11.6 kg (0 
± 13 %) in the non-depleted group, respectively (Figure 3.2C).
Figure 3.2 Limits of agreement according to fat-free mass depletion.
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3.3.3 V02PEAK Correction
As expected, oui patients demonstrated substantial exercise limitation, as judged by the lower 
than normal V O ipeak  (Table 3.1). Consistent with earlier observations, V 0 2 peak in the FFM- 
depleted group was significantly lower than in the non-depleted group (Table 3.1).
In both FFM-depleted and non-depleted groups, allometric correction of VOipeak by 
FFMANTHRO provided higher exponents than either FFMBIE or FFMADP: 1.45-1.41 vs. 
0.97-1.18 and 1.08-1.14, respectively (Figure 3.3). The consequence of this being that for 
both TFM depleted and non depleted patients, the V02peak values corrected by 
FFMANTHRO were substantially lower than those normalised by FFMBIE or FFMADP 
(Table 3.2).
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Figure 3.3 Procedures for extraction of the allometric exponents for vo2peak correction by 
FFM according to body composition evaluation method.
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A. Procedures for extraction of the allometric exponents for V0 2 peak correction by FFM 
according to anthropometry (FFMANTHRO), bioelectrical impedance (FFMBIE) and air 
displacement plethysmography (FFMADP) in FFM-depleted (open circles) and non-depleted
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(solid circles) patients with COPD. Definition of abbreviations; In = natural logaritlini; b 
regression slope; UP: upper 95% limit of agreement; LW: lower 95% limit of agreement.
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3.4 Discussion
The present study demonstrated that the differences in values for FFM estimation based on 
two widely-used (ANTHRO and BIE) methods and an additional new (ADP) method have 
clinical relevance in patients with moderate or severe COPD. In relation to this we found that: 
(i) the between-method limits of agreement were larger than the changes in FFM usually 
ascribed as consequences of interventions in these patients, (Ü) the diagnosis of FFM 
depletion was less frequent when ANTHRO, instead of BIA or ADP, was used for 
measurement of body composition and (iii) these discrepancies were sufficiently large to 
provide different exponents for the allometric correction of voipeak- From our results we 
conclude that a single method of FFM estimation should be used, either in cross-sectional or 
longitudinal evaluations of patients with COPD, and that antlmopometry, in particular, tends 
to underestimate the prevalence of FFM depletion.
The practical importance of body composition determination in patients with COPD is now 
well-established. Several authors have demonstrated that loss of FFM is associated with 
reduced exercise tolerance and a number of negative prognostic indicators (Mostert et al, 
2000; Decramer et al, 1997; Gray-Donald et al, 1996; Baarends et a l,  1997a; Yoshikawa et 
al, 1999). With this in mind, we have analysed our data taking into consideration the 
confounding aspects of FFM-depletion. In addition, others have already shown that there are 
some discrepancies in the estimation of body compartments in COPD patients, depending on 
the specific method used for body composition assessment (Schols et al, 1991b; Pichard et 
ol,  1997; Kyle et al,  1998; Engelen et al, 1998). A novel aspect of the present study is that 
we addressed the clinical significance of potential inter-method differences. We wished to 
determine to what extent these differences would affect clinical aspects that more directly 
relate to body composition measurements in patients with COPD. We have demonstrated that 
these differences are large enough to cast doubt on the validity with which results derived 
from multiple methods can be compared (Figure 3.2). Also, importantly, such differing 
results are also likely to distort the analysis of FFM-corrected V0 2 peak values (Figure 3.3 and 
Table 3.2). These results are consistent with those recently described by Steiner et al. who 
also concluded that ANTHRO tended to overestimate FFM in patients with COPD (Steiner et 
al, 2002). In the present study, we have extended their findings by showing that these 
discrepancies are wide enough to influence the analysis of symptom-limited V0 2 peak in this 
patient population (Figure 3.3 and Table 3.2).
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In this regal’d, vo2peak has been ‘normalised’ for body mass, or more properly, for FFM in 
order to relate the metabolic activity to its structural determinants. We analysed this 
relationship in patients separated by presence or not of FFM-depletion since large differences 
in distribution of the independent variable (here FFM) are known to influence the describing 
parameters. However, the traditional procedure of simply dividing a physiological variable 
(y) by an anthropometric or performance attribute (x) is prone to misinterpretation. It is 
important to emphasise that this approach can provide valid results only when: (i) the 
coefficient of variation for x divided by the coefficient of variation for y equals the Pearson 
product moment correlation between the two variables, (ii) there is no heterocedasticity or 
skewness in the residuals and (iii) the relationship goes through the origin (Nevill & Flolder,
1995). These shortcomings of the so-called ‘ratio standard’ analysis are even more relevant in 
subjects with disproportionately lower x values, such as is the case for patients with COPD: 
in these circumstances, there is a progressive bias which tends to give an advantage to 
individuals with the lowest x values. Conversely, the allometric analysis (power function) 
assumes a multiplicative error around the regression line and is able to scale correctly since 
the relationship passes through the origin (Nevill & Holder, 1995).
In the present study, we found that the inter-method differences were sufficiently wide to 
result in different power function exponents: differences in FFM-corrected vo2peak therefore 
increased exponentially after allometric adjustment (Table 3.2). These exponents, however, 
differed both from the values based on the theory of geometric similarity (i.e., V0 2  in 
geometrically similar bodies varies with the cross-sectional area which, in turn, relates to 
body mass to the power 0.67 (Astrand & Rodahl, 1986)) and those estimated with 
consideration of the elasticity of tissues.
A number of hypotheses could be considered to explain this finding. Firstly a substantial 
portion of the measured V0 2  may not have been related to the functional activity of the 
peripheral muscles, e.g., the V0 2  associated with increased respiratory muscle work. 
Secondly, although it has been previously demonstrated that the metabolic cost of cycle 
ergometry is closely related to leg mass, (Neder et ah, 2000b) in the present study we have 
determined total body mass rather than leg FFM. Lastly, the exponents we derived presented 
relatively wide confidence intervals, indicating that they should be viewed with some caution. 
Regardless of these limitations, however, it should be pointed out that we used allometry 
solely to investigate whether the choice of a specific method for body composition 
assessment would present practical consequences. Therefore, more comprehensive studies are
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warranted to determine the precise allometric relationship between vo2peak and FFM in 
patients with COPD.
We believe that our study is the first to use ADP for body composition determination in 
patients with COPD. This method utilises the inverse relationship between pressure and 
volume (Boyle’s law) to determine body volume (Vb), The basic principles of densitometry 
are subsequently used to determine body composition (body density = body mass/Vb) 
(Dempster & Aitkens, 1995). ADP has been validated against more traditional methods, such 
as hydrostatic weighing (McCrory et a l,  1995; Biaggi et al, 1999). The main advantage of 
ADP is that it is based on air displacement rather than water immersion; i.e., it is simpler, 
more comfortable and might well present wider clinical applications. However, the ADP 
method also requires that lung volumes be taken into account: Vb determined by Boyle’s law 
is underestimated by 40%, since the isothermal nature of the thoracic gas means that this air 
is 40% more compressible than the chamber air which temperature is free to change 
(adiabatic conditions) (Dempster & Aitkens, 1995). While the ADP system allows the 
operator to use predicted lung voliunes, we have demonstrated that this strategy should not be 
used in airflow-obstructed patients with COPD: as shown in Figure 3.IB, it grossly 
overestimated FFM in our sample.
A finding of particular note in our study was the systematic overestimation of FFM by 
ANTHRO (Figure 3.2). As mentioned, these results are consistent with those described by 
Schols et al. (Schols et al, 1991b) and Steiner et ai. (Steiner et aï,, 2002): the latter authors, 
for example, found that the upper 95% limit of agreement between ANTHRO and DEXA 
reached +8.2 kg in favour of ANTHRO. In fact, skinfold measurements are notoriously 
imprecise in older subjects, particularly in those who have more fat mass. Furthermore, the 
measurement outcomes are sensitive to the investigator’s experience with the method (Ellis, 
2000). In our study, as all measurements were performed in triplicate by the same 
experienced investigator, we are confident that this was not a relevant issue to explain our 
results. It is more likely, therefore, that the combined effects of COPD and age influenced the 
pattern of fat distribution (e.g., a more ‘central’ pattern) and also the degree of the hydration 
of the lean tissues (Ellis, 2000;Schols et al, 1991b; Pichard et al, 1997; Kyle et a l,  1998). 
Moreover, it has been demonstrated that some patients with COPD might present relatively 
preserved upper body strength (Gosselinlc et al, 2000). Since our skinfold measurements 
were obtained in these body regions, we might speculate that this led to an overly optimistic
view of the total body FFM. Nonetheless, our results, and those of others,(Schols et al., 
1991b; Steiner et ah, 2002) suggest that anthropometric readings should be viewed with 
extreme caution in patients with COPD.
A major limitation of our study relates to the relatively small sample size. The Bland-Altman 
analysis is sensitive to the number of observations, since a few discrepant values can affect 
the mean bias and its confidence limits when small samples are used. However, the limits of 
agreement found in the present study are remarkably similar to those reported between 
DEXA and ANTHRO by Steiner et al. (Steiner et al, 2002), for example. It should also be 
acknowledged that the ADP and ANTHRO methods are based on the same densitometry 
principles: this might have led to an expectation for improved intrinsic comparability between 
ADP and ANTHRO, to the detriment of BIE.
In conclusion, we have demonstrated that the between-method differences in FFM estimation 
are likely to be sufficiently wide to present clinical consequences in-patients with moderate- 
to-severe COPD. Therefore, it is advisable that a single method be used for FFM estimation 
both in cross-sectional and longitudinal evaluations of this patient population. The degrees of 
exercise limitation and the factors which determine them become more recognised and 
examined in COPD patients yearly. Therefore other aspects, such as means of measurement 
of values, taken to quantify the disability must be examined carefully. The same rigour that is 
applied to the standards of measures such as those of pulmonary function should be 
introduced for practices including FFM estimation, as these methodologies become more 
widely introduced into clinical, as well as research, practice.
CHAPTER 4
CREATINE SUPPLEMENTATION AS AN INTERVENTION FOR 
EXERCISE INTOLERANCE
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Abstract
Background; Skeletal muscle wasting and dysfiinction are strong independent predictors of 
mortality in patients with cluonic obstructive lung disease. Creatine nutritional 
supplementation increases muscle mass and exercise performance in health. We therefore 
performed a controlled study to examine for similar effects in COPD patients.
Methods: Thirty-eight patients with COPD (FEVi= 46+15% predicted) were randomised
between placebo (glucose polymer 40.7g) or creatine (creatine monohydrate 5.7g, glucose
35g) supplements in a double blind trial. After 2-weeks loading (1 dose three times daily),
patients participated in an out-patient pulmonaiy rehabilitation programme combined with
maintenance (once daily) supplementation. Pulmonary function, body composition, and
exercise performance (peripheral muscle strength and endurance, shuttle walking, cycle-
ergometry) took place at baseline (n=38), post loading (PL) (n=36) and post rehabilitation 
(PR) (n=25).
Results: Reporting between group differences as mean (95%CI), we found no
difference in whole body exercise performance e.g. incremental shuttle walk distance, -23.1 
m (-71.7 to 25.5) PL and -21.5 (-90.6 to 47.7) PR. Creatine increased fat-free mass by 1.09 kg 
(0.43 to 1.74) PL and 1.62 kg (0.47 to 2.77) PR. Peripheral muscle performance improved; 
knee-extensor strength by 4.2 (1.4 to 7.1) N.m, and endurance by 411.1 (129.9 to 692.4) J PL, 
Icnee-extensor strength 7.3 (0.69 to 13.92) N.m and endurance 854.3 (131.3 to 1577.4) J PR. 
Between baseline and post rehabilitation creatine improved health status, St. George’s 
Respiratory Questionnaire total score -7.7 (-14.9 to -0.5).
Conclusions: Creatine supplementation led to increases in fat free mass, peripheral muscle 
stiength and endurance, health status, but not exercise capacity. Creatine may constitute a 
novel ergogenic therapy in COPD.
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4.1 Introduction
Chrome obstructive pulmonary disease (COPD) is a disabling condition, predicted to become 
the fourth most common cause of death world-wide by 2020 (Lopez & Murray, 1998), There 
is a growing recognition that the muscle wasting and compromised muscle strength often 
associated with COPD are predictors of handicap, disability and increased mortality (Marquis 
et a i,  2002). Wide-ranging strategies have been employed in an attempt to restore muscle 
mass, such as nutritional manipulations (Steiner et al,  2003), the administration of 
recombinant human growth hormone (Burdet et al, 1997), anabolic steroids (Creutzberg et 
al, 2003) and appetite stimulants (Weisberg et al, 2002). However, despite the majority of 
these strategies leading to an increase in muscle mass, muscle strength and measures of 
whole-body exercise performance were typically unaffected.
Creatine monohydrate is widely used by healthy individuals as an aid to exercise 
performance. In skeletal muscle, creatine undergoes rapid and reversible phosphorylation 
catalysed by the enzyme creatine kinase, a reaction that forms Phosphocreatine (PCr). PCr 
provides an immediate source of high-energy phosphate which is crucial for maintaining the 
rate of ATP resynthesis during the initial stages of exercise, especially when energy demands 
are high. Uptake and incorporation of exogenous creatine into skeletal muscle is evident in 
increased resting intramuscular phosphocreatine (PCr) levels (Harris et al, 1992; Greenliaff 
et al, 1994a). In addition, in healthy young and older subjects, increases in body mass, fat- 
free mass, muscle strength and muscle endurance have been demonstrated (Gotshalk et al, 
2002; Kilduffef a/., 2002b).
These observations raise the interesting premise that creatine supplementation might elicit 
similar ergogenic effects in patients with COPD, especially those who manifest muscle 
wasting. However, there have been few studies of creatine supplementation in disease states, 
particularly those chai'acterised by impaired exercise tolerance secondary to systemic 
dysfunction. Thus, while muscle performance has been reported to be improved following 
creatine administration in cluonic heart failure (Andrews et al, 1998a), in mitochondrial 
myopathies (Tarnopolsky et al, 1997) and following rehabilitation from disuse atrophy 
(Hespel et al, 2001), there have to date been no formal evaluations of creatine 
supplementation in patients with COPD.
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Using a randomised, double-blind and placebo-controlled design, the objective of the present 
investigation was therefore to evaluate the effects of oral creatine supplementation in patients 
with moderate-to-severe COPD, administered both in isolation and in combination with an 
exercise-training programme.
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4.2 Methods
4.2.1 Subjects
Patients referred for pulmonary rehabilitation with an established diagnosis of COPD were 
assessed for inclusion in the study ((1987). Standards for the diagnosis and care of patients 
with cluonic obstructive pulmonary disease (COPD) and asthma.). All were clinically stable, 
as defined by no change in medication dosage or exacerbation of symptoms in the preceding 
4 weeks. No patient presented cardiovascular, locomotor or neurological conditions which 
precluded exercise training; in addition, oral corticosteroids were not allowed in the 
preceding month. All patients were optimised in terms of standard medical therapy; 
maintenance medication included p2-agonists, anticholinergics, theophylline, and inhaled 
steroids. No patient was receiving chronic domiciliary oxygen therapy.
Before the tests, the procedures, including the known risks, were described in detail and 
written, informed consent (as approved by the Glasgow Royal Infirmary Ethics Committee) 
was obtained from all patients.
4.2.2 Study design
This was a double-blind placebo-controlled trial. Patients were randomly assigned to receive: 
(i) creatine monohydrate with glucose polymer (5.7 g of creatine and 35 g of glucose per
dose) or (ii) glucose polymer only (40.7 g per dose). The Cr group ingested 17.1 g-d“' Cr-H20 
(equivalent to 5 g Cr x 3 times daily) for the first 14 days (loading). From day 15, patients
consumed 5.7 g-d‘* Cr-H20 (equivalent to 5 g Cr daily) for the remainder of the study 
(maintenance). This maintenance dose was selected on the basis of work demonstrating that 2
g-d'  ^ C1-H2O was adequate in maintaining elevated muscle PCr stores in patients not involved 
in strenuous exercise (Harris et al, 1992). As the patients in the present study were training
twice a week at high intensities, it was decided to increase the maintenance dose to 5 g-d"'
Cr-H20 in an attempt to maintain muscle PCr stores. Each supplement consisted of 5.7 g of
Cr H2O and 35 g of glucose polymer made up in approximately 500 mis of warm to hot 
water. Dissolving Cr in wann to hot water prevented any detectable formation of creatinine 
and no parts of the supplement remained undissolved. The addition of glucose to the Cr has 
been shown to significantly enliance the uptake of Cr (Green et al, 1996; Steenge el al,
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1998). Patients were instructed to ingest the supplements at equal intervals throughout the 
day. The placebo group consumed 120 g-d"’ of glucose polymer (40 g x 3 times daily) for the 
first 14 days, followed by 40 g a day for the subsequent duration of the study. The placebo 
group followed the same procedure as the Cr group with regard to the preparation of the 
supplements. These preparations were prepared by persoimel not involved in the study and in 
sites separate from the investigators. The two supplements were identical in weight, 
appearance and taste. Randomisation sequences, labelling and quality control were all 
performed independently by the Glasgow Western Infirmary pharmacy production unit. After 
the initial loading period, all patients entered the hospital, out-patient based pulmonary 
rehabilitation programme. The study design is represented below in figure 4.1.
Baseline
Evaluation
2 weeks
I
creatine 5gm tld 
or placebo
Post Loading 
Evaluation
8 weeks creatine 5gm od or placebo
Post Rehabilitation 
Evaluation
Figure 4.1 Study design
The study evaluations were performed on separate days, with at least 2 days rest in-between. 
Randomisation sequences were centrally generated at the Western Infirmary production unit 
and block randomised in groups of four. Patients underwent evaluation on tlnee occasions: 
baseline, post creatine/placebo loading and following exercise training. The study visit 
schedule is detailed in table 4.1 below.
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STUDY
PERIOD
BASELINE POST
LOADING
POST REHAB
FULL PFT, BODY 
COMPOSITION 
and STRENGTH
A A A
INCREMENTAL 
CPET, HEALTH 
STATUS and 
BLOODS
A A
ENDURANCE 
CPET, ISWT and 
ESWT
B B B
Table 4.1 Visit Schedules
Comprehensive evaluations were performed at baseline and after exercise training. Some 
investigations were not performed post loading, as detailed above. Weeks A and B represent 
distinct periods of evaluation, as most exercise tests had to be performed on separate days.
Both supplements had similar taste, texture and appearance and were placed in generic 
containers to ensure double-blind administration. Patients were also requested to eliminate 
caffeine and caffeine containing foods from their diet over the loading phase to minimize the 
possible inhibitory effects of caffeine on the ergogenic effect of Cr (Vandenberghe, et al,
1996), At the end of the study all patients gave verbal assurance that they had complied with 
all instructions.
Considering that the amount of metabolically active tissue (muscle) could affect response to 
the interventions, patients were previously stratified according to muscle mass depletion: 
reduced body mass index (<21 kg.m"^) and/or reduced fat-free mass index: ((FFM,height'^) < 
15 kg.m'^ in females or < 16 kg.m'^ in males) (Schols et al, 1993; Vanltallie et al, 1990). 
Therefore, care was taken that a similar number of FFM-depleted patients were presented in 
each group. Data were pooled for analysis only after certification that there was no effect of 
FFM depletion on the responses to the intervention.
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4.2.3 Procedures
The methodologies employed during the study evaluations are detailed in chapter 2, Full 
pulmonaiy function testing (Section 2.2.1) and health status assessment (Section 2.2,5) were 
performed. Comprehensive evaluations of body composition using air displacement 
plethysmography (Section 2.2.2.3), lower (Section 2.2.3.1) and upper (Section 2.2.3.2) body 
peripheral muscle function, and whole body exercise capacity (Section 2.2.4) we undertaken. 
The pulmonary rehabilitation exercise programme is described in Section 2.3. The approach 
to statistical analysis is detailed in Section 2.5.
4.2.4 Power Calculation
The primary outcome measure of this trial was distance walked on the incremental shuttle 
walk test. The study was powered to detect equivalent effects to those reported for pulmonary 
rehabilitation (mean improvement of 56 metres (SD 58) on ISWT recalculated from Singh et 
al (Singh et al,  1998b)). We aimed to recruit 60 patients, with an expected 33% drop out 
over the rehabilitation period.
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4.3
4.3.1
Results
Study compliance
The supplementation was well tolerated in most subjects without reported side effects. Two 
patients, both allocated to placebo, were unable to take their supplements. These patients 
attributed this to the sweet taste of the drinks. The pattern of recruitment and drop out from 
the study is represented in figure 4.4.
5 3<  X  Q  Û.
IIIIcc
2 unable to perform tests 
1 diagnosed anaemic
2 unable to tolerate supplements 
{2 placebo)
6 exacerbations (4 placebo, 2 creatine) 
5 other reasons (3 placebo, 2 creatine)
25 completed rehabilitation 
Creatine (14) : Placebo (11)
36 completed loading 
Creatine (18) : Placebo (18)
41 subjects assessed  
at baseline
38 assigned to: 
Creatine (18) : Placebo (20)
Figure 4.2 Study recruitment and drop out.
The number of patients unable to complete the course was in keeping with the number of 
drop-outs expected during our standard pulmonary rehabilitation programme. Twenty-five 
patients successfully completed the exercise-training programme. The reasons for study 
discontinuation were as follows (Figure 2): severe exacerbations (6 subjects, 4 placebo, 2 
creatine), poor motivation/non compliance to exercise programme (3 subjects, 2 placebo, 1 
creatine) backache (1 subject, creatine) and vestibular disease (1 subject, placebo). A 
reassuring aspect is that there was no difference in the number of patients imable to complete 
the rehabilitation programme between the creatine and placebo groups (7 subjects placebo vs. 
4 subjects creatine, non significant difference).
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4.3.2 Body composition stratification
Stratification of the patients into groups according to fat free mass depletion was vital to try 
to match subjects as closely as possible with regard to functional parameters. The impact of 
fat-free mass depletion on exercise performance and health related quality of life is illustrated 
below in table 4.2. It is clearly demonstrated that, despite adequate matching for pulmonary 
function, other aspects of health, fundamentally important to COPD patients can be 
significantly different if body composition is not taken into account.
Depleted (n=18, 10 male) Non-depleted (n=18, 13 male)
FEVl % predicted 42.89 ± 11.70 46.72+ 16.52
Body mass, kg 52.66 ± 8.62* 74.71 + 15.64
Fat-free mass, kg 38,52 + 8.72* 46.96+ 11.14
Fat-free mass index, kg/m^ 14.7 + 2.8* 17.1 + 3.3
Body mass index, kg/nf 20.0 + 3.2** 27.3 + 4.4
Peak torque, N.m 71.27 + 26.35* 96.66 + 29.48
Shuttle walk distance, m 293.88 + 105.94 330.56 + 145.62
VO2PEAK51/min 0.71 + 0.24* 1.02 + 0.36
SGRQ total 72.06 + 10.92* 61.28+12.45
SGRQ symptoms 76.06+ 17.36 80.94+ 16.24
SGRQ activities 85.51 + 9.95* 75.40+ 15.45
SGRQ impacts 59.92+ 13.35* 46.60+ 14.10
Table 4.2 Impact of fat free mass upon functional characteristics of our COPD cohort. 
Values aie mean ± SD.
*p<0.05, **p<0.01 for unpaired t test, between group difference
The table demonstrates that the extent of airflow obstruction was comparable in both groups. 
As expected, mean body weight and fat-free mass was significantly higher (p<0.05) in the 
non-depleted group, and interestingly, mean peak torque and exercise capacities were 
significantly greater (p<0.05) in non-depleted patients. In keeping with the definition of 
tissue depletion, significantly lower values for BMI and FFMI were seen in the depleted 
group of patients. Although the mean shuttle walk distance in the non-depleted group was 
greater than in the depleted group, this difference was not significant. The most salient
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finding when considering cm' patients as nutritionally depleted and non-depleted, was the 
significantly greater health-related quality of life (p<0.05) in the non-depieted group, as 
measured by the St. George’s Hospital Respiratory Questionnaire.
4.3.3 Baseline results
We found that there were no significant differences in most baseline characteristics between 
the placebo and creatine groups, although the heterogeneity of the group inevitably makes it 
difficult to match subjects for all of the variables relating to pulmonary function, body 
composition and health related quality of life. In the table below (Table 4.3) pulmonary 
function characteristics for creatine and placebo groups are represented. Vital capacity was 
the only measurement to show a significant between group difference.
Table 4.3 Baseline characteristics; pulmonary function.
Creatine
(n= 18, 10 male)
Placebo
(n= 18,13 male)
Age, years 61.7 ± 8 63.9 ±10
CP year 52.3 ±32 51.8±30
Pulm onaiy Function
FEVi, litres 1.12±0.3 1.12±0.5
FEVi % predicted 45,4 ± 14 44.2 ± 15
FEVi/FVC 35.9 ± 10.6 40.0 ±8.9
VC, litres 3.21 ±0.7 2.76 ±0.9
VC % predicted 103.2 ± 2 2 .0 * » 83.4 ± 16.7
TEC, litres 6.93 ±1.2 7.10± 1.4
TEC, % predicted 125.3 ± 17.2 127.6 ± 16.8
RV, litres 3.72± 1.1 4.40 ± 1.09
RV, % predicted 179.2 ±55.5 210.6 ±58.2
DECO, units 46.4 ±23 44.7 ± 27
MIP, cm FI2O 62.3 ± 25 61.4±30
MEP,cmH20 81.4 ± 3 3 .4 77.2 ±29.5
Significant between group difference. P < 0.01
100
Table 4.4 Baseline body composition and muscle function characteristics.
Creatine 
(n= 18, 10 male)
Placebo 
(n= 18,13 male)
Age, years 61.7 ±8 63.9 ±10
Body Composition
Fat-free mass, Kg 44.3 ± 8.9 42.2 ± 12.6
Fat-free mass, % 71.3± 11.3 65.7± 11.7
BMI, Kg/m^ 23.2 ±3.6 24.3 ± 6.6
Upper Limb Muscle Function
Peak force, N 28.4 ±8.3 25.0 ±7.7
Total repititions 48.9 ± 14.5 50.6 ± 17.8
Lower Limb Muscle Function
Peak Torque, N.m 85.7 ±26.6 82.2 ±34.5
Total Work, J 1832.7 ±740.1 1648.1 ±881.0
There were no demonstrable differences in baseline measurements between the creatine and 
placebo groups with regard to body composition and muscle function. The 'normaT mean 
BMI represents the successfril stratification by body composition classification, but it should 
be noted that within each group there remains a wide spread of individual muscle bulks.
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Table 4.5 Baseline exercise performance indices.
Creatine Placebo
(n= 18, 10 maie) (n= 18, 13 maie)
Field tests
Distance walked ISWT, m 331 ± 111 293 ±142
Maximum Borg ISWT., 7.22 ± 1.80 6.50 ± 1.47
Breathlessness
Time walked ESWT, s 340 ± 209 392 ± 297
Incremental Cycle ergometry
Peak WR, Watts 60.8 ± 27.1 56.4 ± 30.5
VOzPEAK, 1/min 0.858 ± 0.393 0.887 ± 0.288
Peak Borg, Breathlessness 6.82 ± 1.88 6.77 ± 1.68
Peak Borg, Legs 7.00 ± 2.29 7.06 ±2.11
Lactate tlueshold 1/min 0.525 ± 0.15 0.523 ± 0.25
Peak Ventilation, 1/min 41.79 ± 10.2 38.3 ± 9.6
Breathing Reserve, 1/min 3.3 ± 8.2 8.2 ± 12.4
Peak Heart Rate, Beats/min 126.1 ± 17.6 127.1 ± 10.3
Endurance cycle ergometry
Peak Borg Breathlessness 7.79 ± 1.9 6.50 ± 2.2
Tlim, s 164 ±66 126 ±44
Data are presented as group-mean values, ± one standard deviation.
There were no statistically significant differences in baseline exercise capacity for either 
group. The mean distances walked on the ISWT (331m in the creatine and 293m in the 
placebo groups) give predicted oxygen uptakes significantly below that expected of adults, 
where 450m walked would signify an oxygen uptake of greater than 14 ml.kg-l.min"^ (Lewis 
et al,  2001). These findings, coupled with a mean peak oxygen uptake of under 1 1/minute
represents severe exercise impairment in this patient group. From the mean FEVfs, a
predicted maximum voluntary ventilation of between 391 and 451 (depending on the 
multiplier used i.e. 35 or 40(Wasserman et al,  1999)) is found. This determines the likely 
ceiling of maximmn ventilation during exertion. From the values obtained at peak exercise
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during the ramp incremental test it can be seen that both groups approached (38.3 l.min'* for 
placebo) or were within (41.8 l.min"  ^ in the creatine group) this domain, representing the 
fundamental ventilatory impairment present. Subjects stopped exercise with slightly higher 
ratings for leg effort than dyspnoea at maximal exercise during the incremental test; a finding 
previously recognised in this patient group (Killian et al, 1992). The mean ages of the 
patients give a predicted maximum heart rate of approximately 160 beats per minute. Both 
groups had demonstrable heart rate reserve at peak exercise. These findings are typical of 
patients with established disability secondary to COPD (Wasserman el al,  1999).
The table below (Table 4.6) displays health related quality of life for the 2 groups at baseline.
Table 4.6 Health related quality of life at baseline for the placebo and creatine groups.
Creatine Placebo
(n= 18, 10 male) (n= 18,13 male)
HEALTH STATUS 
St George’s Respiratory 
Questionnaire
SGRQ total score 65.6 ± 14.0 67.8 ±11.7
SGRQ symptoms 80.4 ± 18.5 76.6 ±15.1
SGRQ activity 82.5 ± 12.9 78.4 ± 14.7
SGRQ impact 50.5 ± 60.7 56.0 ±13.3
Chronic Respiratory Disease 
Questionnaire
CRQ Dyspnoea 2.35 ± 0.8 2.46 ± 0.7
CRQ Fatigue 2.90 ± 1.5 2.93 ± 0.9
CRQ Emotional Function 3.86 ± 1.5 4.03 ±1.5
CRQ Mastery 4.00 ± 1.7 3.66 ± 1.23
Data are presented as group-mean values, ± one standard deviation.
For all the above baseline characteristics there were no statistically significant differences 
between the placebo and creatine groups. The baseline health status scores in our patient 
group are typical of the deleterious effect COPD has on quality of life. Age matched healthy 
subjects have SGRQ scores of 7 ± 7, 12 ± 15, 11 ± 13, and 3 ± 5 for total, symptoms, activity
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and impact respectively. In fact our patient group displayed worse baseline health status than 
of similar COPD cohorts. In the ISOLDE study, where the mean FEVi was 1.23 1 (somewhat 
higher than our values), mean SGRQ scores were 49, 66, 62 and 37 for total, symptoms, 
activity and impact respectively (Burge et al, 2000). These values are all about 20 points 
worse in our cohort of studied patients. This is likely to represent social deprivation in the 
East end of Glasgow (the main area of subject recruitment).
4.3.4 Effect of creatine supplementation
4.3.4.1 Post-Loading Evaluation
The supplementation was generally well tolerated without reported side effects. However, 
two patients from the placebo group did not complete the loading phase, because of a dislike 
of the sweet taste of the glucose. Therefore, 36 subjects successfully completed this phase 
(Figure 4.4).
For the creatine group, the initial loading intervention was associated with significant 
increases from the pre-intervention baseline (A) in several muscle-performance measures, 
compared to the corresponding changes for the placebo group (Table 4.7). Thus, body weight 
in the creatine group was increased by 1.1 kg or 1.8% 0.1 kg and 0.2% in placebo
(p<0.05, between-group difference); predominantly in the fat-free mass component (A = 0.9 
kg or 1.3% vs. -0.2 kg or 0.5%; p<0.05, between-group difference) (Figures 4.3 and 4.4).
Similarly, lower-limb muscle (knee-extensor) strength (peak torque) was increased in the 
creatine group compared to placebo (A = 3.5 N.m or 4.1% vs. -0.7 N.m or -0.9%; p<0.05, 
between-group difference) (Figure 4.3), as was endurance (knee-extensor total work) (A = 
424 J or 23.1% 13 J or 0.8%; p<0.01, between-group difference). Upper-1 imb muscle
(handgrip) endurance in the creatine group was also increased significantly, relative to 
placebo (A = 3.9 repetitions or 8.0% vj-. 1.1 repetitions or 2.2%; p<0.05, between-group 
difference). Upper-limb strength (peak handgrip force) was unaffected in either group.
II
"ftT3I
<SI
f
ca
.1
rA
iI
I-'I
0
1  
I
gII i
00
I  gI &
Os
oo
o
inoo
ro^o
aa\i>
moo
oo
po
BII
I0
1
ON
tN
in
NO
ON
a(NN
$
in'4-
mo
r-
I I
*
oo'
m'it
mO n
pO
apo
6CIu
w
mTto
OnO
'ItO
a
t
pC)
'S*oX)
:
<D
<Ë
Ûf t
m
COo
app
CNO
COo coocoo coo 6767 o
aO o+-> +-»
P o
p ON oO
f t
G
f2
BII
■S
B
oni
a
COino
oo
CN
o
X(N
O
o
I i
ft Mof t
(Nin
in
aXCN
O nCO
CN
'It
a't*ni
ocncOo
(o
a
ON
ONrn
II
II
n-o
ni't-
o
CN
a' t
rn
po
g  Z
§
ON
Onnj
67
itit
coocoo
67It
am
d .m
rn
COocoo
o '
anrn
It9
ILI If t  f t
mo
m
NO
On
O
Oni
po
ONni
a
p
m
muSm
a
p
n
mn)
oON
P«n
oNO
Orn
vn
po
po
oo
ani
oin
a
O n
lo
a
ON
e no po
o oni
o o
H
Q
n-
n>in
op
ni
a
ONVN
COO
COo
Snio
NO
nim
H
00
W
"OII
<DI
(DX
ISX
p
" a
<L>I
vnO n
SI
I
c§!
I
Q
1
f t
i
I
JI ^Q w
O
I  
ê
c2
I
(DII
p
Vf t
COo
COO
irTOt
Ii1
(+4OI
I
I
8II
É
o>a
Vf t
*
*
vno
t
cjX
Figure 4.3 Group mean outcomes for major measures.
7 . 5
5
2 .5
0
2 . 5
S
IÎL PL PR
4 0 “
IHI
PL PR
BL PL PR
2 0
1 0
0
JO
20
3  0
BL PR
Group-mean responses (+ one standard deviation) of fat-free mass, knee-extensor peak 
torque, time walked on the endurance shuttle-walk test (ESWT) and the total score on the St. 
George’s Respiratory questionnaire (SGRQ) to the initial loading phase (post-loading: PL) 
and the subsequent training phase with supplementation maintained (post-rehabilitation: PR). 
Creatine group: solid circles; Placebo group: open squares. Responses are expressed as 
percentage changes from baseline (BL). Statistically significant within-group differences 
from BL: * p<0.05, ** p<0.01.
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Figure 4.4 Group body composition outcomes. 
2.6  -1
2.0
1
f
P Q
15
...
(g 0.6o
^ 0.6
Cr Group (n-18) 
a -  Placebo Gmup (n~1 S)
BM (kg) FFM (kg) FM (kg)
3 0  -
Hi“  Gr Group (ri=^  14)
-D - Placebo Group (n-11)
- 2.0 
BM (kg) FFM (kg) FM (kg)
Group-mean responses (+ one standard deviation) of body mass (BM), fat-free mass (FFM) 
and fat mass (FM) to the initial loading phase (upper panel) and the subsequent training 
phase with supplementation maintained (lower panel) for the Creatine group (solid bars) and 
the Placebo group (open bars). Responses are expressed as absolute changes from baseline 
(A); bars represent ± one standard deviation.
The effects of the initial creatine loading on measures of whole-body endurance exercise 
capacity were more variable, however (Table 4.6). In the creatine group, there was a
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significant increase in time walked on the endurance shuttle-walk test, compared to baseline 
(A = 132 s or 38.8%; p<0,01, within-group difference) which was greater than that for the 
placebo group (A = 92 s or 23.5%; p=0.21, within-group difference) (Figure 4.3); however 
the between-group difference did not reach statistical significance (p=0.8). The distance 
walked on the incremental shuttle-walk test was unaffected in either group, compared to 
baseline. For the symptom-limited constant work-rate exercise test, there was a non­
significant increase in exercise time for the creatine group (15 s or 9.1%; p^O.49, within- 
group difference) and, surprisingly, a significant increase for the placebo group (A = 54 s or 
42.8%; p<0.05); but with no between-group difference (p=0.17). The associated degrees of 
breathlessness and perceived exertion at end-exercise for the constant work-rate exercise test 
were unaffected.
43.4.2 Post-Training Evaluation
Twenty-five patients successfully completed the exercise training programme (Figure 4.4). 
The reasons for study discontinuation were: severe exacerbations (n=2 creatine; n=4 
placebo), poor motivation and/or non compliance with the exercise programme (n=l creatine 
group; n=2 placebo group), back ache (n=l creatine group) and vestibular disease (n=l 
placebo group).
4.3.4.2.1 Exercise Training
Changes seen in response to exercise training, with or without creatine, are calculated from 
baseline entry into the study for both groups. The effects of the exercise training itself are 
demonstrated by responses of the placebo group (Table 4.7). Lower-limb (knee extensor) 
muscle strength was increased, relative to baseline (A = 12.2 N.m or 14.8%; p<0.05, within- 
group difference) (Figure 4.3), as was lower-limb muscle endurance (A = 362 J or 22%; 
p<0.01, within-group difference). Upper-limb muscle endurance (total handgrip repetitions) 
was also increased (A = 8.4 or 16.6%; p<0.05, within-group difference), although strength 
(peak handgrip force) was unaffected.
Whole-body exercise capacity was improved, as judged by the results of the incremental 
shuttle-walk test (A = 76m or 25.9%; p<0.05, within-group difference) and the endurance
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shuttle-walk test (A = 275 s or 70.1%; p<0.01, within-group difference) (Figure 4.3). In 
addition, exercise time on the symptom-limited constant work-rate test was increased 
(although with considerable individual variability), which was on the borderline of statistical 
significance (A = 243 s or 193%; p=0.05, within-group difference). The associated 
breathlessness and perceived exertion at end-exercise on the constant work-rate test were 
unaffected. Vo  ^peak and the lactate threshold on the incremental exercise test were also 
unaffected
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There was no significant change in the total score of the St George’s Respiratory Questionnaire. 
However, there was a surprising and significant worsening of the activity domain for the placebo 
group over the study duration (A = 11.0 or 14,0%; p<0.05, within-group difference).
43.4.2.2 Exercise Training with Creatine
The effects of the exercise training being performed in conjunction with ongoing creatine 
supplementation, relative to those to training alone, are provided by comparing the training 
responses of the creatine group with those of the placebo group (Table 4.8).
Fat-free mass following combined training and creatine was substantially greater than for the 
training alone (A == 2.0 kg or 2.8% vs. 0.4 kg or 0.6%; p<0.05, between-group difference; Table
4.7) (Figures 4.3 and 4.4).
The gains in lower-limb muscle performance with combined training and creatine were 
enhanced, relative to the training alone, both with regard to peak torque (A -  19.5 N.m or 22.8% 
V5. 12.2 N.m or 14.8%; p<0.05, between-group difference: Table 4.8) (Figure 4.3) and total work 
(A = 1216 J or 66% vs. 362 J or 22.0%; p<0.05, between-group difference: Table 4.8).
In addition, the improvements in upper-limb performance with combined training and creatine 
were greater than for training alone, both for peak handgrip force (A = 2.9 N or 10.9% vj-. 0.6 N 
or 2.3%; p<0.05, between-group difference: Table 4.8) and for total handgrip repetitions (A = 
15.6 or 31.9% vs. 8.4 or 16.6%; p<0.05, between-group difference: Table 4.8).
As judged by shuttle-walk or cycle-ergometer performance, creatine supplementation combined 
with training provided no further statistically significant improvement in whole-body exercise 
capacity than with training alone (Table 4.8). For example, the improvement in the tolerable 
duration of the symptom-limited constant work-rate test was not different between placebo and 
creatine groups, although the change from baseline was significant in the creatine group (Table
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4.8). Again, Vo  ^PEAK was unaffected, although the lactate threshold significantly increased from 
baseline in the creatine group (A = 0.11 1/min or 20%; p<0.05, within-group difference; Table
4.8). There were no significant differences between or within groups in exercise-related 
symptoms at peak exercise for the incremental exercise test (Table 4.8). While there were no 
differences between groups in exercise-related symptoms at peak exercise for the incremental 
exercise test, there was a significant decline in breathlessness for the creatine group at end- 
exercise for the constant work-rate test, compared to baseline (A -  -1.3 or -16.7%; p<0.05, 
within-group difference: Table 4.8).
The magnitude of improvement in quality-of-life (SGRQ total and activity domain scores) was 
significantly enhanced by the combined creatine supplementation and training: SQRQ total score 
was decreased by 5.9 or 9.0% vs-, an increase of 1.8 or 2.7% for placebo (p<0.05; between-group 
difference: Table 4.7, Figure 4.3) and SGRQ activity domain score was decreased by 5.3 or 
6.4% v^ -. an increase of 11.0 or 14% for placebo (p<0.01; between-group difference: Table 4.8).
There were no significant relationships between baseline functional indices (i.e. pulmonary 
function, body composition, exercise tolerance) and the subsequent benefit from creatine 
supplementation, without or with exercise training.
Importantly, the average improvements seen post-training in both exercise capacity and health- 
related quality-of-life represent clinically-significant improvements. Thus, there was an increase 
in the incremental shuttle-walk test of over 50m for both the creatine and the placebo groups, 
with 6 patients in each group exceeding this value(2001). Likewise, the St. George’s Respiratory 
questionnaire total score decrease of more than 4 points in the creatine group should be noted, 
with 6 patients in this group exceeding this value and one in the placebo group (Jones et al, 
1991).
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4.3.4.2.3.1 Influence of Fat-Free Mass
We were unable to discern any statistically significant effects of the loading intervention or the 
subsequent training regimen relative to the presence or absence of fat-free mass depletion. 
Indeed, it should be pointed out that as the study was powered primarily to examine the effect of 
creatine administration per se, it was therefore likely underpowered for fat-free mass 
comparisons. Also we did not find any correlation between change in fat free mass and peak 
torque (i- 0.08, p= 0.8 for post loading and r= 0.24, p= 0.4 for post rehabilitation) over the study 
period.
4.3.4.4 4 Pulmonary function
There were no significant changes in pulmonary function measures, either following Cr loading 
or rehabilitation. We did not anticipate any alteration of static lung volumes over the course of 
the intervention. An initial trend of increased maximal inspiratory respiratory muscle pressure 
over creatine loading did not persist following rehabilitation. No specific respiratory muscle 
training was being performed.
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4.4 Discussion
This study has demonstrated that 2 weeks of oral creatine supplementation (15 g/day) was 
effective in increasing fat-free mass, lower-limb muscle strength and endurance in patients with 
moderate to severe COPD. Furthermore, compared to pulmonary rehabilitation alone, 
subsequently incorporating a 10-week pulmonary rehabilitation programme with maintained 
creatine administration (5 g/day) proved to be more effective in increasing fat-free mass and 
lowei-body muscle performance, as well as inducing gains in upper-body muscle performance 
and quality of life. While there were clear training-induced effects on whole-body exercise 
performance, these were not systematically enhanced in the presence of creatine.
This study demonstrates that oral creatine monohydrate supplementation is associated with 
beneficial effects on skeletal muscle mass and function in patients with moderate-to-severe 
COPD. These effects can be further enhanced with whole-body exercise training. This study, 
theiefoie, suggests that creatine supplementation, either in isolation or in combination with 
physical exercise, constitutes a novel ergogenic aid for patients with COPD.
4.4.1 Creatine supplementation in COPD
Energy production (via ATP genesis) for skeletal muscle work is derived from one of three
souices. anaerobic breakdown of phosphocreatine via the Lohmann reaction, also anaerobic and
aerobic glycolysis. During moderate intensity exercise, as oxygen uptake increases to reach a
steady state sufficient to meet the energy demands solely by aerobic glycolysis, the shortfall (or
oxygen debt ) is met by phosphocreatine breakdown. This Lohmann reaction can be represented 
by the equation:
Phosphocreatine + ADP -------------- ► ATP + Creatine
ATP -------------- ► ADP + Pi
The enzyme creatine kinase enables the Lohmann reaction to proceed in either direction. 
Creatine, or methyl gaunidine acetic acid (Cr) is a substance found naturally in foodstuffs such as
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meat and fish. At present there is much interest in creatine supplementation in health and this is 
reflected in a number of reviews on the subject recently published (Terjung et al, 2000b; Jacobs, 
1999; Kraemer & Volek, 1999). Creatine monohydrate is widely used by healthy individuals 
worldwide as an aid to exercise performance (Terjung et al, 2000a). In the skeletal muscle, 
creatine undergoes suffers rapid and reversible phosphorylation catalysed by the enzyme creatine 
kinase, a reaction that forms phosphocreatine (PCr). PCr provides an immediate quick source of 
high-energy phosphate which is crucial for maintaining the rate of ATP resynthesis and 
generation during the initial stages of exercise, especially when demands are high (Kilduff et al, 
2003). Studies have shown that oral supplementation with creatine monohydrate increases total 
and free intra-muscular creatine (Harris et al, 1992), in addition to increasing intra-mu seul ar PCr 
stores during exercise and recovery (Greenhaff et al, 1994b). An increased availability of PCr 
may allow for a ‘proton sink’ to be formed as initially energy release from the breakdown of PCr 
to ATP and Cr consumes a hydrogen ion. This has potential for beneficial effects in the muscle, 
through the delay of the development of acidosis. This also has particular relevance to COPD 
patients because of the role of systemic acidosis in determining ventilatory demands (Wasserman 
et al, 1999). It has a proven benefit upon physical performance, most specifically in those 
activities that involve repeated short bouts of high intensity exercise (Terjung et al, 2000b). In 
healthy subject creatine has an impact on short bursts of high intensity exercise, such as 
sprinting, leading to an increased maximum and total power produced. These effects have been 
demonstrated in placebo controlled double blind experiments. Repeated maximal voluntary 
contraction on an isokinetic dynamometer, after creatine supplementation, led to significantly 
increased peak torque production (Greenhaff et al, 1993). Repeated episodes of maximal power 
output during cycling were increased following creatine supplementation (Birch et al, 1994). 
This is thought to result from increased rate of phosphocreatine resynthesis resulting from raised 
muscle creatine levels. Creatine is considered to benefit subjects taking it to different degrees; so 
called ‘responders’ and ‘non-responders’. These groups are characterised by the extent to which 
they uptake creatine. Determining those who will become responders is a focus of research and 
cannot presently be predicted. The higher the resting stores of creatine are, the less exogenous 
creatine is likely to be taken up. Thereby one may expect increased uptake in groups such as 
vegetarians. So far there is no evidence published on this matter. However there are data to 
suggest that the degree of benefit derived from creatine supplementation is relative to the amount
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taken up (Casey et al, 1996). In normal subjects, resting phosphocreatine levels are between 70- 
90 mmol.kg Fs % which does not allow for sustained energy production from this source. 
Creatine supplementation may be expected to increase this by approximately 20% (to between 
85-105 mmol.kg'\s'^) (Febbraio et al, 1995; Hultman et al, 1996).
However many published creatine studies are hampered by small sample sizes, poor control 
groups and the short-term nature of the investigations. There is evidence that creatine can have 
anabolic benefits in the context of muscle rehabilitation (Hespel et al, 2001). The benefits 
described, in body composition and performance, have also been demonstrated in elderly 
subjects (Gotshalk et al, 2002). More recently there has been evidence that creatine can exert an 
ergogenic effect in elder healthy persons (Gotshalk et al, 2002). Disease groups have been 
studied, albeit in small numbers and most usually in uncontrolled trials. In a well conducted 
investigation Cr was demonstrated to improve lower limb muscle performance in patients with 
chronic heart failure (Gordon et al, 1995).
There are no established common side effects of creatine administration. A meta-analysis has 
concluded that the supplement is safe (Graham & Hatton, 1999). In particular a long-term study 
found no evidence of impact upon renal function (Poortmans & Francaux, 1999). This is 
supported by our investigation where the dropout rate, both due to intolerance of the supplement 
and total, was higher in the placebo group than in the Cr group.
4.4.2 Body Mass and Fat-free Mass
Consistent with earlier reports in healthy young (Birch et al, 1994; Balsom et al, 1995; Kreider 
et al, 1998;Kilduff et al, 2002b) and older (Gotshalk et al, 2002; Chrusch et al, 2001; Jakobi et 
al, 2001) subjects, in healthy young subject following rehabilitation from disuse atrophy (Hespel 
et al., 2001) and in patients with myaesthenias gravis (Stout et al, 2001), the initial two-week 
loading phase of creatine supplementation in our cohort of COPD patients led to an increased 
body mass that was effectively accounted for by an increase in fat-free mass, compared to the 
placebo group (Table 4.7; Figures 4.3 and 4.4). The subsequent phase of maintenance
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supplementation and training was associated with a further increase in fat-free mass of similar 
magnitude (2.0 kg, on average: Table 4.8) to those reported for healthy subjects (Kilduff et al, 
2002b; Gotshalk et al, 2002), but no further increase in body mass, consistent with our 
observation of a reduced fat mass (Table 4.8 Figures 4.3 and 4.4).
The exact mechanism underlying this creatine-induced increase in fat-free mass is unclear. 
Creatine ingestion has been shown to cause water retention that is presumed to reflect local gains 
within skeletal muscle rather than more-generalised water retention. However, the technique 
used to measure FFM in this study (air-displacement plethysmography) is known to be 
insensitive to variations on tissue water content. Therefore, we cannot exclude body water 
retention as an explanation for the gain in fat-free mass. Whether other body composition 
methodologies that account for tissue water content, such as BIA, or regional body composition, 
such as DEXA, would be more enlightening in relation to mechanistic changes is of interest. It 
has been suggested that creatine-induced intramuscular water retention can, through myocyte 
swelling, induce an increase in protein synthesis (Haussinger et al, 1993). Also protein synthesis 
in cultured myocytes has been shown to be stimulated with increased creatine availability 
(Ingwall et al, 1974), which may involve up-regulation of myogenic transcription factors (e.g. 
MRF4 and myogenin) (Hespel et al, 2001). There is evidence to suggest that the changes found 
after exercise training relate to appropriate increases in intracellular water accompanying 
anabolism (Francaux & Poortmans, 1999).
The potential importance of this finding should be viewed in the recognition that peripheral 
muscle wasting is a strong independent predictor of mortality in COPD, irrespective of disease 
subtype (Schols et al, 1998b; Marquis et al, 2002). There is increasing realisation of the 
importance of skeletal muscle, both in the causation, and amelioration of exercise intolerance 
(Palange et al, 1995; Gosselink et al, 1996). Skeletal muscle dysfunction is likely to be multi 
factorial in nature and is distinct from corticosteroid myopathy. Disuse atrophy, cellular hypoxia, 
circulating inflammatory cytokines and malnutrition are almost certain to be major components 
{Wouters et al, 2002). It manifests itself most obviously through reduced muscle bulk and 
strength of COPD patients compared to healthy controls (Bernard et al, 1998b). Within the
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skeletal muscle there is seen a selective loss of type IIx fibres, (Gosker et al, 2002) decreased 
resting levels of PCr (Jakobsson et al, 1990) and oxidative enzymes (Jakobsson et al, 1995) and 
evidence of increased levels of oxidative stress. The muscle groups themselves are found to have 
relatively well preserved function in more the proximal muscle groups (Gosselink et al, 2000). 
Patients with muscle bulk loss are found to have worse health status, increased exacerbation 
frequency and increased mortality; moreover these impacts may be reversible (Schols et al, 
1998a). Also patients who gained weight following either a nutritional intervention (Schols et al, 
1998b) or treatment with an anabolic steroid (Schols et al, 1995b) had decreased mortality 
compared to those who did not. Consequently, considerable attention has been given to 
identifying tolerable intervention strategies that might reverse muscle wasting in patients with 
COPD. For example, Burdet et al (Burdet et al, 1997), Yeh et al (Yeh et al, 2002) and 
Creutzberg et al (Creutzberg et al, 2003) have demonstrated that recombinant growth hormone 
and anabolic agents (Oxandrolone, Nandrolone), respectively, increase fat-free mass in this 
patient group. We have demonstrated in the present study that creatine supplementation, over a 
continuous period of up to 12 weeks, also induced gain of fat free mass and was well tolerated 
(with no patients reporting any associated side-effects).
4.4.3 Muscle Strength and Endurance
The initial creatine loading in the present study was associated with gains in lower-limb muscle 
strength and endurance and upper-limb endurance (Table 4.7; Figure 4.3). The subsequent 
maintenance period of creatine supplementation combined with exercise training elicited further 
improvements in both lower and upper limb strength and endurance (Table 4.8; Figure 4.3). It 
has been shown that lower-limb muscle strength is compromised to a greater degree than that of 
the upper limbs in patients with COPD (Hamilton et al, 1995; Gosselink et al, 1996), likely 
reflecting the reduced habitual use of the locomotor muscles expected in this patient group. This 
might predispose the lower-limb musculature to be more sensitive to the effects of the 
supplementation, consistent with a supposition that muscle performance gains with creatine are 
greater for muscle groups which are relatively detrained.
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There have been a number of interventions performed that have attempted to counter the 
progressive skeletal muscle dysfunction seen in COPD. The most successful, and only one with 
proven good efficacy, is exercise training, particularly if in combination with strength training 
(Bernard et al, 1999b). To our knowledge, this is the first additional intervention study in COPD 
to show an increase in muscle function as measured by strength or endurance in association with 
an increased fat-free mass. Previously-reported intei'ventions in COPD patients such as 
administration of anabolic steroids (Ferreira et al, 1998a; Yeh et al, 2002; Schols et al, 1995b; 
Creutzberg et al, 2003), recombinant growth hormone (Burdet et al, 1997), appetite stimulants 
(Weisberg et al, 2002), hypercaloric protein-rich diets (Slinde et al, 2002) and high- 
carbohydrate diets (Steiner et al, 2003) while successfully effecting some restoration of fat-free 
mass, were without effect on peripheral muscle performance. Control groups are often not 
present, and have not been on placebo. There is a difficulty in blinding subjects and the 
investigators. Also study numbers have often been very small. These factors are liable to have 
been instrumental to the findings of the recently published Cochrane review on this subject; 
namely that outpatient nutritional intervention is ineffective in COPD with regard to 
anthropometry or muscle function (Ferreira et al, 2000b). A 6-month study of testosterone and 
stenozalol was able to demonstrate increases in body weight and fat-free mass but not functional 
capacity (Ferreira et al, 1998b). Growth hormone administered over 2 months during a 
pulmonary rehabilitation programme induced increases in fat free mass, but did not influence 
muscle performance and seemed to worsen exercise capacity (Burdet et al, 1997). A recently 
published study examining the effects of anabolic stroids in a cohort of male COD patents with 
low serum testosterone, was suggestive of an effect upon muscle strength (Casaburi et al, 2004). 
Flowever the changes seen in one repetition maximum quadriceps strength did not have 
significantly different changes between placebo and testosterone groups in those who received 
exercise training. Therefore the benefits upon muscle function, exercise capacity and health 
status from interventions other that exercise training are unproven at present.
COPD patients can also manifest reduced lower-limb muscle endurance, with Serres et al (Serres 
et al, 1998) reporting that COPD patients achieved fewer dynamic contractions of the 
quadriceps muscles than controls, when matched for maximal strength. It is of interest, therefore, 
our patients demonstrated a significant increase in quadriceps and forearm endurance following
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creatine loading (as measured by total work and total repetitions respectively), compared to the 
placebo group. This finding is in agreement with previously-published data in healthy resistance- 
trained young adults (Kilduff et al, 2002b), healthy older subjects (Rawson et al, 1999; 
Gotshalk et al, 2002) and heart-failure patients (Gordon et al, 1995; Andrews et al, 1998b).
The exact mechanisms responsible for these observed creatine-induced increases in muscle 
strength and endurance are uncertain. As we did not make any direct measurement of creatine 
uptake in our patients, we can only speculate on the potential mechanisms. Interestingly, 
peripheral muscle abnormalities in COPD include low resting ATP and PCr concentrations 
(Gertz et al, 1977;Jakobsson et al, 1990) and lower intracellular pH and slower PCr resynthesis 
during recovery from exercise (Payen et al, 1993; Sala et al, 1999a). Both an increase in resting 
PCr levels and an accelerated rate of post-exercise PCr resynthesis may be involved in the 
mediation of the ergogenic effect of creatine supplementation, certainly in healthy subjects 
(Greenhaff et at., 1994a; Balsom et al, 1995). It is tempting to speculate, therefore, that the 
muscle performance gains our COPD patients demonstrated following creatine supplementation 
derive from an amelioration of PCr-related abnormalities in muscle bioenergetics.
The subsequent inclusion of exercise training with continuing creatine supplementation 
amplified the muscle performance gains in our patients. Compared to the effects of the training 
alone, both quadriceps and handgrip strength and endurance were increased (Table 4.8; Figure 
4.3) This raises the interesting possibility that the supplementary creatine may have acted as an 
extra stimulus during training, thus allowing patients in the creatine group to train at a greater 
exercise intensity and therefore leading to a greater improvement in muscle performance 
(Earnest et al, 1995; Volek et al, 1999). And while we did not comprehensively document work 
completed in each training session for each patient, the significantly greater loss of fat mass 
observed in the Cr group could support this notion (Table 4.8). The enhanced muscle 
performance seen in the present study when combined with exercise training has also been 
observed in both healthy young subjects (Vandenberghe et al, 1997; Kreider et al, 1998; Volek 
et al, 1999) and healthy older subjects (Chrusch et al, 2001) but not before in patient groups. 
However, the fact that functional improvements were obtained without training suggests that
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creatine supplementation in isolation may be beneficial for patients with advanced COPD who, 
not uncommonly, are unable to undertake formal whole-body exercise training sessions.
4.4.4 Whole-Body Exercise Performance
The effects of creatine supplementation on whole-body exercise performance in healthy subjects 
are generally acknowledged to be more variable. The consensus is that performance for high- 
intensity sprint exercise (e.g. intermittent exercise) can be improved (Greenhaff et al, 1993; 
Terjung et al, 2000b). However, for graded exercise and step tests (and for which reliance on 
PCr is less marked), the effects are more variable (Stroud et al, 1994; Smith et al, 1998; Balsom 
et al, 1993). In this context, therefore, the more variable results in our COPD patients for 
shuttle-walking and with symptom-limited cycle-ergometry are perhaps not entirely surprising. 
The improvements in endurance shuttle-walk test performance that resulted from creatine 
supplementation were clinically significant when compared to baseline, but not when compared 
with placebo (Table 4.7; Figure 4.3). Similarly, exercise time on the symptom-limited step test 
was increased in some of the supplemented patients, but not in others, with the overall 
prolongation of the exercise time not being statistically significant. Similarly, there was a lack of 
effect on Voj p e a k  and the lactate threshold (Table 4.7).
Training per se induced some performance gains for whole-body exercise, notably for shuttle- 
walking, consistent with expected gains (Laçasse et al, 1996). The lack of effect on VO2 max 
and lactate threshold is not without precedent, especially in patients who are substantially 
impaired in terms of respiratory limitation (Reardon et al, 1994). There was considerable 
variability in the changes seen in exercise endurance time following intervention. This is 
consistent with the influence of learning effects and the high variability of these tests (Revill et 
al, 1999; Noseda et al, 1989). We were unable to incorporate additional familiarisation 
sessions into our protocol.
There is established evidence that training responses are specific to training modalities. A 
strength training programme will have less of an impact on endurance ability than an endurance
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based programme. Anabolic steroids have been demonstrated to induce weight gain (largely lean 
mass) in COPD patents. Improvements in strength have been seen, however the failure of impact 
upon endurance activity or whole body exercise has been attributed to the nature of the muscle 
adaptation seen following anabolic agents. The potential for strength training/muscle bulk 
intervention to increase whole body exercise capacity is highlighted by the demonstration that a 
severely disabled group of COPD patients had significant increases in peak O2 uptake following 
neuromuscular electrical stimulation administration (Neder et al, 2002). More practically they 
were able to then partake in a standard pulmonary rehabilitation programme. This may indicate 
that anabolic agents, which we believe includes creatine, have a clear potential to impact upon 
whole body exercise.
4.4.5 Quality of Life
We also found clinically meaningful improvements in health related quality of life when 
combined creatine and training was compared with the training alone (Table 4.8; Figure 4.3). 
The extent of this is striking and was seen largely to arise from the activity domain of the SGRQ. 
Peripheral muscle weakness is thought to contribute to the “dyspnoea spiral” through inactivity 
and disuse atrophy. An intervention which benefits skeletal muscle therefore has the theoretic 
advantage of favourably influencing activities of daily living. A short-term study such as ours 
was not powered to detect differences in exacerbation frequency, which is clearly one of the 
main factors that influence health status. We are not aware of any interventions that when 
combined with exercise training lead to significantly greater changes in health related quality of 
life.
4.4.6 Study Limitations
To our knowledge this is the first study of creatine supplementation in patients with COPD. We 
were well aware of the weakness of previous investigations of nutritional and specifically 
creatine supplementation that have been performed in health and disease. Therefore we aimed to 
conduct a double-blind, placebo-controlled trial, that was sufficient in power and duration. 
Although it was our initial primary outcome measure, it is likely that we were underpowered to
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detect any between group differences in exercise capacity as the variability of these measures is 
so high. Specifically, whereas we can report a coefficient of variation for the shuttle walking 
distance, once learning effect has been accounted for, of 13,9%, this compares unfavourably to 
the repeatability of the strength measurements which over the first 2 peak torque bouts of 
quadriceps was 3.7% for the same subjects. The published studies that demonstrate 
improvements in exercise capacity with treatments, out with those involving exercise training, 
have utilised cross over designs. The incorporation of exercise training meant that such a design 
was not feasible. Also the beneficial effects of creatine in healthy subjects seem largely to relate 
to short-term high intensity exercise. There is no established means of assessing this aspect of 
whole body exercise in patient groups and our evaluations therefore may not have been the most 
appropriate. It is also possible that the magnitude of effect was insufficient, perhaps made less 
likely by the positive health status findings.
We have demonstrated convincing beneficial changes in the skeletal muscle in both bulk and 
function when compared with simple carbohydrate administration. These changes were 
persistent over at least 12 weeks. These effects on muscle strength and endurance have not been 
previously demonstrated with any previously investigated putative ergogenic aid.
We were not able to measure creatine uptake, either by repeated muscle biopsy or through 
urinary excretion of creatine. Neither were we able to assess dietary behaviour and dietary intake 
of creatine in our patient group. Therefore we are not able to examine subgroups of “responders” 
or “non responders” to creatine. We attempted to minimise this potential confounder by 
including carbohydrate in the supplementation mixture which has been shown to enhance the 
uptake of Cr by 60-100% (Green et al, 1996).
The design of our study also does not allow us to resolve the relative potencies of creatine 
supplementation and the training regimen on body composition and muscle performance 
benefits, nor the longer term impact of creatine administration and separate studies would be 
required to clarify this.
We are also unable to provide any insight on the relative effect of creatine supplementation in 
COPD patients who demonstrate appreciable muscle wasting, compared to those who do not.
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That is, while we classified our patients in this way, the small numbers of patients constrained 
the analysis because of underpowering. This is clearly an issue of considerable importance that 
will, therefore, require a substantially larger study; the primary purpose of our study was to 
explore the effects of creatine alone and with exercise training in a largely unselected patient 
group. However the main study limitation remains that of insufficient sample size, though we 
believe that our investigation does represent the largest examination of Cr supplementation 
published to date in health or disease. The cohort of patients from inner city Glasgow represents 
a very severely diseased and socially deprived group. This explains the high rehabilitation drop 
out rate; one that is expected with our local programme. Although we did see improvements in 
strength and exercise capacity in both groups following rehabilitation, the placebo group did not 
have any significant change in health status. This may relate partly to the reasonably small 
number of placebo patients that finished the exercise training. However a more intensive 
rehabilitation service would have been preferable, as our twice-weekly 8-week programme was 
the minimum recommended for successful outpatient exercise training (ATS statement, 1987). 
Our placebo group were administered carbohydrate, as well as the Cr cohort. Although this 
means that we did not provide a true placebo, this regime has successfully removed carbohydrate 
as a confounding factor, establishing that the effect seen were solely due to creatine.
It is likely that our study was underpowered to detect differences in exercise capacity. As 
expected, approximately a third of our patient group dropped out of the study during exercise 
training, albeit more in the placebo arm. However our data do not suggest that creatine was 
leading towards benefits in whole body exercise capacity, though it is possible that trends in 
perceived breathlessness and exertion could have become significant with increased numbers of 
subjects.
Finally, we cannot comment on issues of mortality and morbidity in the context of our findings 
to date. A much larger study would be required to determine whether the observed improvement 
in fat-free mass proved to be beneficial in this regard.
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4.4.7 Conclusions
In summary, this study demonstrates that oral creatine monohydrate supplementation, 
both in isolation and in combination with exercise training, improved fat-free mass, skeletal 
muscle function and health-related quality of life in a group of patients with advanced COPD. 
These data therefore suggest that creatine may constitute a novel ergogenic aid for clinical use in 
this patient population.
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CHAPTER 5
THE EFFECT OF FORMOTEROL 12 |nG TWICE DAILY ON 
EXERCISE TOLERANCE AND DYNAMIC HYPERINFLATION 
IN STABLE MODERATE-TO-SEVERE COPD PATIENTS
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ABSTRACT
Introduction: Exercise intolerance is a hallmark of COPD. Long acting bronchodilators
have established benefits upon lung function, health status and exacerbation frequency. 
Formoterol is a well tolerated and effective bronchodilator in COPD patients. However its 
impact upon dynamic hyperinflation, and therefore potentially exercise tolerance, is not known. 
We wished to determine whether this long acting beta agonist significantly enhances exercise 
tolerance and reduces the associated dynamic hyperinflation in COPD patients.
Methods: Patients with established COPD were enrolled: history of smoking (>20 pack-
years) and diagnosis of COPD according to American Thoracic Society criteria, with pre­
broncho dilator FEVl <60% and FEVl/FVC <70% of predicted normal value, and an increase in 
FEVl <12% from predicted normal value following inhalation of 400 pg salbutamol. This was a 
randomized, double-blind, placebo controlled, crossover study consisting of two 2-week 
treatment periods separated by a 2 day washout phase of formoterol 12pg b.i.d. versus placebo. 
The primary efficacy parameter was the time to limit of tolerance (Tlim), taken as the interval 
between onset of constant work rate and the point at which the patient could no longer maintain 
60 revolutions per minute on a cycle ergometer. Secondary endpoints included Mahler’s 
questionnaire of Chronic Activity-Related Breathlessness, Borg dyspnea scores during exercise 
and measures of dynamic hyperinflation.
Results: Twenty one patients (14 male, age 60 +- 9 years, FEVi 1.00 +- 0.34 1) were
enrolled, giving eighteen evaluable subjects. From the results of the ANCOVA, the estimated 
difference between treatments was 130 seconds (Cl -1.2 to 261.8 seconds), to the advantage of 
formoterol (formoterol 479 seconds, placebo 349 seconds) and was very close to achieving 
statistical significance (p=0,052). The secondary parameters showed advantages to formoterol, 
those of end expiratory lung volume (-0.13 1, -0.27 to -0.00 at Tlim, p = 0.045), inspiratory 
reserve volume (0.2 1, 0.09 to 0.3 at isotime, p = 0.0019) and Mahler’s questionnaire of chronic 
activity-related breathlessness (p < 0.05 for all three indices) being statistically significant.
Conclusions: Formoterol led to significant amelioration of dynamic hyperinflation
without a significant effect upon absolute exercise tolerance (p=0.052). However this study 
suggests that formoterol may improve the time to limit of exercise tolerance by approximately 2 
minutes.
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5.1 Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by chronic, and only partially 
reversible, airways obstruction (ATS Standards, 1995). COPD therefore presents with symptoms 
of breathlessness; the result of irreversible ehanges in the lung parenchyma and airways 
attributed in most cases to cumulative exposure to tobacco smoke. The multi-factorial functional 
impairment in COPD frequently reduces exercise tolerance within this group, thereby decreasing 
activity levels. This usually progressive deterioration of symptoms and health is often referred to 
as the “dyspnoea spiral”. Exercise intolerance is therefore a hallmark of the disease and 
commonly associated with reduced quality-of-life, increased morbidity and mortality (Ries et ai, 
1995; Gerardi et al, 1996).
Exercise limitation in COPD has traditionally been ascribed to flow limitation and gas exchange 
disturbances. Patients usually stop exercise when their level of ventilatation reaches a severely- 
reduced maximum capacity (Neder et al, 2000). This ventilatory driven exercise ceiling is 
further exacerbated by dynamic hyperinflation, whereby lung volumes progressively increase 
with consequent impact upon associated work of breathing. Any intervention, therefore, which 
leads to diminished ventilatory demand (e.g. physical training) (Casaburi et al, 1997), an 
improved ventilatory capacity (e.g. bronchodilation) (Belman et al, 1996) or reduced work of 
breathing (eg reduced dynamic hyperinflation, ventilatory support, heliox administration) for a 
given ventilation has the potential to improve exercise tolerance in patients with COPD. Both 
short acting (atroveiit, salbutamol) and, more latterly, long acting (salmeterol, tiotropium) 
bronchodilators have been demonstrated to impact upon dynamic hyperinflation in COPD 
patients (O'Donnell et al, 2004b; O'Donnell et al, 2004a; O'Donnell et al, 1999).
Formoterol fumarate (Foradil®) is a bronchodilator drug of the class of long-acting (32- 
adrenoceptor agonists. It is a formylamino-substituted catecholamine derivative: 2-hydroxy-5- 
[(lRS)-l-hydroxy-2-[[(lRS)-2-(p-methoxyphenyl)-l-methyl]ethyl amino] ethyl] formanilide 
fumarate dihydrate. In vitro and in vivo formoterol exerts a preferential effect on |32~adrenergic 
receptors of bronchial smooth muscle. Bronchodilator activity can be demonstrated at very low 
doses following oral administration and at even lower doses after inhalation (Anderson, 1993).
Foradil delivered via the Aerolizer has been shown to have beneficial effects on pulmonary 
function and quality of life measures in patients with COPD (Friedman et al, 2002). Dose
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titration studies demonstrated a duration of action of about 12 hours after inhalation of 12 and 
24pg of formoterol (Wallin et al, 1993). In asthma, formoterol has been shown to be 
therapeutically effective and well tolerated for periods of up to 12 months without significant 
changes in bronchoprotective and bronchodilating activities (Hekking et al., 1990). In single­
dose studies in asthmatic adults, 12 and 24pg of formoterol aerosol and dry powder provided a 
rapid onset of action within one to three minutes, similar to that of the short-acting (32- 
adrenoceptor agonist salbutamol (Wegener et al,  1992). In COPD regular (32-agonist treatment 
is intended to provide “round the clock” relief of symptoms already in existence and in 
conjunction therefore has more striking benefits upon health status, breathlessness and 
exacerbation frequency (Jarvis & Markham, 2001; Friedman et al., 2002; Mahler, 2002).
Exercise intolerance results when a patient is unable to sustain a designated physical task 
sufficiently long for its successful completion. Most patients with COPD therefore confine their 
activities of daily living to tolerable sub-maximal exercise intensities. Exercise capacity has been 
traditionally assessed by rapid-incremental exercise tests performed to a symptom-limited 
maximum, which provides relatively little information about a patient’s actual ability to carry on 
activities of daily living. More recent test formats that focus on endurance capacity in COPD, 
provide a better frame of reference as to whether a patient is able to carry on activities of daily 
living -  an important goal of any intervention in patients with COPD. The sub-maximal 
constant-load test performed to the limit of tolerance is one such test (Oga et al, 
2000;Wasserman et al, 1999). When performed in conjunction with direct measurements of 
flow-volume reserves and systematic symptom assessment this strategy should provide a more 
reproducible and sensitive approach for quantifying exercise tolerance (Van't et al, 2003).
Therefore the primary objective of this study was to demonstrate that treatment with formoterol 
fumarate, delivered for 14 days significantly enhances exercise tolerance in COPD patients with 
moderate-to-severe stable airflow obstruction, compared to placebo. Formoterol has a faster 
onset of action than other long acting bronchodilators and therefore may have particular 
pertinence to use in relation to exercise in COPD patients. Secondary objectives were to evaluate 
whether formoterol reduces effort-related breathlessness during everyday activities and whether 
formoterol reduces dynamic hyperinflation during exercise.
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5.2 Methods
5.2.1 Subjects
Twenty one patients (14 male) were enrolled to the study, which had a randomized, double- 
blind, placebo-controlled, cross-over design. Key inclusion criteria were: 1) male and (non- 
pregnant/non-lactating) female patients aged >40 years with a history of smoking (>20 pack- 
years) and a diagnosis of COPD according to the American Thoracic Society criteria, 2) pre- 
bronchodilator FEVi <60% and FEVi/FVC <70% of predicted normal value and 3) at screening, 
30 minutes after inhalation of 400pg salbutamol, an increase in FEVi of <12% of the patient’s 
predicted normal value.
Exclusion criteria were 1) left ventricular heart failure, myocardial ischemia, QTc from a resting 
ECO >0.46 s, or history or presence of significant cardiovascular disease including coronary 
artery disease, arrhythmia and uncontrolled hypertension 2) either hospitalization for a COPD 
exacerbation or presence of a respiratory tract infection within 1 month prior to screening, 
current or childhood asthma, a history of allergic rhinitis or other atopic disease, or a total blood 
eosinophil count over 400 mm\ 3) inability to interrupt treatment with usual bronchodilator 
medication prior to testing, need for long-term oxygen therapy, or arterial oxygen saturation 
<85% at rest, or history of untoward reactions to sympathomimetic amines or inhaled 
medication, 4) anaemia, hypo- and hyperthyroidism, hyperadrenergic state, uncontrolled insulin 
dependent diabetes mellitus, malignancy, or any disease or condition which limits exercise 
performance, other than COPD, 5) History of alcohol or drug abuse, history of non-compliance
to medical regimens, or treatment with any investigational drug js.yjthin '^i"rtftufrti  ^
screening. 6) Change in the use of inhaled or nasal ^ icg g g fm d s, change in the use of oral 
modified-release theophy 1 line,^jorJreat oral corticosteroids, within 1 month prior to
screening. 7) Use of short acting p2-agonists within 6 hours, long acting p2-agonists within 24 
hpurs, Or inhaled anticholinergics within 8 hours, prior to Visit 1. 8) The use of the following 
after Visit 1 (screening): non-potassium sparing diuretics, beta-blocking agents, quinidine or 
quinidine-like medications (anti-arrhythmies), tricyclic antidepressants, fluoxetine and other 
selective serotonin reuptake inhibitors, monoamine oxidase inhibitors, or antihistamines.
133
Before the tests, the procedures, including the known risks, were described in detail and written, 
informed consent (as approved by the Glasgow Royal Infirmary Ethics Committee) was obtained 
from all patients.
5.2.2 Study design
The study consisted of a one week screening phase and two 2-week treatment periods separated 
by a 2 day washout phase. Eligible patients who completed the screening phase were randomized 
to one of two treatment sequences: formoterol 12pg b.i.d followed by matching placebo, or vice 
versa. The study design is illustrated below in Figure 5-1.
Figure 5-1 Study design
^'Screening period Treatment period
Screening 
Day “ 7  
Visit 1
Sequence 1 
Sequence 2
Treatment period I Washout Treatment period 11 
Day 1 Day 14. Days 1 5 -1 6  Day 17 Day 3 0  
Visit 2  Visit 3 Visit 4  Visit 5
Formoterol
Placebo
Placebo 
Formoterol
5.2.3 Treatment administration
During thie active treatment periods of the study (Periods I and II) patients took study medication 
twice daily: one dose in the morning (6.00-9.00 hrs), and one in the evening (18:00-21:00 hrs) 
about 12 hours later. On visit days patients took their morning dose at the study centre.
Study medication was supplied as dry powder capsules containing 12pg formoterol fumarate and 
inhaled using the Aerolizer™ device (illustrated below in Figure 5.2).
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Figure 5.2 The Aeroliser™ inhaler device.
Study medication capsules were supplied by the Novartis Corporation in blisters of 8 capsules, 
packed in boxes and supplied with the Aerolizer™ device. Study medication was supplied to 
Glasgow Royal Infirmary as individual randomized patient packs containing two period packs - 
one for each treatment period. Study medication was then dispensed to each patient at the start of 
the two treatment periods (Visits 2 and 4). Patients were randomly assigned to one or other 
treatment sequence (formotero 1/placebo or placebo/formoterol). Blinding was maintained by the 
use of identical active or placebo capsules. Randomization was performed by Novartis Drug 
Supply Management using a validated system that automates the random assignment of 
treatment groups to randomization numbers. Only when the study had been completed, the data 
file verified, and the protocol violations determined were the drug codes broken and made 
available for data analysis.
Patients were permitted to take rescue medication for worsening COPD symptoms. Two puffs of 
Combivent were permitted as rescue medication delivered via a metered dose inhaler (lOOpg 
salbutamol/ 20pg ipratropium bromide per actuation) not to exceed 8 inhalations per 24 hour 
period. Patients requiring 8 inhalations on two consecutive days were required to contact the 
Department of Respiratory Medicine, Glasgow Royal Infirmary. Taking rescue medication 
within 8 hours prior to a study visit required postponement of that visit. Visits 2 and 4 could be 
rescheduled at the investigator’s discretion whilst visits 3 and 5 could be rescheduled such that 
the total period treatment duration did not exceed 17 days.
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Drug compliance was checked during study visits and at completion. Patients were requested to 
return all unused medication including rescue medication as well as inhalers, empty blisters and 
containers.
5.2.4 Measurements
Details of the evaluations performed at scheduled visits are presented in Table 5-1.
Patients with mild ailments at screening or evidence of sub-optimal exercise performance were 
re-evaluated after one week. If they had not resolved by then, the patient was excluded from the 
study.
Details of the methodology of pulmonary function testing (spirometry, static lung volumes, CO 
diffusing capacity, respiratory muscle pressures) is contained in the general methods chapter 
(chapter 2, Section 2.2.1). Incremental and cardiopulmonary exercise testing methodologies are 
also explained in Chapter 2, Sections 2,2,4.2 and 2,2.4.3 respectively.
Table 5-1 Evaluation and visit schedule.
Kxamiiiation Screening Visit 2 Visit 3 Visit 4 Visit 5
Day -7 Day 1 Day 14 Day 17 Day 30
Informed consent X
Eligibility X X
Randomization X
Resting spirometry X X X X X
Full PFT X '
Inc CPET X
CW CPET X X X X
Concomitant Medications, ECG X X X X X
Chest X-Ray^ X
Dyspnoea questionnaires X X X
Adverse Experiences X X X X
where a recent chest X-Ray (within 6 months) was not available.
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5.2.5 Outcome Variables
5.2.5.1 Primaiy outcome variable
The primary efficacy variable was the time to limit of tolerance (Tlim), being the interval 
between the onset of the imposed work rate and the point at which the patient could no longer 
consistently maintain the required cycling rate.
5.2.5.2 Secondary efficacy variables
Secondary efficacy measurements consisted of various lung mechanical and respiratory 
parameters, perceived leg effort and dyspnea recorded during the CW CPET and the Mahler 
Transitional Dyspnea index which was administered at the start and end of each treatment 
period. Each parameter recorded during the CW CPET was measured at four time points these 
being:
• at rest -  with the patient sitting on the cycle ergometer, but not pedalling
• unloaded cycling -  cycling at the required rate of revolutions with no resistance imposed .
• isotime -  this was defined as the shortest duration of exercise challenge an individual patient 
completed during either treatment period.
• Tlim -  defined as the point the patient could no longer consistently maintain the required 
cycling rate
The secondary efficacy assessments were oxygen uptake ( Vo^  absolute), carbon dioxide output, 
leg effort, dyspnea, ventilation, end expiratory lung volume, inspiratory reserve volume, flow 
limitation, Mahler’s Questionnaire of Chronic Activity-Related Breathlessness, heart rate, 
ventilation, respiratory frequency, tidal volume, arterial oxygen saturation and inspiratory 
capacity.
In addition, patients recorded the number of inhalations of rescue medication taken during the 
night and the day in a Patient Diary. Patients completed the diary twice daily, before the morning 
and evening doses of study medication.
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3.2.6 Safety assessm ents
Safety assessments consisted of monitoring and recording all adverse events, serious adverse 
events (with their severity and relationship to study drug), a routine hematology and blood 
chemistry screen at Visit 1 (with additional monitoring of potassium 3 days after Visits 3 and 5 
for patients receiving theophylline), the regular measurement of vital signs and performance of 
physical examinations. Pre-dose ECGs were recorded at each visit and continuous ECG 
monitoring took place during exercise tests. Laboratory measurements were performed by the 
Departments of Haematology and Biochemistry at Glasgow Royal Infirmary.
5.2.7 Statistical methods
All statistical analysis took place using version 6.12 of the SAS statistical package. For
continuous variables the following summary statistics were calculated: mean, standard deviation,
median, inter-quartile range, and minimum and maximum values. For discrete variables the 
following summary statistics were calculated: number of values in each category, and percentage 
in each category of the total number of non-missing values for that variable.
The intent-to-treat population was defined as being all patients randomized to study medication 
and who received at least one dose of randomized medication. Patients were not excluded from 
the intent-to-treat population even if they did not fulfil all inclusion and exclusion criteria or 
violated the protocol.
Only patients who had measurements of Tlim available for both treatment periods, including the 
measurements made during the CW CPET before the start of trial treatment at Visits 2 and 4, 
were included in the statistical analyses. These patients will be referred to as the efficacy 
population. This population was used for the efficacy analyses of all primary and secondary 
parameters.
The safety population was defined as being all randomized patients who received at least one 
dose of study medication, the same as the intent-to-treat population.
The primary efficacy variable was the time to limit of tolerance (Tlim), being the interval 
between the onset of the imposed work rate and the point at which the patient could no longer 
consistently maintain the required cycling rate.
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The null hypothesis tested was that there was no difference in Tlim following 14 days of 
treatment with formoterol 12pg compared with the Tlim following 14 days of treatment with 
placebo.
Analysis of covariance (ANCOVA) was used to test the null hypothesis, with terms for sequence 
group, patient within sequence (fitted as a random effect), period, treatment and baseline Tlim as 
a covariate, where baseline Tlim is the value measured before treatment for that period. The 
treatment difference between formoterol and placebo was presented together with the 95% 
confidence intervals. The treatment effect was tested at the 5% significance level.
Most secondary efficacy parameters were analyzed using the same ANCOVA model as for the 
primary efficacy parameter, except Mahler’s Questionnaire (dyspnea index) and Borg dyspnea, 
was analyzed using Koch’s non-parametric method for a two-period cross-over design, based 
upon the Wilcoxon Rank Sum Test (Koch, 1972). The estimate of the median difference between 
treatments (Hodges-Lehmann estimator) and the associated 95% confidence interval have been 
calculated (Conover & Iman, 1982).
Sample size and power considerations.
No suitable data was available from other studies using the same exercise technique. Therefore 
no information was obtainable concerning the variability of the primary efficacy variable, the 
Tlim. Consequently no formal sample size calculations were possible. The number of patients 
chosen (26, with the aim of having 20 evaluable patients) was considered appropriate based upon 
our current understanding of the patient population being studied and the exercise test being 
used.
Twenty-one patients were randomized into the study, with 18 evaluable patients. Recruitment 
was stopped before the planned sample size was enrolled because of recruitment difficulties and 
an approaching expiry date of the study drug. The study was therefore potentially underpowered 
for its primary outcome measure.
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5.3 Results
5.3.1 Study participants
Thirty (30) patients were screened (at Visit 1) and 21 patients were randomized into the study at 
Visit 2: 10 to the formoterol/placebo treatment sequence group and 11 to the placebo/formoterol 
sequence group. Of the 9 patients who were not randomized, 3 were not because of test 
procedure results excluding continuation, 4 because of unacceptable use of excluded 
medications/therapies prior to study commencement and 2 patients withdrew consent.
Eighteen patients completed treatment as planned. Three patients discontinued prematurely, 
because of increased breathlessness and rescue medication use (two during placebo period, one 
during formoterol). These three patients could not be included in the efficacy population as they 
did not complete both treatment periods.
The mean age of enrolled subjects was 60 years. The mean duration of smoking was 39 years, 
with all patients having smoked for at least 25 years. The mean FEVi was 1.0 1, the mean 
FEVl/FVC was 38%, the mean FEVi as a percentage of predicted was 39% and the mean 
reversibility as a percentage of predicted normal was 6%. All these reflect the severe nature of 
the COPD in the patients included in the study. Table 5.2 below summarizes the main results 
concerning demography and disease status.
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Table 5.2 Demographic and disease characteristics.
Total Mean SD Range
(N=21,14 male)
Age (yr) 60.0 9.0 42.0-75.0
Number of years smoking 38.5 10.0 25.0-60.0
Duration of illness (yr) 4.0 2.3 1.0-11.0
FEVl (1) 1.00 0.34 0.49-1.73
FEVl percentage predicted 38.8 11.7 21.0-58.3
Reversibility as percentage of 5.5 3.3 -0 .9-10.7
predicted normal
Reversibility (%) 14.3 8.9 -2 .7-35.2
FEVl/FVC (%) 37.5 7.0 25.9-52.5
5.3.2 Primary efficacy results
Table 5.3 shows the results from the ANCOVA analysis of the primary efficacy variable, time to 
limit of tolerance (Tlim): both the estimated treatment means and the estimated treatment 
difference are presented as least squares (LS) means.
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T able 5.3 Tim e to lim it o f  tolerance (secs).
Least
T rea tm en t/co n trast sq u a re  95%
(n=18) m ean  confidence p-value
Formoterol 4 7 8 .9
Placebo 3 4 8 .5
Formoterol vs placebo 1 3 0 .3  - 1 . 2 , 2 6 1 . 8  0 .0 5 1 8
All statistics ore based on the ANCOVA model.
Both estimated treatment means and the estimated treatment difference ore 
presented as least square means.
The treatment difference in favour of formoterol, estimated as 130 seconds (over 2 minutes) was 
very close to achieving statistical significance at the 5% level (p=0.052). It is possible that the 
sample size was not large enough as it was chosen for practical purposes on empirical grounds, 
given there was no information available on the variability of Tlim. This is supported by an 
exploratory analysis of the percentage change from baseline in Tlim, which was carried out after 
the trial was unblinded, in which the treatment difference in favour of formoterol was 
statistically significant. The same ANCOVA model was used as for the primary efficacy 
variable. The mean percentage increase from baseline in Tlim was 29.7% with formoterol with a 
mean decrease o f 8.2% with placebo. The treatment difference in favour of formoterol was 
37.8%, with a 95% confidence interval of 9.4% to 66.2% (p=0.012).
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5.3.3 Secondary efficacy results
The secondary efficacy parameters identified prior to study enrolment (change in dyspnoea per 
time, change in the end expiratory lung volume per time, end expiratory lung volume, inspiratory 
reserve volume per time, Borg dyspnoea index and Mahler’s questionnaire) are reported in this 
results section. Other exploratory analyses are referred to, and are represented in more detail, 
where statistical significance was achieved.
Rate of the A dyspnoea per second
A reduction in the rate of the A dyspnoea per seconds would indicate that the rate of increase in 
breathlessness with time was attenuated.
Table 5.4 shows the results from the ANCOVA analysis. The least square means (at isotime 
from unloaded cycling and from at rest) show lower values when the patients were under 
formoterol than when the patients were under placebo (as seen in the negative estimated 
difference).
The differences (from unloaded and from at rest) between treatments were not statistically 
significant. The between treatment difference at rest was larger than the difference during 
unloaded cycling.
143
Table 5.4 Rate of the A Dyspnoea per second.
Treatment / contrast LS mean 95% p-value 
confidence 
interval
Isotime - unloaded Formoterol 0.0226
(n=17) Placebo 0.0265
Formoterol vs placebo -0.0039 -0.016,0.008 0.5072
Isotime -  at rest Formoterol 0.0307
(n=18) Placebo 0.0472
Formoterol vs plaeebo -0.0165 -0.036,0.003 0.0857
Tlim - unloaded Formoterol 0.0202
(n=I7) Placebo 0.0226
Formoterol vs placebo -0.0024 -0.011,0.006 0.5515
Tlim -  at rest Formoterol 0.0304
(n=18) Placebo 0.0346
Formoterol vs placebo -0.0042 -0.031,0.023 0.7434
All statistics based on the ANCOVA model: A Dyspnea/Time = sequence group+ patient + 
treatment + period + Baseline A Dyspnea/Time where Baseline is the value measured before 
treatment for that period
Rate of the A end expiratory lung volume per second
A reduction in the rate of the A end expiratory lung volume per second would indicate that the 
rate of increase in lung hyperinflation with time was attenuated.
Table 5.5 shows the result from the ANCOVA analysis. The least square means (from unloaded 
cycling and from at rest) show lower values when the patients were under placebo than when the 
patients were under formoterol.
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The differences (from unloaded and from at rest) between the treatments were not statistically
significant.
Table 5.5 Rate of the A End expiratory lung volume (I) per second.
T reatment / contrast LS mean 95%
confidence
interval
p-value
Isotime - unloaded Formoterol 0.0010
(n~16) Placebo 0.0007
Formoterol vs placebo -0.0003 -0.000, 0.001 0.3545
Isotime -  at rest Formoterol 0.0022
(n=14) Placebo 0.0019
Formoterol vs placebo 0.0003 -0.001,0.001 0.4173
Tlim - unloaded Formoterol 0.0010
(n-17) Placebo 0.0008
Formoterol vs placebo 0.0002 -0.000, 0.001 0.2842
Tlim -  at rest Formoterol 0.0025
(n=16) Placebo 0.0028
Formoterol vs placebo -0.0003 -0.002,0.001 0.6011
All statistics based on the ANCOVA model: A End expiratory lung volume/Time = sequence 
group+ patient + treatment + period + Baseline A end expiratory lung volume/Time where 
Baseline is the value measured before treatment for that period
End expiratoiy lung volume (1)
A reduction in the end expiratory lung volume would indicate a reduction in the absolute degree 
of lung hyperinflation.
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Table 5.6 shows the result from the ANCOVA analysis. The least square means show lower
values when the patients were under formoterol than when the patients were under placebo.
The differences between the treatments were statistically significant at the 5% level of 
significance at rest, at unloaded cycling and at Tlim, and was close to statistical significance at 
isotime. These data are illustrated in Figure 5.3.
Table 5.6 End expiratory lung volume (1).
Treatment / contrast LS mean 95%
confidence
interval
p-value
At rest Formoterol 4.84
(n=16) Placebo 5.13
Formoterol vs placebo -0.29 -0.45, -0.14 0.0013
Unloaded Formoterol 5.18
(n=17) Placebo 5.40
Formoterol vs placebo -0.22 -0.39 , -0.05 0.0133
Isotime Formoterol 5.17
(n=16) Placebo 5.30
Formoterol vs placebo -0.12 -0.27, 0.02 0.0825
Tlim Formoterol 5.49
(n=18) Placebo 5.62
Formoterol vs placebo -0.13 -0.27 , -0.00 0.0448
All statistics based on the ANCOVA model: End expiratory lung volume -  sequence group+ 
patient + treatment + period + Baseline end expiratory lung volume where Baseline is the 
value measured before treatment for that period
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Figure 5.3 End expiratory lung volume (1), estimated treatment differences (formotero 1-
placebo) and 95% confidence intervals.
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Rate of change of inspiratoiy reserve volume with time
An increase in A Inspiratory Reserve Volume / Time would indicate that more volume was 
available for inspiration, but not used, for a given change in time.
Table 5.7 shows the results from the ANCOVA analysis. The least square means show higher
values when the patients were under formoterol than when the patients were under placebo at 
each time point except for the difference at isotime from at rest.
The differences between the two treatments were not statistically significant at any time point.
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Table 5.7 A Inspiratory Reserve Volume (1) per second.
Treatment / contrast LS mean 95%
confidence
interval
p-value
Isotime -  unloaded 
(n=16)
Formoterol
Placebo
Formoterol vs placebo
-0.0018
-0.0020
0.0002 -0.001,0.001 0.7382
Isotime -  at rest 
(n=14)
Formoterol
Placebo
Formoterol vs placebo
-0.0040
-0.0036
-0.0003 -0.002,0.001 0.6977
Tlim -  unloaded 
(11=17)
Formoterol
Placebo
Formoterol vs placebo
-0.0013
-0.0017
0.0004 -0.000,0.001 0.3198
Tlim -  at rest 
(n=16)
Formoterol
Placebo
Formoterol vs placebo
-0.0033
-0.0044
0.0011 -0.001,0.003 0.2031
All statistics based on the ANCOVA model: A Inspiratory reserve volume/Time = sequence 
group+ patient + treatment + period + Baseline A Inspiratory reserve volume where Baseline 
is the value measured before treatment for that period.
Mahler’s questionnaire of chronic activity-related breathlessness
A positive value indicates an improvement compared with the baseline values. Table 5.8 shows 
the median for the transition values of the dyspnoea index. All three parameters showed an 
increase when the patients were under formoterol and no change when the patients were under 
placebo (Figure 5.4). The minimal clinically important difference for each focal score is 1 unit.
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Table 5.8 Mahler’s Questionnaire of chronic activity-related breathlessness, transition
dyspnoea index, efficacy population.
Change in 
(11=18)
Time point Formoterol
(median score)
Placebo
(median score)
Functional Impairment 
Magnitude of Task 
Magnitude of Effort
After treatment 
After treatment 
After treatment
1.5
1.0
1.0
0.0
0.0
0.0
Table 5.9 shows the results from Koch’s non parametric method. Statistically significant 
treatment differences in favour of formoterol were seen in all 3 parameters.
Table 5.9 Mahler’s Questionnaire of chronic activity-related breathlessness, transition 
dyspnoea index -  Analyses.
Treatment contrast
(n = 18)
Change in Hodges-
Lehman
estimator
95% confidence 
interval
P-
value
Formoterol vs. Functional 1.50 0.50 , 2.00 0.0035
Placebo Impairment
Magnitude of Task 1.00 0.00, 2.00 0.0193
Magnitude of Effort 1.00 0.00, 2.00 0.0221
Based on Koch’s non parametric method
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Figure 5.4 Mahler’s questionnaire activity-related breathlessness, transition dyspnea index
score, estimated treatment differences (formoterol -  placebo) and 95% confidence interval.
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Borg dyspnoea index
The Borg index rates a patient’s degree of breathlessness on a scale from 0 (none) to 10
(maximal). Lower scores indicate a lower level of breathlessness.
After treatment, the median of the Borg dyspnoea index at isotime was lower when the patients 
were under formoterol than when the patients were under placebo (Table 5.10).
Table 5.10 Borg dyspnoea index.
1
Time point Formoterol
(median score)
Placebo
(median score)
At rest Before treatment 0.0 0.0
(n=18) After treatment 0.0 0.5
Unloaded Before treatment TO" 1.0
(n=18) After treatment 1.0 1.0
Isotime Before treatment 7.0 6.0
(n=18) After treatment 4.5 7.0
Tlim Before treatment 8.5 7.0
(11=18) After treatment 9.0 7.0
5i=17 due to missing data. The analysis is based on the after treatment data and does not use 
the before treatment data.
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Table 5.11 shows the results from Koch’s non parametric method. The estimated difference 
between the treatments was in favour of formoterol at unloaded cycling and at isotime but was 
not statistically significant.
Table 5.11 Borg dyspnoea index -  Analyses.
Treatment contrast 
(n = 18)
Hodges-
Leliman
estimator
95% confidence 
interval
P-
valne
Formoterol vs. 
Placebo
At rest 0.00 -0.05 , 0.00 0.2312
Unloading -0.50 -1.00, 0.00 0.1742
Isotime -1.50 -2.50 , 0.50 0.0833
Tlim 0.00 -1.00, 1.00 0.9375
Based on Koch’s non parametric method
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Inspiratory Reserve Volume (1)
An increase in this parameter would indicate that the elastic load of inspiration was being 
reduced at these time points. Table 5.12 shows that the inspiratory reserve volume was higher 
when the patients were treated with formoterol than when the patients were treated with placebo. 
These data are also illustrated in Figure 5.5.
The differences between treatments at rest and at isotime were statistically significant.
Table 5.12 Inspiratory reserve volume (L).
Treatment / contrast LS mean
(L)
95%
confidence
interval
p-value
At rest Formoterol 1.47
(n=16) Placebo 1.16
Formoterol vs placebo 0.31 0.01 , 0.61 0.0444
Unloaded Formoterol 0.98
(n=17) Placebo 0.82
Formoterol vs placebo 0.16 -0.02, 0.33 0.0709
Isotime Formoterol 0.59
(n=16) Placebo 0.40
Formoterol vs placebo 0.20 0.09, 0.30 0.0019
Tlim Formoterol 0.47
(n=18) Placebo 0.36
Formoterol vs placebo 0.11 -0 .02 , 0.23 0.0870
All statistics based on the ANCOVA model: Inspiratory reverse volume = sequence group+ 
patient + treatment + period + Baseline inspiratory reverse volume where Baseline is the value 
measured before treatment for that period
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Figure 5.5 Inspiratory reserve volume (1), estimated treatment differences (formoterol
placebo) and 95% confidence intervals.
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Additional exploratoiy parameters
fheie were no significant differences between formoterol and placebo groups for oxygen uptake 
(mL/min), A Leg effort / A Oxygen uptake, A Dyspnoea / A Oxygen uptake, A Dyspnoea / A 
ventilation, A Leg effort / Time, A End Expiratory Lung Volume / A Ventilation, A Inspiratory 
Reserve volume / A Ventilation and flow limitation in relation to time or ventilation.
IC measurement allows measurements to be calculated which allow us to infer conclusions 
regarding the degree of dynamic hyperinflation. As is illustrated below in Figure 5.6, it was IC 
that had the most consistent change with formoterol, in comparison to the other parameters 
described in detail above.
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Figure 5.6 Inspiratory capacity (1), estimated treatment differences (formoterol -  placebo)
and 95% confidence intervals.
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We were interested as to whether resting 1C or FEVl would relate to the exercise or dynamic 
hyperinflation changes seen after the bronchodilator administration. Both IC and FEVl differed 
after Foradil, compared to placebo at rest. The between group differences were significant as 
illustrated in table 5.13 below.
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Table 5.13 Between group differences for resting post treatment lung function.
Between group 
difference
95% lower Cl 95% upper Cl p-value
IC (%) 12.6 2.0 23.2 0.02
FEVl (%) 14.5 7.3 21.7 0.0003
However, although there was a positive correlation between these two measures as seen 
following Foradil administration, this was not statistically significant (R= 0,35, p= 0.15). The 
percentage change of FEVl and IC following placebo and Foradil administration is illustrated in 
the scattergram below (Figure 5.3).
156
Figure 5.7 Bivariate scattergram for percentage responses of IC and FEVl with placebo and 
Foradil treatments.
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5.3.4 Safety results
The safety information collected included adverse events, baseline routine blood tests 
(haematology, biochemistry), pre exercise ECG’s and data on vital signs. There were no 
incidences of findings that indicated lack of safety of the trial design. Apart from the episodes of 
increased breathlessness, leading to study discontinuation, there were no severe adverse events or 
deaths during the study. The profile of adverse experiences is detailed below (Table 5.13),
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however these findings would be in keeping with that expected for subjects of this age and
disease severity.
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5.4 Discussion
This study demonstrates that the long acting bronchodilator, formoterol, has a beneficial effect 
upon exercise induced dynamic hyperinflation and resting breathlessness. This is despite 
selecting a group of severe patients that have poorly reversible expiratory flow in response to 
inhaled bronchodilator. The impact of the drug upon exercise capacity was less clear, with only 
subgroup analyses of percentage change of Tlim achieving unambiguous statistical significance. 
We believe that this is the first study of the effects of fomoterol, which is a rapidly acting but 
long duration bronchodilator, on exercise tolerance and dynamic hyperinflation in COPD.
The primary efficacy endpoint was very close to, but did not, achieve statistical significance 
(p-0.0518). The estimated difference between the treatments was large (130 seconds) and to the 
advantage of formoterol. Whilst there is no generally recognized formal definition of a clinically 
meaningful increase in Tlim during a CW CPET, it is highly probable that the increase in Tlim 
observed in this study would equate to benefits in patient’s ability to perform their normal day- 
to-day physical tasks. In a recently published study of the effects of salmeterol on endurance 
exercise, with 23 patients completing the study, an increase of 96 seconds or 58% was seen, 
representing similar findings to ours (O'Donnell et al., 2004b). As we were unable to reach our 
target recruitment then it is likely that the study was underpowered and this is discussed in more 
detail later.
A large number of secondary efficacy variables were analyzed in this study. The majority of 
these variables have not previously been examined in the context of a long acting bronchodilator 
clinical trial. The effect of formoterol on such parameters was therefore very difficult to predict 
at the time this study was designed.
There was a statistically significant decrease in end-expiratory lung volume (EELV) at rest, 
during unloaded cycling and at Tlim. In addition at isotime the decrease almost achieved 
significance (p=0.083). Similarly, formoterol significantly increased inspiratory reserve volume 
at rest and at isotime (almost achieving significance during unloaded cycling, p=0.071), and at 
Tlim, p=0.087). Both of these measures are indicators of dynamic hyperinflation, which is 
known to be a crucial component of the factors which limit exercise capacity in COPD patients 
(O'Donnell, 2001). In COPD the slower rate of lung emptying leads to the expiratory time being 
insufficient to exhale what has been previously inspired. The subsequent increase in operating
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lung volumes, although it may allow increased flow-generating capacity, leads to static tidal 
volumes despite a greater work of breathing. This is largely due to the respiratory system 
working on the flat portion of the pressure/volume relationship. It seems likely that the dynamic 
hyperinflation induced positive end expiratory pressure is crucial in elevating the work of 
breathing in these patients, a factor likely altered by bronchodilatation (Sliwinski et al, 1998). 
The respiratory muscles are placed at a mechanical disadvantage as they are required to work at 
near maximal lengths and loads. The subsequent increased work of breathing Increases the 
oxygen demands of the exercising muscles, which may have deleterious effects upon oxygen 
delivery elsewhere (Aliverti & Macklem, 2001). The decrease in EELV and concurrent increase 
in IRV demonstrated in this study may therefore have been instrumental in allowing the patients 
to continue the CW CPET for longer due to the beneficial effects of decreased work of breathing. 
Reproducibility of inspiratory capacity measurements during exercise is high in COPD, 
irrespective of the disease severity, and more so, may be more repeatable during exercise 
compared to rest (DoImage & Goldstein, 2002; Taube et al, 2000).
The three parameters evaluated by Mahler’s questionnaire showed an improvement when the 
patients were taking formoterol. Differences between treatments in all the 3 parameters 
‘functional impairment’, ‘magnitude of task’ and ‘magnitude of effort’, were statistically 
significant at the 5% level of significance, indicating that formoterol decreased patients’ dyspnea 
during their two weeks of treatment. The results from the Borg dyspnea scale measured during 
the exercise challenge whilst being in favour of formoterol were not statistically significant. 
Effects of long acting bronchodilators on breathlessness at rest are well established and these 
findings offer additional support for this (Di Marco et al, 2003; Ram irez-Venegas et al, 1997). 
Long acting bronchodilators are being seen to have a role in symptomatic COPD patients, 
irrespective of bronchodilator response. This is principally for two reasons. Firstly, traditional 
measures of reversibility, such as FEVl response, may remain largely unaltered, whereas other 
indices, perhaps inspiratory capacity or lung volumes, show changes (Newton et al, 2002; 
Duranti et al, 2002; O'Donnell et al, 2004b). Secondly, such bronchodilator responses, either 
through steroid or beta agonist administration, do not predict longer term benefit in the form of 
symptoms or exacerbations for these drugs (Calverley et al, 2003b; Tashkin & Kesten, 2003). 
Our data support the use of bronchodilators in severe groups of patients without significant 
bronchod i 1 ator revers ib i 1 ity.
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A cross-over design was chosen to allow for a with in-patient placebo-controlled comparison 
thereby limiting the number of patients required. The fourteen day duration for each treatment 
period was considered sufficient to allow for the patients’ respiratory status to be stable whilst 
allowing a total study duration for each patient of not more than one month. During a one month 
period the patients’ lung function was not expected to decline significantly and the relatively 
short evaluation period was not expected to hinder patient compliance. A formoterol dose of 
12pg b.i.d is commonly used in the treatment of COPD and is the lower of two formoterol doses 
submitted for licensing approval in COPD.
The primary outcome of time to limit of tolerance (Tlim) was based on a constant woiic-load 
challenge. This type of challenge was chosen because it is more representative of the type of 
activity level and exertion with which COPD patients need to cope during their daily routine 
activities. Endurance type tests are more sensitive than incremental exercise test to intervention 
as they are likely gauged to be near to the “critical power” of any activity (Neder et al, 2000a). 
This is also applies to “field” based exercise tests such as incremental and endurance shuttle 
walking (Revill et al, 1999). For this study we chose to utilise a more formal laboratory based 
assessment of exercise endurance as that setting allowed the concurrent evaluation of dynamic 
hyperinflation. A CW CPET was performed at the start of each study treatment period prior to 
receiving study medication and at the end of each treatment period 2 hours after study 
medication inhalation, this time point being chosen because this was when a clinically significant 
effect was expected to be seen for most patients. O’Donnell has, in a comprehensive review on 
the subject, concluded that measures of dynamic hyperinflation during exercise, in conjunction 
with dyspnoea and quality of life, are more sensitive than spirometric measures to the effects of 
bronchodilators (O'Donnell et al, 1998).
FE V l reversibility testing following inhalation of 400|ig of salbutamol during screening provided 
evidence of a non-reactive obstructive defect. It was hoped that by selecting the more severe end 
of the COPD spectrum, any resulting improvement in exercise capacity would be seen to have 
potential for a wide applicability.
This study has a clear limitation, in that the projected number of patients required to show 
benefit in exercise capacity were not recruited. The reasons for this shortcoming were mainly 
due to pressures relating to expiry time of the study drug provided. However it must also be said
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that a significant majority of the patients attending Glasgow Royal Infirmary were already 
established on long acting bronchodilators, and in that setting a placebo -  formoterol crossover 
study did not seem appropriate in the context of the established benefits of these therapies in 
COPD (Pauwels et al, 2001). We do believe that a larger sample size would have led to a 
significant impact upon exercise capacity being demonstrated. Such a supposition is supported 
by our exploratory analysis of percentage changes in exercise capacity, which demonstrated clear 
benefit to formoterol. In general, the study had a high completion rate, with only three subjects 
discontinuing prematurely (Two due to due to increased breathlessness and one because of 
excess rescue medication use). Otherwise only minor adverse occurrences were documented as 
expected with this well tolerated therapy (Rabe, 2003).
This study suggests that formoterol may improve the time to limit of exercise tolerance in 
patients with COPD. We did not achieve statistical significance for the primary outcome of 
absolute endurance exercise time (p=0.052), however percentage improvements in exercise 
capacity were significantly greater in the formoterol group (p=0.012). In addition, and likely in 
relation, dynamic hyperinflation was significantly lessened with formoterol.
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CHAPTER 6
CONCLUSIONS AND FUTURE RESEARCH
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6.1 Thesis summary
This thesis contains studies that have examined the assessment and management of disability in 
chronic obstructive lung disease. Whereas there was until relatively recently little focus of 
attention on this disease, there is now a much-improved understanding of the pathogenesis, 
clinical course and multi-system manifestations of COPD. Diagnosis is a simple matter of a 
compatible history, environmental antigen exposure and spirometry (Pauwels et al, 2001). 
Evaluation of the impact of the disease is much more complex. More sophisticated respiratory 
function is commonly undertaken, with current controversy as to which resting lung volume 
measurement is most meaningful (Newton et al, 2002). To further classify the impairment 
produced by the disease, one can examine body composition or exercise capacity, utilising either 
simple or complex means. These methodologies have themselves largely been used in the 
context of pulmonary rehabilitation, but with more recent clarification of the important 
prognostic indices in COPD, these are likely to enter routine outpatient clinical practice (Marquis 
et al, 2002;Celli et al, 2004). It is undoubtedly the hope of researchers and clinicians that the 
assessments made in the COPD patient will not only provide prognostic information, but also be 
useful as guides for the most appropriate treatment approaches to take.
In chapter 3 we have considered to what extent utilising a complex method of body composition 
assessment adds meaningful information over that provided by body mass index or 
anthropometry. We have concluded that the inaccuracies of anthropometry, compared to a more 
complex measurement, are such to lead to significant discrepancies in estimates of exercise 
capacity. Therefore more detailed assessment clearly can improve accuracy of impairment 
evaluation. Systematic bias can exist with some measures, meaning that consistency of 
measurement methodology is of particular importance in individual centres when longitudinal 
changes are being looked for in body composition. This valid observation should not, however, 
discourage clinicians from addressing body composition through other means. This is because 
an understanding of whether a patient is depleted or not of muscle bulk, and to what extent, is 
crucial to the understanding of their clinical phenotype, required intervention and prognosis. The 
impact of fat-free mass depletion on strength, exercise capacity, and health-related quality of life, 
independent of lung function is clearly demonstrated from the cohort of patients taking part in 
the creatine intervention study.
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In chapter 4, the effect of creatine supplementation was examined. This included assessment 
after two weeks loading and following a period of outpatient exercise training. The supplement 
was well-tolerated and lead to demonstrable beneficial effects. Unequivocal improvements in 
muscle bulk, muscle strength and endurance, and health status were seen. For reasons that may 
relate to the test involved (insensitivity or lack of reproducibility) or efficacy of the intervention, 
exercise capacity was not seen to be affected. This finding may highlight the gulf between those 
aspects of a disease that we can measure and the elements that relate to the patients well being. 
For health status to be altered, particularly in activity domains, suggest that there may well be an 
effect of an intervention such as creatine on aspects not measurable clinical in the laboratory. 
The investigation of the utility of alternative measures such as activity monitors is underway in a 
number of centres. Creatine has been shown to be efficacious and safe. Its applicability to the 
wider population of COPD patients, particularly which form, duration or timing of 
administration is most appropriate requires further evaluation. Our study would suggest that 
creatine benefits are present for a wide range of severe COPD patients, irrespective of body 
habitus, and that these benefits are of a meaningful magnitude.
In chapter 5 the impact of a long acting bronchodilator, formoterol, upon dynamic hyperinflation, 
exercise tolerance and breathlessness was assessed. Once again a severe cohort was examined, 
this one with features of poorly reversible lung disease. The partial fallacy of this statement is 
evident as the flow limitation remains largely fixed while inspiratory manoeuvres neatly 
demonstrate the benefits that can be derived from bronchodilation. We found a borderline, and 
likely so because of underpowering, benefit in regard to endurance exercise capacity. Significant 
effects upon dynamic hyperinflation were clearer, along with the expected changes in resting 
measures of breathlessness. Bronchodilators evidently have benefits to patients, irrespective of 
their FEVi response to pa-agonists.
In all of the studies presented, complex methods of assessment have demonstrated benefits of 
intervention in patients selected through very simple criteria. We may in the future require in- 
depth evaluations outside of research settings, but at present the utility of novel treatments seems
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wide and interventions such as inhaled bronchodilators or nutritional supplements can be 
targeted to appropriate patients through straightforward means.
6.2 Future research
A large body of research is addressing the causes of skeletal muscle dysfunction in COPD. This 
becomes of particular importance as its role in relation to morbidity and mortality in this patient 
group becomes clearer. My research has addressed measures of disease status in COPD and has 
evaluated two specific treatments.
We would consider the following areas to be a natural progression of the research undertaken in 
this thesis.
6.2.1 Assessment of disease
Bio-electrical impedance is likely to emerge as the most convenient measure of body
composition, without compromise of the findings. There is no evidence to help clarify to what
extent performing these measures in a general respiratory setting can alter outcome through
targeted means. Although some groups have enthusiastically addressed this area in the setting of 
pulmonary rehabilitation, the transition from prognostic indicator to management guide has not 
yet been shown to be appropriate.
Bronchodilator reversibility remains the standard means of diagnosing COPD. Its utility as a 
method of identifying asthmatic tendencies seems accepted by clinicians. However if measures 
of inspiratory reserve are more sensitive to change, then further research is clearly required to 
guide clinicians as to what determines meaningful bronchodilator response, if any response is 
meaningful at all.
Measures of endurance exercise are effective in showing response to interventions that directly 
target that exercise testing modality. They are currently relatively crude means of identifying 
benefit from muscle or lung treatments that are not exercise based. The applicability of activity 
monitors or questionnaires, or other laboratory exercise tests warrant investigation.
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6.2.2 Treatment
Creatine has been shown to be beneficial to a small cohort of stable patients entering a 
rehabilitation programme. Specific research is required to address aspects of this treatment to 
include; optimal duration, optimal dose, requirements of a loading regime, optimal setting, effect 
on morbidity and mortality.
Long acting bronchodilators and more latterly combination therapy with inhaled corticosteroids 
are established therapies for patients with symptomatic COPD. An investigation that helped 
unravel the relative importance of symptom relief, exercise improvement and exacerbation 
frequency in COPD patients would help direct the direction of further research.
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